



**Manchester
Metropolitan
University**

Hopewell, Sally, Keene, David J, Heine, Peter, Marian, Ioana R, Dritsaki, Melina, Cureton, Lucy, Dutton, Susan J, Dakin, Helen, Carr, Andrew, Hamilton, Willie, Hansen, Zara, Jaggi, Anju, Littlewood, Chris ORCID logoORCID: <https://orcid.org/0000-0002-7703-727X>, Barker, Karen, Gray, Alastair and Lamb, Sarah E (2021) Progressive exercise compared with best-practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP factorial RCT. Health Technology Assessment, 25 (48). pp. 1-158. ISSN 1366-5278

Downloaded from: <https://e-space.mmu.ac.uk/628233/>

Version: Published Version

Publisher: NIHR Journals Library

DOI: <https://doi.org/10.3310/hta25480>

Usage rights: Creative Commons: Attribution 4.0

Please cite the published version

<https://e-space.mmu.ac.uk>

Health Technology Assessment

Volume 25 • Issue 48 • August 2021

ISSN 1366-5278

Progressive exercise compared with best-practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP factorial RCT

Sally Hopewell, David J Keene, Peter Heine, Ioana R Marian, Melina Dritsaki, Lucy Cureton, Susan J Dutton, Helen Dakin, Andrew Carr, Willie Hamilton, Zara Hansen, Anju Jaggi, Chris Littlewood, Karen Barker, Alastair Gray and Sarah E Lamb on behalf of the GRASP Trial Group



Progressive exercise compared with best-practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP factorial RCT

Sally Hopewell^{1*}, David J Keene², Peter Heine², Ioana R Marian¹, Melina Dritsaki¹, Lucy Cureton², Susan J Dutton¹, Helen Dakin³, Andrew Carr², Willie Hamilton⁴, Zara Hansen², Anju Jaggi⁵, Chris Littlewood⁶, Karen Barker², Alastair Gray³ and Sarah E Lamb^{2,4} on behalf of the GRASP Trial Group

¹Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK

²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK

³Nuffield Department of Population Health, University of Oxford, Oxford, UK

⁴College of Medicine and Health, University of Exeter, Exeter, UK

⁵Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK

⁶Manchester Metropolitan University, Manchester, UK

*Corresponding author

Declared competing interests of authors: Sally Hopewell is a member of the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Clinical Evaluation and Trials committee (2018 to present). David J Keene holds a NIHR Postdoctoral Fellowship (PDF-2016-09-056). Ioana R Marian holds a NIHR Pre-Doctoral Fellowship (reference NIHR300479). Helen Dakin is partly funded by a NIHR Senior Research Fellowship through the Biomedical Research Centre (Oxford, UK). Andrew Carr has a patent BioPatch issued and is a member of the UK Research and Innovation/Medical Research Council Developmental Pathway Funding Scheme Panel. He was chief investigator of the NIHR HTA UK Rotator Cuff Surgery (UKUFF) trial and the Can Shoulder Arthroscopy Work (CSAW) trial. He is a consultant to the Novartis Pharmaceuticals UK Ltd Musculoskeletal Board (London, UK). He is chief investigator of a NIHR Innovation for Innovation (i4i) trial of a novel electrospun patch and of a Wellcome Trust (London, UK)-funded trial of a novel electrospun suture in rotator cuff repair surgery. He was director of the NIHR Musculoskeletal British Research Unit (2008–17) and is musculoskeletal theme lead for the NIHR Oxford Biomedical Research Centre (Oxford, UK). He reports personal fees from Novartis Pharmaceuticals UK Ltd Musculoskeletal Advisory Board. Zara Hansen receives personal fees from various health-care trusts and individuals to train health-care professionals in cognitive-behavioural approaches outside the submitted work. Anju Jaggi is currently a council member of the British Shoulder & Elbow Society (London, UK). She is co-applicant of the NIHR HTA PRO CURE (Partial Rotator Cuff Repair) trial. Chris Littlewood is chairperson of the Chartered Society of Physiotherapy Scientific Panel (London, UK). He is chief investigator of the NIHR postdoctoral fellowship-funded SPeEDy (Surgery versus Physiotherapist-led exercise for traumatic tears of the rotator cuff) study

(reference PDF-2018-11-ST2-005). He was previously lead researcher for the NIHR Research for Patient Benefit-funded RaCeR (Rehabilitation following Rotator Cuff Repair) study (PB-PG-081620009) and chief investigator for the NIHR Doctoral Fellowship-funded SELF study (DRF-2011-04-090). Sarah E Lamb reports grants from the NIHR HTA programme during the conduct of the study and was a member of the following boards: HTA Additional Capacity Funding Board (2012–15); HTA Clinical Trials Board (2010–15); HTA End of Life Care and Add on Studies (2015); HTA Funding Boards Policy Group (formerly Clinical Studies Group) (2010–15); HTA Maternal, Newborn and Child Health Methods Group (2013–15); HTA post-board funding teleconference (2010–15); HTA Primary Care Themed Call board (2013–14); HTA Prioritisation Group (2010–15); and the NIHR Clinical Trials Unit Standing Advisory Committee (2012–16).

Published August 2021

DOI: 10.3310/hta25480

This report should be referenced as follows:

Hopewell S, Keene DJ, Heine P, Marian IR, Dritsaki M, Cureton L, *et al.* Progressive exercise compared with best-practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP factorial RCT. *Health Technol Assess* 2021;**25**(48).

Health Technology Assessment is indexed and abstracted in *Index Medicus*/MEDLINE, *Excerpta Medica*/EMBASE, *Science Citation Index Expanded* (SciSearch®) and *Current Contents*®/Clinical Medicine.

Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.014

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 15/26/06. The contractual start date was in October 2016. The draft report began editorial review in November 2020 and was accepted for publication in April 2021. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

Copyright © 2021 Hopewell *et al.* This work was produced by Hopewell *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: <https://creativecommons.org/licenses/by/4.0/>. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

NIHR Journals Library Editor-in-Chief

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

Professor Matthias Beck Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk

Abstract

Progressive exercise compared with best-practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP factorial RCT

Sally Hopewell^{1*}, David J Keene², Peter Heine², Ioana R Marian¹, Melina Dritsaki¹, Lucy Cureton², Susan J Dutton¹, Helen Dakin³, Andrew Carr², Willie Hamilton⁴, Zara Hansen², Anju Jaggi⁵, Chris Littlewood⁶, Karen Barker², Alastair Gray³ and Sarah E Lamb^{2,4} on behalf of the GRASP Trial Group

¹Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK

²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK

³Nuffield Department of Population Health, University of Oxford, Oxford, UK

⁴College of Medicine and Health, University of Exeter, Exeter, UK

⁵Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK

⁶Manchester Metropolitan University, Manchester, UK

*Corresponding author sally.hopewell@csbm.ox.ac.uk

Background: Rotator cuff-related shoulder pain is very common, but there is uncertainty regarding which modes of exercise delivery are optimal and the long-term benefits of corticosteroid injections.

Objectives: To assess the clinical effectiveness and cost-effectiveness of progressive exercise compared with best-practice physiotherapy advice, with or without corticosteroid injection, in adults with a rotator cuff disorder.

Design: This was a pragmatic multicentre superiority randomised controlled trial (with a 2 × 2 factorial design).

Setting: Twenty NHS primary care-based musculoskeletal and related physiotherapy services.

Participants: Adults aged ≥ 18 years with a new episode of rotator cuff-related shoulder pain in the previous 6 months.

Interventions: A total of 708 participants were randomised (March 2017–May 2019) by a centralised computer-generated 1 : 1 : 1 : 1 allocation ratio to one of four interventions: (1) progressive exercise (*n* = 174) (six or fewer physiotherapy sessions), (2) best-practice advice (*n* = 174) (one physiotherapy session), (3) corticosteroid injection then progressive exercise (*n* = 182) (six or fewer physiotherapy sessions) or (4) corticosteroid injection then best-practice advice (*n* = 178) (one physiotherapy session).

Main outcome measures: The primary outcome was Shoulder Pain and Disability Index (SPADI) score over 12 months. Secondary outcomes included SPADI subdomains, the EuroQol 5 Dimensions, five-level version, sleep disturbance, fear avoidance, pain self-efficacy, return to activity, Global Impression of Treatment and health resource use. Outcomes were collected by postal questionnaires at 8 weeks and at 6 and 12 months. A within-trial economic evaluation was also conducted. The primary analysis was intention to treat.

Results: Participants had a mean age of 55.5 (standard deviation 13.1) years and 49.3% were female. The mean baseline SPADI score was 54.1 (standard deviation 18.5). Follow-up rates were 91% at 8 weeks and 87% at 6 and 12 months. There was an overall improvement in SPADI score from baseline in each group over time. Over 12 months, there was no evidence of a difference in the SPADI scores between the progressive exercise intervention and the best-practice advice intervention in shoulder pain and function (adjusted mean difference between groups over 12 months -0.66, 99% confidence interval -4.52 to 3.20). There was also no difference in SPADI scores between the progressive exercise intervention and best-practice advice intervention when analysed at the 8-week and 6- and 12-month time points. Injection resulted in improvement in shoulder pain and function at 8 weeks compared with no injection (adjusted mean difference -5.64, 99% confidence interval -9.93 to -1.35), but not when analysed over 12 months (adjusted mean difference -1.11, 99% confidence interval -4.47 to 2.26), or at 6 and 12 months. There were no serious adverse events. In the base-case analysis, adding injection to best-practice advice gained 0.021 quality-adjusted life-years ($p = 0.184$) and increased the cost by £10 per participant ($p = 0.747$). Progressive exercise alone was £52 ($p = 0.247$) more expensive per participant than best-practice advice, and gained 0.019 QALYs ($p = 0.220$). At a ceiling ratio of £20,000 per quality-adjusted life-year, injection plus best-practice advice had a 54.93% probability of being the most cost-effective treatment.

Limitations: Participants and physiotherapists were not blinded to group allocation. Twelve-month follow-up may be insufficient for identifying all safety concerns.

Conclusions: Progressive exercise was not superior to a best-practice advice session with a physiotherapist. Subacromial corticosteroid injection improved shoulder pain and function, but provided only modest short-term benefit. Best-practice advice in combination with corticosteroid injection was expected to be most cost-effective, although there was substantial uncertainty.

Future work: Longer-term follow-up, including any serious adverse effects of corticosteroid injection.

Trial registration: Current Controlled Trials ISRCTN16539266 and EudraCT 2016-002991-28.

Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 25, No. 48. See the NIHR Journals Library website for further project information.

Contents

List of tables	xiii
List of figures	xvii
List of abbreviations	xix
Plain English summary	xxi
Scientific summary	xxiii
Chapter 1 Introduction	1
Scientific background	1
<i>Problem and diagnosis</i>	1
Explanation of rationale	1
Choice of comparators	2
<i>Exercise interventions</i>	2
<i>Corticosteroid injection</i>	3
Objectives	3
Chapter 2 Methods	5
Trial design	5
<i>Internal pilot</i>	5
<i>Study setting</i>	6
<i>Participants</i>	6
<i>Inclusion criteria</i>	6
<i>Exclusion criteria</i>	6
Recruitment	6
<i>Recruitment of participants, screening and eligibility assessment</i>	6
<i>Informed consent and baseline assessment</i>	7
Randomisation	8
Blinding	8
Interventions	8
<i>Subacromial corticosteroid injection</i>	8
<i>Progressive exercise intervention</i>	9
<i>Best-practice advice intervention</i>	9
<i>Concomitant care</i>	9
<i>Training and monitoring of intervention delivery</i>	9
Outcomes	10
<i>Primary outcome</i>	10
<i>Secondary outcomes</i>	10
Adverse events	11
Follow-up data collection	11
Data management	12
Statistical methods	12
<i>Sample size</i>	12

Statistical analysis	12
<i>Interaction</i>	13
<i>Primary outcome analysis</i>	14
<i>Secondary outcome analyses</i>	14
<i>Missing data</i>	14
<i>Sensitivity analysis</i>	14
<i>Prespecified subgroup analysis</i>	14
<i>Supplementary/additional analyses</i>	15
Cost-effectiveness analysis	15
Patient and public involvement	15
Ethics approval and monitoring	16
<i>Ethics committee approval</i>	16
<i>Trial Management Group</i>	16
<i>Trial Steering Committee</i>	16
<i>Data Monitoring and Ethics Committee</i>	16
Chapter 3 Intervention description and rationale	17
Developing the GRASP trial exercise interventions	17
<i>Intervention development</i>	17
<i>Internal pilot</i>	18
The GRASP trial interventions	18
<i>GRASP trial exercise interventions</i>	21
Strategies to encourage exercise adherence	26
Monitoring, quality assurance and safety	26
Conclusion	27
Chapter 4 Results	29
Trial sites	29
<i>Centre characteristics</i>	29
<i>Participating clinicians</i>	29
Participant flow	29
Recruitment	29
<i>Screening</i>	29
Baseline data	32
<i>Baseline characteristics of participants</i>	32
Follow-up	35
<i>Withdrawals</i>	35
Intervention delivery	35
<i>Compliance with intervention</i>	35
<i>Timing of delivery of interventions</i>	37
<i>Content and adherence to interventions</i>	37
Best-practice advice intervention	38
Progressive-exercise intervention	38
<i>Exercise progression</i>	39
<i>Participant-reported adherence to exercise</i>	41
Quality assurance	41
Outcomes and estimations	41
Primary outcome: shoulder pain and function – SPADI	41
Interaction	41
SPADI: progressive exercise compared with best-practice advice	42
SPADI: injection compared with no injection	42

Sensitivity analysis	44
<i>Complier-average causal effect analysis</i>	44
<i>Progressive exercise compared with best-practice advice</i>	44
<i>Injection compared with no injection</i>	44
Secondary outcomes	44
<i>Progressive exercise compared with best-practice advice</i>	45
<i>SPADI: shoulder pain subscale</i>	46
<i>SPADI: shoulder function subscale</i>	46
<i>Fear Avoidance Belief Questionnaire – Physical Activity</i>	46
<i>Pain Self-efficacy Questionnaire</i>	47
<i>Insomnia Severity Index</i>	47
<i>Return to desired activities</i>	47
<i>Global Impression of Treatment</i>	47
<i>Injection compared with no injection</i>	47
<i>SPADI: shoulder pain subscale</i>	47
<i>SPADI: shoulder function subscale</i>	49
<i>Fear Avoidance Belief Questionnaire – Physical Activity</i>	49
<i>Pain Self-efficacy Questionnaire</i>	49
<i>Insomnia Severity Index</i>	50
<i>Return to desired activities</i>	50
<i>Global Impression of Treatment</i>	50
Other outcomes	50
<i>Participant-reported shoulder condition</i>	50
<i>Participant-reported injection outside the trial</i>	50
Harms	50
Missing data	51
Prespecified subgroup analysis	51
<i>Progressive exercise compared with best-practice advice</i>	51
<i>Injection compared with no injection</i>	52
Chapter 5 Health economics	53
Introduction	53
Methods	53
Aim	53
Measurement of resource use and costs	53
Costing of the interventions	54
Subacromial corticosteroid injection	54
Best-practice advice	54
Progressive exercise	54
Training	55
Base-case analysis	56
Worst-case scenario	57
Best-case scenario	57
Measurement of broader resource use	57
Valuation of resource use	58
Calculation of utilities and quality-adjusted life-years	58
Missing data	58
Analyses of resource use, costs and outcome data	59
Cost-effectiveness analysis	59
Regression analysis with interaction term (base-case analysis)	59
Regression analysis without interaction term (sensitivity analysis)	60

CONTENTS

Results of economic analysis	60
<i>Completion rate</i>	60
Cost-effectiveness results	64
<i>Base-case results</i>	64
Discussion	66
Chapter 6 Discussion	69
Interpretation	69
<i>Aim and overview of trial findings</i>	69
Generalisability	70
<i>Internal validity and methodology</i>	70
External validity and generalisability of study findings	71
Overall evidence: comparison with other literature	72
<i>Exercise intervention</i>	72
<i>Corticosteroid injection</i>	73
Chapter 7 Conclusion	75
Implications for health care	75
Implications for research	76
Acknowledgements	77
References	81
Appendix 1 Chapter 1 appendix	91
Appendix 2 Chapter 2 appendix	93
Appendix 3 Chapter 3 appendix	95
Appendix 4 Chapter 4 appendix	105
Appendix 5 Chapter 5 appendix	125
Appendix 6 Chapter 6 appendix	141

List of tables

TABLE 1 Outcomes measured and time points assessed	7
TABLE 2 Factorial 2 × 2 analysis diagram	13
TABLE 3 Overview of GRASP trial exercise interventions, as per Template for Intervention Description and Replication criteria	18
TABLE 4 Contents of the GRASP trial participant information booklet	21
TABLE 5 Number of participants screened by site	31
TABLE 6 Participant baseline characteristics ('inside the table')	32
TABLE 7 Participant withdrawals and reason for withdrawal	35
TABLE 8 Intervention received	36
TABLE 9 Content of subacromial corticosteroid injection	38
TABLE 10 Content of best-practice advice intervention	39
TABLE 11 Content of progressive-exercise intervention	40
TABLE 12 Shoulder Pain and Disability Index summary at each time point by randomised group	42
TABLE 13 Progressive exercise vs. best-practice advice at-the-margins analysis of SPADI	43
TABLE 14 Injection vs. no injection at-the-margins analysis of SPADI	43
TABLE 15 Analysis of secondary outcomes for progressive exercise vs. best-practice advice at 8 weeks, 6 months and 12 months	45
TABLE 16 Analysis of secondary outcomes for injection vs. no injection at 8 weeks, 6 months and 12 months	48
TABLE 17 Unit cost of consumables associated with trial per participant	55
TABLE 18 Assumptions for costing physiotherapist time	55
TABLE 19 Cost (£) of intervention per participant	56
TABLE 20 Completion rate (%) of health resource use by treatment interventions and follow-up time points	61
TABLE 21 Response rate (%) of EQ-5D-5L by follow-up time point and treatment	62
TABLE 22 Health-care cost (£) over the 12-month follow-up (available cases, without imputation of missing data)	62

TABLE 23 Non-NHS costs (£) over the 12 months (available cases, without imputation of missing data)	62
TABLE 24 Utility and QALY estimates: EQ-5D-5L scores (available cases with and without imputation and adjustment for baseline utility)	63
TABLE 25 Regression analysis with an interaction term, including imputation of missing values and adjustment for baseline utility, sex and age (base-case analysis)	64
TABLE 26 Categories of exercise considered by the delegates of the GRASP trial intervention development meeting	95
TABLE 27 Behavioural strategies to address barriers to exercise, highlighting common and discrete components to each exercise intervention	95
TABLE 28 Characteristics of participating NHS trusts	105
TABLE 29 Characteristics of participating physiotherapists	105
TABLE 30 Reasons participants were ineligible or declined to participate	106
TABLE 31 Baseline characteristics detailed (inside the table)	108
TABLE 32 Participant demographics at baseline: categorical outcomes (at the margins)	110
TABLE 33 Participant demographic characteristics at baseline: continuous outcomes (at the margins)	113
TABLE 34 Stratification factors (at the margins)	114
TABLE 35 Response rates	114
TABLE 36 Timing of intervention delivery	115
TABLE 37 Exercises prescribed: progressive-exercise intervention	115
TABLE 38 Progression of exercise intervention: progressive-exercise intervention	117
TABLE 39 Participant-reported exercise adherence	117
TABLE 40 Progressive exercise vs. best-practice advice and injection vs. best-practice advice: inside-the-table analysis of SPADI overall	118
TABLE 41 Progressive exercise vs. best-practice advice and injection vs. best-practice advice: inside-the-table analysis of SPADI at each time point	119
TABLE 42 Secondary outcomes analysis: unadjusted mean and SD	120
TABLE 43 Summary of prescribed medication unit cost (in 2019 £)	125
TABLE 44 Unit costs of health and social care items and additional financial cost due to rotator cuff disorder	126

TABLE 45 Mean health resource utilisation: baseline to 8 weeks (available-case analysis, excluding patients with missing data on that resource)	129
TABLE 46 Mean health resource utilisation: 8 weeks to 6 months (available-case analysis, excluding patients with missing data on that resource)	131
TABLE 47 Mean health resource utilisation: 6–12 months (available-case analysis, excluding patients with missing data on that resource)	133
TABLE 48 Mean NHS costs (SD) by treatment group and follow-up time point (2019 prices): baseline to 8 weeks (available cases)	135
TABLE 49 Mean NHS costs (SD) by treatment group and follow-up time point (2019 prices): 8 weeks to 6 months (available cases)	135
TABLE 50 Mean NHS costs (SD) by treatment group and follow-up time point (2019 prices): 6–12 months (available cases)	136
TABLE 51 Mean prescribed drug cost	136
TABLE 52 Utilisation of steroid injections outside the GRASP trial	137
TABLE 53 Utility and QALY estimates: EQ-5D visual analogue scale scores (available cases with no adjustment for baseline utility)	138
TABLE 54 Regression analysis without interaction term, including imputation of missing values and adjustment for baseline utility, sex and age	138
TABLE 55 Regression analysis with an interaction term, including both NHS and broader societal perspective	138
TABLE 56 Results of the worst-case scenario for training costs: regression analysis with an interaction term, including imputation of missing values and adjustment for baseline utility, sex and age	139
TABLE 57 Results of the best-case scenario: regression analysis with an interaction term, including imputation of missing values and adjustment for baseline utility, sex and age	139
TABLE 58 Summary of trials comparing the effects of supervised vs. unsupervised exercise interventions	142
TABLE 59 Studies comparing subacromial corticosteroid injection with no injection or placebo injection	152

List of figures

FIGURE 1 Process map of the GRASP trial progressive exercise intervention	22
FIGURE 2 Guidance for setting level 2 resistance exercises in the GRASP trial	24
FIGURE 3 Participant flow diagram	30
FIGURE 4 Marginal adjusted mean SPADI values from the repeated measures mixed-effects model and associated 99% CIs for the two treatment groups from baseline to 12 months: best-practice advice vs. progressive exercise	43
FIGURE 5 Marginal adjusted mean SPADI values from the repeated measures mixed-effects model and associated 99% CIs for the two treatment groups from baseline to 12 months: injection vs. no injection	44
FIGURE 6 Marginal adjusted mean SPADI pain values from the repeated measures mixed-effects model and associated 95% CIs for the two treatment groups from baseline to 12 months: best-practice advice vs. progressive exercise	46
FIGURE 7 Marginal adjusted mean SPADI function values from the repeated measures mixed-effects model and associated 95% CIs for the two treatment groups from baseline to 12 months: best-practice advice vs. progressive exercise	47
FIGURE 8 Marginal adjusted mean SPADI pain values from the repeated measures mixed-effects model and associated 95% CIs for the two treatment groups from baseline to 12 months: injection vs. no injection	49
FIGURE 9 Marginal adjusted mean SPADI function values from the repeated measures mixed-effects model and associated 95% CIs for the two treatment groups from baseline to 12 months: injection vs. no injection	49
FIGURE 10 Subgroup-adjusted SPADI analysis for progressive exercise over 12 months	51
FIGURE 11 Subgroup-adjusted SPADI analysis for injection over 12 months	52
FIGURE 12 The CEAC for the comparison between treatment groups (base-case analysis)	65
FIGURE 13 The BESS diagnostic algorithm	91
FIGURE 14 Injection referral form and treatment log	94
FIGURE 15 Progressive exercise intervention: action planner	97
FIGURE 16 Progressive exercise intervention: exercise diary	98
FIGURE 17 Progressive exercise intervention: level 1 simple shoulder movement exercises	99
FIGURE 18 Progressive exercise intervention: level 2 essential resistance exercises	100

FIGURE 19	Progressive exercise intervention: level 2 optional resistance exercises	101
FIGURE 20	Progressive exercise intervention: level 2 optional resistance exercises	102
FIGURE 21	Best-practice advice intervention: exercise progression ladder	102
FIGURE 22	Best-practice advice intervention: exercise diary	103
FIGURE 23	Best-practice advice intervention: action planner	104
FIGURE 24	Predicted vs. actual recruitment rate per month	107
FIGURE 25	Subgroup-adjusted SPADI analysis for progressive exercise vs. best-practice advice at 8 weeks	121
FIGURE 26	Subgroup-adjusted SPADI analysis for progressive exercise vs. best-practice advice at 6 months	122
FIGURE 27	Subgroup-adjusted SPADI analysis for progressive exercise vs. best-practice advice at 12 months	122
FIGURE 28	Subgroup-adjusted SPADI analysis for injection vs. no injection at 8 weeks	123
FIGURE 29	Subgroup-adjusted SPADI analysis for injection vs. no injection at 6 months	123
FIGURE 30	Subgroup-adjusted SPADI analysis for injection vs. no injection at 12 months	124

List of abbreviations

BESS	British Elbow & Shoulder Society	ISI	Insomnia Severity Index
BNF	<i>British National Formulary</i>	ITT	intention to treat
CACE	complier-average causal effect	MCID	minimally clinically important difference
CEAC	cost-effectiveness acceptability curve	MD	mean difference
CI	confidence interval	NICE	National Institute for Health and Care Excellence
CINHAL	Cumulative Index to Nursing and Allied Health Literature	NIHR	National Institute for Health Research
DMEC	Data Monitoring and Ethics Committee	NMB	net monetary benefit
DVD	digital versatile disc	OCTRU	Oxford Clinical Trials Research Unit
EQ-5D	EuroQol-5 Dimensions	PPI	patient and public involvement
EQ-5D-5L	EuroQol-5 Dimensions, five-level version	PSEQ-2	Pain Self-Efficacy Questionnaire, two-item version
FABQ	Fear Avoidance Belief Questionnaire	PSS	Personal Social Services
FABQ-PA	Fear Avoidance Belief Questionnaire – Physical Activity	QALY	quality-adjusted life-year
GCP	Good Clinical Practice	RDA	return to desired activities
GIT	Global Impression of Treatment	RPE	Rating of Perceived Exertion
GP	general practitioner	SAE	serious adverse event
GRASP	Getting it Right: Addressing Shoulder Pain	SAP	statistical analysis plan
HTA	Health Technology Assessment	SD	standard deviation
ICER	incremental cost-effectiveness ratio	SE	standard error
IQR	interquartile range	SMD	standardised mean difference
		SPADI	Shoulder Pain and Disability Index
		TSC	Trial Steering Committee

Plain English summary

The rotator cuff is a group of muscles and tendons that stabilise the shoulder and allow it to move. Problems with the rotator cuff are very common. Symptoms include pain, which can affect a person's ability to work, sleep well or perform daily tasks. It is not known which treatments work best for shoulder pain, how exactly they should be delivered and whether or not people do better if they are given a steroid injection.

The GRASP (Getting it Right: Addressing Shoulder Pain) trial tested whether or not people with a rotator cuff disorder would do better after a progressive exercise programme (supervised by a physiotherapist over six appointments spread out over 16 weeks) compared with a one-off best-practice advice session with a physiotherapist. The trial also tested whether or not giving a corticosteroid injection in the shoulder before starting either regime would help people recover more. We assessed the cost of delivering these treatments to the NHS.

We recruited 708 people from 20 NHS-based musculoskeletal centres in the UK. People were allocated to one of four treatment groups at random: (1) progressive exercise (six or fewer physiotherapy sessions), (2) best-practice advice (one physiotherapy session), (3) corticosteroid injection then progressive exercise (six or fewer physiotherapy sessions) or (4) corticosteroid injection then best-practice advice (one physiotherapy session). Trial participants were asked to complete a questionnaire that asked about their level of shoulder pain and their ability to perform basic daily tasks before treatment, and then again at 8 weeks and at 6 and 12 months.

Participants' shoulder pain and function improved over time in each of the four treatment groups. The GRASP trial showed that there was no difference between the best-practice advice session with a physiotherapist and the more comprehensive exercise programme. Corticosteroid injection improved people's shoulder pain and function, but only by a small amount and in the short term. No serious side effects were observed during the 12-month follow-up period. Best-practice advice in combination with corticosteroid injection is likely to be most cost-effective to the NHS.

Scientific summary

Background

Shoulder pain is very common, with around 70% of cases due to rotator cuff-related shoulder pain. Despite the widespread use of physiotherapy, there is uncertainty regarding which type of exercise therapy is associated with the best outcomes. There is also uncertainty about the long-term benefits and harms of corticosteroid injection therapy, which is often used in addition to physiotherapy.

Objectives

The GRASP (Getting it Right: Addressing Shoulder Pain) trial assessed (1) if an individually tailored progressive home exercise programme prescribed and supervised by a physiotherapist provided greater improvement in shoulder pain and function over 12 months compared with a best-practice advice session with a physiotherapist supported by high-quality self-management materials; and (2) if subacromial corticosteroid injection provided greater improvement in shoulder pain and function over 12 months compared with no injection.

Methods

Design

This was a pragmatic multicentre superiority randomised controlled trial using a 2 × 2 factorial design. Participants and physiotherapists were not blinded to group allocation.

Setting

Participants were recruited from 20 NHS primary care-based musculoskeletal and related physiotherapy services.

Participants

Adults aged ≥ 18 years with a new episode of shoulder pain (i.e. in the previous 6 months) attributable to a rotator cuff disorder (e.g. cuff tendonitis, impingement syndrome, tendinopathy or rotator cuff tear), as per British Elbow & Shoulder Society guidelines, not currently receiving physiotherapy or being considered for surgery.

Interventions

Participants ($n = 708$) were randomised (March 2017–May 2019) using a centralised computer-generated 1 : 1 : 1 : 1 allocation ratio to one of four interventions: (1) progressive exercise ($n = 174$) (six or fewer physiotherapy sessions), (2) best-practice advice ($n = 174$) (one physiotherapy session), (3) corticosteroid injection then progressive exercise ($n = 182$) (six or fewer physiotherapy sessions) or (4) corticosteroid injection then best-practice advice ($n = 178$) (one physiotherapy session).

Participants randomised to the progressive exercise intervention received up to six individual face-to-face sessions with a physiotherapist over 16 weeks. Participants were provided with a folder containing an advice booklet, an exercise action planner and diary, and instructions on their exercise programme, which was set up in collaboration with their physiotherapist. A resistance band was issued as required. The progressive exercise programme was highly structured, but could be tailored to the needs and preferences of participants.

Participants randomised to the best-practice advice intervention received a single individual face-to-face session with a physiotherapist. Participants were given an advice booklet. The content of the advice in the booklet was the same as that provided for the progressive exercise group, with the exception of a different exercise programme. Participants were given a simple set of self-guided exercises, at least one level of resistance band and access to an exercise video (available on a website and a digital versatile disc), which could be progressed and regressed, depending on their capability. The exercises were designed using similar concepts to the progressive exercise intervention, such as increased resistance, but these were a simpler range. An exercise diary was provided in addition to an exercise action planner that was simpler than the one provided to those in the progressive exercise group.

Follow-up

Measurements for the primary and secondary outcomes were collected by postal questionnaires at 8 weeks and at 6 and 12 months after randomisation. Telephone follow-up was used to contact those who did not respond or fully complete the returned questionnaire.

Clinical outcomes and analysis

The primary outcome was the mean difference in Shoulder Pain and Disability Index (SPADI) total score over 12 months. The scale is from 0 to 100, with higher values representing worse pain. Secondary outcomes were the pain and function SPADI subdomains, health-related quality of life (assessed using the EuroQol-5 Dimensions, five-level version), sleep disturbance, fear avoidance, pain self-efficacy, return to activity, global impression of treatment, health resource use, out-of-pocket expenses and work disability. Prespecified subgroup analyses included age, sex, smoking status, higher baseline SPADI score (≥ 50) and higher baseline pain self-efficacy score (≥ 8). The planned sample size was 704 participants, assuming 20% loss to follow-up at 12 months, and based on 90% power and 1% two-sided statistical significance to detect a minimally clinically important difference of eight points on the SPADI total scale. The primary analysis was intention to treat. The two main effect comparisons for this 2×2 factorial trial were (1) progressive exercise compared with best-practice advice to determine the efficacy of progressive exercise and (2) subacromial corticosteroid injection compared with no injection to determine the efficacy of subacromial corticosteroid injection. The presence of an interaction effect was formally investigated before testing their effects on the primary outcome. The difference in SPADI score between the two intervention groups was estimated overall and at each data collection time point using a repeated measures linear mixed-effects regression model adjusted for baseline and other covariates.

Economic analysis

The cost-utility of interventions was evaluated from an NHS and Personal Social Services perspective, using a within-trial intention-to-treat analysis. Quality-adjusted life-years were estimated from data collected from the EuroQol-5 Dimensions, five-level version, at baseline, 8 weeks and 6 and 12 months. Costs were estimated for each participant over 12 months of follow-up based on patient-reported use of health-care services attributable to their rotator cuff disorder. The cost of delivering each intervention, including physiotherapists' training, materials, delivery of the progressive exercise and advice sessions, and corticosteroid injections, was also estimated.

Results

The mean age of participants was 55.5 (standard deviation 13.1) years, 49.3% of participants were female and the mean duration of symptoms was 4 (interquartile range 3–6) months. Intervention groups were well matched in terms of demographic data and clinical and generic health-related quality-of-life measures. Overall, 92% (324/352) of participants randomised to the best-practice advice intervention and 95% (339/356) of participants allocated to progressive exercise either partially or fully completed the intervention. High levels of protocol adherence were achieved across all intervention groups. Follow-up data were obtained for 87% (618/708), 87% (615/708) and 91% (641/708) of participants at 12 months, 6 months and 8 weeks, respectively.

The overall mean baseline SPADI score was 54.1 (standard deviation 18.5), with higher baseline levels of shoulder pain (mean SPADI pain subscale score 63.9; standard deviation 17.1) than impaired function (mean SPADI function subscale score 44.3; standard deviation 22.1). There was an overall improvement in SPADI score in each of the four groups from baseline over time, representing a 32.2-point improvement (standard deviation 23.9 points) on the SPADI scale [with a SPADI score of 21.9 (standard deviation 23.4) at 12 months]. There was no evidence of an interaction effect and so results were analysed for the two main effect comparisons.

Clinical results

Over 12 months, there was no evidence of a difference in the SPADI scores between the progressive exercise intervention and best-practice advice intervention (adjusted mean difference between groups over 12 months -0.66, 99% confidence interval -4.52 to 3.20); nor was there evidence of a difference when analysed at the 8-week and 6- and 12-month time points (adjusted mean difference at 12 months -3.10, 99% confidence interval -7.85 to 1.64). There was also no difference between groups for secondary outcome measures, with the exception of progressive exercise, which resulted in an improvement in patient-reported global impression of treatment over the 12 months (adjusted mean difference over 12 months 0.38, 95% confidence interval 0.10 to 0.66) and at the 6- and 12-month time points.

Over 12 months, there was also no evidence of a difference in SPADI scores between the injection and the no injection groups (adjusted mean difference over 12 months -1.11, 99% confidence interval -4.47 to 2.26). There was a small difference in SPADI scores at 8 weeks (adjusted mean difference at 8 weeks -5.64, 99% confidence interval -9.93 to -1.35) in favour of the injection group, but not at the 6- and 12-month time points (adjusted mean difference at 12 months 1.93, 99% confidence interval -2.41 to 6.27). There was no difference between groups for secondary outcome measures, with the exception of the injection group at 8 weeks, which resulted in a small improvement in shoulder pain, shoulder function, sleep disturbance, return to desired activities and global impression of treatment.

Prespecified subgroup analysis showed that the effect of injection was stronger at 8 weeks in people with a higher baseline SPADI score (adjusted mean difference at 8 weeks -9.67, 99% confidence interval -15.37 to -3.97) than in those who received injections but had a lower baseline SPADI score (adjusted mean difference at 8 weeks -0.36, 99% confidence interval -8.87 to 6.16). No differences were observed for other prespecified subgroup analyses. No serious adverse events were associated with treatment interventions.

Economics results

The base-case cost-effectiveness analysis showed that, over the 12-month period, participants in the best-practice advice treatment group gained, on average, 0.74 quality-adjusted life-years (95% confidence interval 0.710 to 0.763) and an NHS cost of £195. Adding progressive exercise to best-practice advice resulted in a gain of an additional 0.019 quality-adjusted life-years ($p = 0.220$), compared with best-practice advice alone, at an additional cost of £52 ($p = 0.247$). Adding corticosteroid injection to best-practice advice resulted in a gain of 0.021 quality-adjusted life-years ($p = 0.184$), compared with best-practice advice alone, and increased the cost by £10 per participant ($p = 0.747$). At a £20,000 per quality-adjusted life-year ceiling ratio, best-practice advice plus injection was found to have a 54.93% probability of being best value for money of the four treatments evaluated in the trial. Best-practice advice plus injection cost £475.59 per quality-adjusted life-year gained compared with best-practice advice alone, and strongly dominated progressive exercise alone and progressive exercise plus injection, being less costly and accruing more quality-adjusted life-years. Sensitivity analyses assuming additive effects, taking a societal perspective and varying the cost of training physiotherapists, confirmed the base-case conclusion that best-practice advice plus injection is expected to be best value for money at a ceiling ratio of £20,000 per quality-adjusted life-year, although there was substantial uncertainty around this conclusion in all analyses.

Conclusion

Implications for health care

The GRASP trial shows that the progressive exercise intervention was not superior to a best-practice advice session with a physiotherapist. Subacromial corticosteroid injection improved shoulder pain and function at 8 weeks, but provided modest short-term benefit only, with the greatest benefit being in those with higher levels of pain and functional impairment. Best-practice advice in combination with corticosteroid injection has a 54.93% probability of being the most cost-effective intervention for the NHS.

Recommendations for research

There is a case to extend follow-up to assess long-term outcomes, as some participants still reported ongoing pain and impaired shoulder function at 12 months. There is a need to better understand the natural history of rotator cuff disorders, including whether symptoms resolve over an extended period or persist in the longer term. Longer-term follow-up would also address concerns regarding later surgery and corticosteroid injection, and potential long-term harm due to its possible effects on tendon structure.

Trial registration

This trial is registered as ISRCTN16539266 and EudraCT 2016-002991-28.

Funding

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 25, No. 48. See the NIHR Journals Library website for further project information.

Chapter 1 Introduction

Scientific background

Problem and diagnosis

Shoulder pain is common. Annually, around 1% of adults aged > 45 years in primary care present with a new episode of shoulder pain, accounting for 2.4% of all general practitioner (GP) consultations in the UK.¹ This is most commonly attributed to the rotator cuff, which causes around 70% of cases.² The rotator cuff is a group of four muscles and their tendons/attachments. The rotator cuff actively moves and stabilises the shoulder joint, enabling a wide range of efficient movements at the shoulder. Disorders of the rotator cuff can be associated with substantial, persistent disability (e.g. being unable to dress independently) and pain. Rotator cuff disorders can persist for long periods. Up to half of those who present for treatment, particularly older people, continue to have pain and/or functional disturbance for up to 2 years.³

The majority of shoulder pain is managed in primary care or in musculoskeletal interface services by physiotherapists and GPs. Musculoskeletal interface services are led by specialist practitioners who manage patients with musculoskeletal disorders through assessment, treatment, investigation and by referring to appropriate health-care professionals. Musculoskeletal interface services aim to promote more community-based management options for patients, rather than traditional hospital-based secondary care, and provide a more efficient, cost-effective and sustainable model for dealing with high-volume conditions. Treatments for rotator cuff disorders aim to improve pain and function. Standard primary care options include rest, advice, analgesia, non-steroidal anti-inflammatory drugs, physiotherapy and corticosteroid injections.^{4,5} However, usual care can be highly variable and there are no National Institute for Health and Care Excellence (NICE) clinical guidelines.

A diagnostic algorithm² has been developed as part of the NICE-accredited standards developed by the British Elbow & Shoulder Society (BESS) and other professional bodies (e.g. the Royal College of Surgeons, the Chartered Society of Physiotherapy and the British Orthopaedic Association) to confirm when a diagnosis of rotator cuff disorder is highly likely, based on a patient's history and simple shoulder tests⁴ (see *Appendix 1, Figure 13*). The recommended tests have been selected with primary care application in mind,⁶ although they do require a reasonable degree of clinical skill. Imaging is not recommended in primary care because of the poor fit between structural change and symptomatic presentation.⁷ We have used the BESS algorithm (see *Appendix 1, Figure 13*) to define the entry criteria for the GRASP (Getting it Right: Addressing Shoulder Pain) trial, thereby ensuring that the trial is consistent with national guidance.

Explanation of rationale

Problems associated with rotator cuff disorders can seriously affect patient health and well-being. The prevalence of shoulder complaints in the UK is estimated at around 14%,⁸ increasing with age¹ and highest in those aged ≥ 60 years. Shoulder problems are a significant cause of morbidity and disability in the general population and have a significant socioeconomic burden, as they affect an individual's capacity to work and ability to perform daily tasks and social activities. They have a significant impact on primary care services. The average cost per patient with a musculoskeletal condition in the NHS is £461.13 per head per year,⁹ with wide geographical variability. The estimated cost to the UK economy is £7.4B per year.

The NHS currently invests considerable amounts of money in unproven therapies and corticosteroid injections. One common treatment prescribed for rotator cuff disorders is corticosteroid injection, which typically costs £47–332, depending on the mode of delivery (the cheapest of which is by a physiotherapist without ultrasound guidance). In comparison, a set of six physiotherapy sessions costs approximately £206 and an assessment and advice session costs £45 (see *Chapter 5*). It is important for the NHS to develop cost-effective, pragmatic methods for dealing with high-volume conditions. Rotator cuff disorders may be self-limiting if they are managed effectively in primary care, as patients can regain function and pain can be reduced. However, the consequences of poor initial management are an increased likelihood of recurrent or persistent problems in older age and the need for surgical intervention.⁴

We planned to conduct a large, well-powered randomised controlled trial, using a factorial design, to co-test two interventions commonly used in the management of rotator cuff disorders in primary care: (1) progressive exercise delivered by a physiotherapist and (2) corticosteroid injection. We used a best-practice advice session with a physiotherapist and no injection as the respective comparators. The interventions tested used current patient pathways for people with a rotator cuff disorder. We wanted to assess which of these interventions, or combination of interventions, are most clinically effective and cost-effective for the NHS. The primary outcome for the trial is shoulder pain and function, which is assessed using the well-validated Shoulder Pain and Disability Index (SPADI).^{10,11} The SPADI is a tool that was developed to measure current shoulder pain and disability in an outpatient setting.

Choice of comparators

Exercise interventions

In designing the trial, we looked at existing evidence regarding the choice of comparator interventions. There is promising evidence from small, short-term trials that physiotherapist-prescribed exercise is effective.^{12–14} However, there is a lack of evidence regarding its long-term clinical effectiveness and cost-effectiveness,^{12–14} despite the widespread provision of physiotherapy for these conditions. There is also uncertainty about which types of exercise and delivery mechanisms (e.g. supervised or home based) are associated with the best outcomes.^{12,13,15–17} This evidence is limited by problems in study design and choice of comparators.¹³ There are also competing ideologies around which exercise programmes should be considered to ensure a worthwhile trial. Resistance training to improve muscular strength, whether supervised or home based, has been identified as a core component of exercise for rotator cuff disorders, although there is no evidence that any specific programme is superior.^{18,19} Manipulation of the exercise volume and intensity is achieved by varying the frequency, load, number of sets, repetitions and rest intervals.²⁰ A trial of strength training found that duration, specificity of exercises, progression criteria and individualisation (i.e. adjusting the programme to suit each participant) were also important.²¹ We did not consider other forms of physiotherapy-led interventions, such as electrotherapy, acupuncture, soft tissue mobilisation, manipulation or stratified care, because of the lack of evidence of their efficacy.^{22,23}

Little attention has been paid to the need for behavioural frameworks to enhance adherence to advice and exercise programmes and to tackle pain beliefs and behaviour in this context.²⁴ Non-adherence to physiotherapy treatment is estimated to be up to 70%.²⁵ In a large trial of exercise for lower back pain that did not include a behavioural component to increase exercise adherence, only half of the participants attended the minimum number of treatment sessions.²⁶ Risk factors for low adherence include low levels of physical activity, low self-efficacy, depression, anxiety, poor social support and greater perceived barriers to exercise.²⁴ Some of these risk factors are modifiable in the context of a physiotherapy intervention. We have previous expertise in this area²⁷ and planned to include a behavioural component as part of the progressive exercise intervention.

Corticosteroid injection

There is systematic review evidence that, in comparison with placebo, corticosteroid injections have a short-term benefit in the shoulder, as in other areas of the body. However, there are some concerns about the longer-term benefits and harms of corticosteroid injections.^{28–30} The combination of injection and physiotherapy has intuitive appeal, with some evidence of an additive, but not interactive, effect in the short term (3–4 months).^{30–33} The longer-term benefits of injections require further study. We planned to use a no-injection comparison, as finding an inert robust placebo is challenging and, given the existing evidence,^{28–30} we believed that it was unethical and undesirable to progress a placebo arm in a large Phase III trial. In our study based in NHS musculoskeletal services, extended-scope physiotherapists typically deliver the corticosteroid injections. This is increasingly common practice in the NHS, where therapists undertake additional post-registration training to deliver injections, working within a local Patient Group Direction and/or becoming qualified non-medical independent prescribers.³⁴ Although the use of ultrasound to guide injections in primary care has become increasingly common, evidence from the SUPPORT (SUBacromial imPingement syndrome and Pain: a randomised controlled trial Of exeRcise and injeCtion) trial³⁵ and other trials³ have demonstrated that it is no more effective than standard injection practice. Ultrasound guidance also substantially increases the cost and reduces the practicality of injection therapy. Therefore, we planned to deliver injections without the use of ultrasound guidance.

Objectives

The aim of the GRASP trial was to assess the clinical effectiveness and cost-effectiveness of individually tailored progressive exercise compared with best-practice advice, with or without corticosteroid injection, in patients with a new episode of a rotator cuff disorder. The primary objectives were to assess the following:

- whether or not an individually tailored progressive exercise programme, including behavioural change strategies and led by a physiotherapist, provides greater improvement in shoulder pain and function over the 12 months post randomisation compared with a best-practice advice session with a physiotherapist supported by high-quality materials
- whether or not subacromial corticosteroid injection provides greater improvement in shoulder pain and function over the 12 months post randomisation compared with no injection.

The secondary objectives of the GRASP trial were to investigate if there were any differences at 8 weeks and at 6 and 12 months in shoulder pain, shoulder function, health-related quality of life, fear avoidance, pain self-efficacy, sleep disturbance, return to desired activities (RDA) (including work, social life and sport activities), patients' global impression of change, adherence to exercises, use of medication (prescribed and over the counter), time off work, health resource use (consultation with primary and secondary care) and additional out-of-pocket expenses.

A parallel within-trial health economic analysis was also conducted.

Chapter 2 Methods

Parts of this chapter have been reproduced with permission from Hopewell *et al.*³⁶ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>. The text below includes minor additions and formatting changes to the original text.

Parts of this chapter have been reproduced with permission from Marian *et al.*³⁷ This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Trial design

The GRASP trial protocol³⁶ and the statistical analysis plan (SAP) have been reported previously.³⁷

The GRASP trial is a 2 × 2 factorial trial, which was used to test the following four physiotherapy-led interventions:

1. Progressive exercise programme (i.e. an individually tailored, progressive, home exercise programme prescribed and supervised by a physiotherapist, involving up to six face-to-face sessions over 16 weeks).
2. best-practice advice (i.e. one face-to-face session with a physiotherapist and a home exercise programme supported by high-quality self-management materials).
3. Progressive exercise programme (as described above) preceded by a subacromial corticosteroid injection.
4. best-practice advice session (as described above) preceded by a subacromial corticosteroid injection.

A parallel within-trial health economic analysis was also conducted.

The factorial design allowed two primary comparisons, based on the assumption that there was no interaction effect: (1) progressive exercise programme compared with best-practice advice session and (2) subacromial corticosteroid injection compared with no injection.

Internal pilot

An internal pilot was included as an integral part of the GRASP trial design, which mirrored the procedures and logistics undertaken in the main GRASP trial. The purpose of the internal pilot was to test and refine the recruitment process and explore treatment acceptability. The decision to progress to the main trial was made in collaboration with the Trial Steering Committee (TSC) and the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme based on a predefined progression criterion: reaching the target recruitment rate (42 participants) within the specified time frame (4 months). Data from the internal pilot trial contributed to the final analysis, as there were no substantive changes in design or delivery of the trial interventions.

Study setting

The GRASP trial was conducted across 20 primary care-based musculoskeletal services and their related physiotherapy services in the NHS. These services treat people with a range of musculoskeletal conditions and are run by specialist practitioners, including extended-scope physiotherapists, GPs with a specialist interest in musculoskeletal conditions, clinical nurse specialists and, in some instances, rheumatologists and orthopaedic consultants. Sites were chosen so that they reflected a range of settings (urban and rural) and were able to deliver the trial interventions. The local principal investigator was responsible for the conduct of the research at their site.

Participants

Participants were recruited if referred by their GP or physiotherapist for treatment of a new, but not necessarily first, episode of shoulder pain attributable to a rotator cuff disorder. Participants were predominantly seeking treatment for one shoulder. People who self-referred directly to the musculoskeletal service were also assessed for eligibility, as the typical route of referral varied across services. The participants did not routinely undergo diagnostic imaging, such as magnetic resonance imaging or ultrasound, as a requirement of the trial, as this is generally not recommended in primary care.

Inclusion criteria

- Men and women aged ≥ 18 years.
- A new episode of shoulder pain (i.e. within the previous 6 months) attributable to a rotator cuff disorder (e.g. cuff tendonitis, impingement syndrome, tendinopathy or rotator cuff tear), using the diagnostic criteria set out in the BESS guidelines⁴ (see *Appendix 1, Figure 13*).
- Not currently receiving physiotherapy.
- Not being considered for surgery.
- Able to understand spoken and written English.

Exclusion criteria

- Participants with a history of recent significant shoulder trauma (e.g. dislocation, fracture or full-thickness tear requiring surgery).
- Those with a neurological disease affecting the shoulder.
- Those with other shoulder disorders (e.g. inflammatory arthritis, frozen shoulder or glenohumeral joint instability) or with red flags consistent with the criteria set out in the BESS guidelines.⁴
- Those who had received corticosteroid injection or physiotherapy for shoulder pain in the previous 6 months.
- Those with contraindications to corticosteroid injections.

Recruitment

Recruitment of participants, screening and eligibility assessment

Potentially eligible participants were identified by clinicians in NHS musculoskeletal services. People attended their clinic appointments in accordance with standard NHS procedures. The treating practitioner in the musculoskeletal services undertook a clinical assessment according to their usual practice. If a patient fulfilled the criteria for a rotator cuff disorder, they were assessed to see whether or not they met the GRASP trial eligibility criteria. Patients were provided with a copy of the participant information sheet and asked if they wished to be considered for the trial. Those who met the eligibility criteria and wanted to participate were approached for informed consent. Participants who did not meet the eligibility criteria or who did not wish to participate received standard NHS treatment. We recorded anonymous information on the age and sex of those who declined to participate so that we could assess the generalisability of those recruited. Reasons for declining were also recorded.

Informed consent and baseline assessment

After participants had been assessed for eligibility, informed consent for participation in the GRASP trial was obtained by a research facilitator at the site who was trained in Good Clinical Practice (GCP). The following was explained to the participant: the exact nature of the study; what it would involve for the participant, including expectations that the participant would be willing and able to attend sessions to receive the study intervention; and any risks involved. The potential participant was provided with a patient information sheet and was given the opportunity to discuss issues and ask questions. In most cases, the process of obtaining informed consent took place during the initial musculoskeletal clinic appointment. Some participants required a second research appointment because they required more time to consider the study or because of local resources at site. Participants were then asked to complete a baseline assessment questionnaire that recorded simple demographic information and baseline measurements for the primary and secondary outcomes (Table 1).

TABLE 1 Outcomes measured and time points assessed

Outcome	Measurement	Time point
Demographic	Age, sex, height, weight, ethnicity, marital status, smoking, date of rotator cuff diagnosis, duration of symptoms, hand dominance, affected shoulder, current work status, level of education, place of residence, household income and state benefits	Baseline
Primary		
Pain and function	SPADI ^{10,11} 13-item total scale	Baseline, 8 weeks, 6 months, 12 months
Secondary		
Pain	SPADI ^{10,11} five-item subscale	Baseline, 8 weeks, 6 months, 12 months
Function	SPADI ^{10,11} eight-item subscale	Baseline, 8 weeks, 6 months, 12 months
Health-related quality life	EQ-5D-5L score ³⁸	Baseline, 8 weeks, 6 months, 12 months
Psychological factors	FABQ-PA five-item subscale ³⁹ and PSEQ-2 ⁴⁰	Baseline, 8 weeks, 6 months, 12 months
Sleep disturbance	ISI ⁴¹	Baseline, 8 weeks, 6 months, 12 months
GIT	Patient-rated Likert scale ⁴²	8 weeks, 6 months, 12 months
RDA	Patient-reported RDA, including work, social life and sport activities	Baseline, 8 weeks, 6 months, 12 months
Exercise adherence	Patient-reported adherence to exercise	8 weeks, 6 months, 12 months
Medication usage	Prescribed and over-the-counter medications, additional steroid injection	8 weeks, 6 months, 12 months
Work disability	Sick leave (days)	8 weeks, 6 months, 12 months
Health-care use	NHS outpatient and community services (e.g. GP, additional physical therapy), NHS inpatient and day case (e.g. radiography, MRI) and private health-care services	8 weeks, 6 months, 12 months
Out-of-pocket expenses	Patient-related out-of-pocket expenses recording form	8 weeks, 6 months, 12 months

EQ-5D-5L, EuroQol 5 Dimensions, five-level version; FABQ-PA, Fear Avoidance Belief Questionnaire – Physical Activity; GIT, Global Impression of Treatment; ISI, Insomnia Severity Index; MRI, magnetic resonance imaging; PSEQ-2, Pain Self-Efficacy Questionnaire, two-item version.

Randomisation

Consented participants were randomised to one of the four physiotherapy-led intervention groups (1 : 1 : 1 : 1) (see *Trial design*), using a centralised computer randomisation service RRAMP (Registration/Randomisation and Management of Product; URL: <https://rramp.octru.ox.ac.uk>) provided by the Oxford Clinical Trials Research Unit (OCTRU). This was undertaken directly by the research facilitator at the site or by the research facilitator contacting the central randomisation centre by telephone, who then accessed the system on their behalf, depending on the facilities available at the study sites. Randomisation was computer generated and stratified by centre, age (18–35 years, > 35 years) and sex, using a variable block size to ensure that participants from each study site had an equal chance of receiving each intervention.

Blinding

Both the physiotherapists delivering the intervention and the study participants were informed of treatment allocation at the initial appointment. Because of the nature of the interventions being tested, it was not possible to blind them to the treatment allocation once treatment allocation was revealed. Where practical, team members were blinded until after data analysis was complete. Trial statisticians had access to treatment assignment during the study for the purposes of data monitoring and safety. Data entry personnel entered data from anonymised questionnaires, which included some details on treatments received.

Interventions

Full details of the exercise interventions are described in *Chapter 3* and have been reported previously.⁴³ A summary is provided here for continuity.

Subacromial corticosteroid injection

The subacromial corticosteroid injection was delivered prior to the progressive-exercise or best-practice advice intervention. The injections were predominantly carried out by extended-scope physiotherapists with appropriate post-registration qualifications in injection therapy who worked within a local patient group directive or as non-medical independent prescribers.³⁴ This reflects an increasingly common practice in the NHS and ensured that the injections were delivered in the most cost-effective manner possible. The corticosteroid injection was given as per its marketing authorisation and in accordance with its normal indication and therapeutic dosage.⁴⁴

The corticosteroid and local anaesthetic were given together in one injection or separately in two injections, depending on local treatment protocols at sites. The corticosteroid injected was either methylprednisolone acetate (Depo-Medrone®, Pfizer Ltd, Walton Oaks, UK; up to 40 mg) or triamcinolone acetonide (Kenalog™, Bristol-Myers Squibb, Mulhuddart, Ireland; up to 40 mg), as per local treatment protocols. These are the two routinely injected corticosteroids for shoulder pain. There is no clear evidence that either corticosteroid is more effective than the other.³⁰ The local anaesthetic was either 1% lidocaine (up to 5 ml) or 0.5% bupivacaine hydrochloride (up to 10 ml). We selected sites that adhered to these prescribing boundaries. The choice and dose of corticosteroid, local anaesthetic (including volume) and the injection site were recorded for each participant on a trial injection data collection form (see *Appendix 2, Figure 14*).

Participants were advised to take care and avoid heavy lifting for 24–48 hours after the injection. Appointments were co-ordinated so that participants typically received their injection within 10 days of randomisation. Very occasionally, a second injection was given after 6 weeks in accordance with the trial protocol (but within 16 weeks of the patient being randomised), but this injection was administered to only those patients who received good initial benefit from their first injection and who requested further pain relief to facilitate their exercises. Any participants who received a second injection had the dose, drug and date of administration recorded on a trial injection data collection form.

Progressive-exercise intervention

Participants randomised to the progressive-exercise intervention received up to six individual face-to-face sessions with a physiotherapist over 16 weeks. These sessions included a behavioural component to encourage adherence to the exercises. A similar rationale has been used to good effect in other trials.^{21,45} We chose the number of sessions, spread over this time, to enable progression of the intensity of exercise and provide a sufficient amount of time for a physiological response in the neuromuscular system.⁴⁶ Appointments were co-ordinated so that participants typically started their first exercise session within 14–28 days of randomisation, as per local appointment availability. The initial session lasted up to 60 minutes for assessment and setting up the home exercise programme, followed by up to five 20- to 30-minute follow-up sessions. Participants were provided with a folder containing an advice booklet, an exercise action planner and diary, and instructions on their exercise programme set up in collaboration with their physiotherapist. A resistance band was issued as required. The physiotherapists recorded the number of treatment sessions attended by each participant. The intervention was designed to support participants through a progressive dose of exercises and optimise adherence to the home exercise plan. The progressive-exercise programme was highly structured, but could be tailored to the needs and preferences of participants, with the aim of helping them achieve their rehabilitation goals. Importantly, the intervention could be delivered within the current NHS commissioning paradigm.⁴⁷

Best-practice advice intervention

Participants randomised to the best-practice advice intervention received a single, individual face-to-face session with a physiotherapist, lasting up to 60 minutes. Again, appointments were co-ordinated so that participants typically started their exercise session within 14–28 days of randomisation, as per local appointment availability. After a comprehensive shoulder assessment, participants were given an advice booklet. The content of the advice in the booklet was the same as that provided for the progressive-exercise group, with the exception of the different exercise programme. An exercise diary was also provided, along with a simplified version of the exercise action planner (see *Chapter 3*). Tailored education, reassurance and self-management exercise advice, including advice on pain management and activity modification, was offered. Participants were also given a simple set of self-guided exercises, including at least one level of resistance band and an exercise video [available on a website and digital versatile disc (DVD)], which could be progressed and regressed, depending on their capability. The exercises were designed using similar concepts to those of the progressive-exercise intervention, such as increased resistance, but with a simpler range of exercise options that were not supervised.

The best-practice advice intervention was selected as the comparator because it is consistent with current clinical practice guidelines regarding the self-management advice that should be provided to people with rotator cuff disorders.^{4,5} In addition, people may find a single advice session and DVD preferential to a course of face-to-face physiotherapy sessions, as they do not have to come back to the hospital or clinic, take time off work or make carer arrangements.

Concomitant care

All participants were advised that they could take over-the-counter analgesia as required (e.g. paracetamol with or without codeine, or an oral non-steroidal anti-inflammatory drug) in accordance with the BESS guidelines.⁴ Participants could seek other forms of treatment during the follow-up period, but were informed that they should use usual routes (predominantly NHS referral) to do so. Additional treatments, including contact with their GP or other health professional, changes in medication, use of physical treatment and alternative therapies, were recorded as a treatment outcome through the patient questionnaires at 8 weeks, 6 months and 12 months post randomisation.

Training and monitoring of intervention delivery

All physiotherapists delivering study interventions, progressive exercise and best-practice advice had access to a comprehensive intervention manual and were required to have undertaken trial-specific training by a GRASP trial research physiotherapist. A rigorous quality control programme was also conducted to ensure intervention fidelity (see *Chapter 3*).

Outcomes

Primary outcome

The primary outcome was shoulder pain and function over the 12 months post randomisation measured using the SPADI,^{10,11} which was developed to measure current (i.e. in the last week) shoulder pain and disability in an outpatient setting. The SPADI scale is based on 13 questions, all scored on a 0–10 scale, on which 10 is the worst score. In addition, the SPADI scale has a five-item pain subscale and an eight-item disability subscale. The subscale items are summed and converted to a 0–100 scale, where a higher value denotes more pain and/or disability. A systematic review of outcome measurement sets for shoulder pain trials showed that SPADI is the most commonly used measure to assess pain and disability.⁴⁸ The SPADI scale has good psychometric properties, is used widely in the field and can be completed using a postal questionnaire.

Secondary outcomes

Secondary outcomes (see *Table 1*) were subdomains of the SPADI, which are pain measured using the SPADI five-item pain subscale^{10,11} and function measured using the SPADI eight-item disability subscale;^{10,11} health-related quality of life, measured using the well-validated EuroQol 5 Dimensions, five-level version (EQ-5D-5L) score;³⁸ psychological factors, measured using the Fear Avoidance Belief Questionnaire – Physical Activity (FABQ-PA) five-item subscale³⁹ and the Pain Self-Efficacy Questionnaire, two-item version (PSEQ-2);⁴⁰ sleep disturbance, measured using the Insomnia Severity Index (ISI);⁴¹ patient global impression of change;⁴² RDA, including work, social life and sport activities; patient adherence to exercise; any serious adverse events (SAEs); health resource use, including consultation with primary and secondary care, prescribed and over-the-counter medication use, additional physiotherapy or injection use, and hospital admission; additional out-of-pocket expenses; and work absence (i.e. number of sickness days).

The EQ-5D-5L³⁸ is a validated, generic health-related quality-of-life measure comprising five dimensions, each with a five-level answer possibility and a health thermometer scale. The EQ-5D-5L can be used to report health-related quality of life in each of the five dimensions and each combination of answers can be converted into a health utility score, where 1 represents perfect health and 0 indicates health states equal to death. The health thermometer scale (EuroQol visual analogue scale) takes values between 0 and 100, where 0 represents worst imaginable health and 100 best imaginable health. It has good test–retest reliability and gives a single preference-based index value for health status that can be used for broader cost-effectiveness comparative purposes.

The Fear Avoidance Belief Questionnaire (FABQ)³⁹ is a validated measure of fear-avoidance behaviour. The FABQ-PA is a subscale of the FABQ that measures fear-avoidance beliefs about physical activity using five items scored on a 0 (strongly disagree) to 6 (strongly agree) scale. The total score range for FABQ-PA is 0–24, with higher scores representing greater levels of fear-avoidance behaviour.

The PSEQ⁴⁰ is a well-established 10-item measure of pain self-efficacy (i.e. a belief in one's ability to carry out activities despite pain). PSEQ-2 is a two-item, short measure of pain self-efficacy.⁴⁰ The two items reflect the confidence in ability to work and lead a normal life despite the pain, on a 0 (not at all confident) to 6 (completely confident) scoring scale. The total PSEQ-2 score is summed from the two items, giving a range from 0 to 12, with higher values representative of higher confidence levels despite the pain.

The ISI⁴¹ is a brief self-report measure of a patient's perception of their insomnia, targeting the subjective symptoms and consequences of insomnia, as well as the degree of concerns or distress caused by those difficulties. The ISI has seven items rated on a 0–4 scale and the total score is a summation of these

items, with a value ranging from 0 to 28. Higher scores are suggestive of more severe insomnia. A detailed interpretation of the ISI total score is as follows:

- A score of 0–7 indicates no clinically significant insomnia.
- A score of 8–14 indicates subthreshold insomnia.
- A score of 15–21 indicates clinical insomnia of moderate severity.
- A score of 22–28 indicates severe clinical insomnia.

The Global Impression of Treatment (GIT)⁴² is a simple method of measuring change in health status, with respect to shoulder problems, by charting self-assessed clinical progress on an 11-point scale that ranges from –5 (very much worse) to 5 (completely recovered). Psychometric properties include a minimum detectable change of 0.45 points and a minimally clinically important difference (MCID) of 2 points.

Return to desired activities is a self-reported outcome that aims to measure physical function during social life, recreational activities and work. RDA is an adapted version of the Disabilities of the Arm, Shoulder and Hand (QuickDASH), using three questions with a five-point Likert scale answer option, with lower scores indicating better function.

Other secondary outcomes (including medication usage, work disability, health-care use and out-of-pocket expenses) are analysed separately as part of a health economics analysis (see *Chapter 5*).

Adverse events

Expected adverse events occurring as a result of the trial intervention(s) were not recorded as part of the trial. Participants were provided with information on the potential adverse events resulting from exercise and corticosteroid injection (if applicable) as part of their treatment, including what they should do if they experienced an adverse event, as would happen as part of standard NHS procedures. SAEs (defined as any medical occurrence that could result in death, is life-threatening or results in hospitalisation or incapacity) were considered highly unlikely to occur as a result of either the exercise or the corticosteroid injection therapy delivered in this trial. However, if a SAE arose in the period from the participant's enrolment in the trial to their final visit for their allocated intervention, standard procedures for recording and reporting SAEs applied.

Follow-up data collection

Measurements for the primary and secondary outcomes were all patient reported and collected using postal questionnaires at 8 weeks, 6 months and 12 months after randomisation (see *Table 1*). Participants were asked to complete the questionnaire and return it to the GRASP study team in the prepaid envelope. For those who did not respond to the initial questionnaire, at least one postal reminder was sent. A web-based version of the questionnaire, and telephone and e-mail follow-up were used to contact those who did not respond to the postal questionnaire. Telephone and e-mail follow-up was also used to collect a core set of questionnaire items if these had not been fully completed on the returned questionnaire. To maximise response rates for the 12-month follow-up, a small monetary incentive (in the form of a gift voucher) was sent to all participants along with their 12-month follow-up questionnaire as a thank you for the time and effort involved.

Data management

All data were processed according to the General Data Protection Regulation 2018 and all documents were stored safely in confidential conditions.⁴⁹ All trial-specific documents, except for the signed consent form and follow-up contact details, referred to the participant using a unique study participant number/code and not by name. Participant identifiable data were stored separately from study data and in accordance with local procedures. All trial data were stored securely in offices that were accessible using a swipe card by the central co-ordinating team staff and authorised personnel only.

Statistical methods

Sample size

The target sample size for the trial was 704 randomised participants (176 in each treatment arm). This sample size was based on 90% power and 1% two-sided statistical significance to detect a minimally clinically important between-group difference of 8 points on the SPADI total scale,¹⁰ assuming a baseline standard deviation (SD) of 24.3 (chosen as representative of the patient population⁵⁰). This difference is the equivalent of a standardised effect size of 0.33, which required a sample size of 550 participants [Power Analysis and Sample Size 13 NCSS Statistical Software Kaysville, UT, USA; URL: www.ncss.com (accessed 20 May 2021)]. Allowing for a potential loss to follow-up of 20% at 12 months inflated the sample size to 688. We further inflated the sample size to take into account the potential for a small clustering by physiotherapist effect in the progressive-exercise intervention group. We used an interclass correlation (ICC) of 0.001, based on our experience with individually tailored physiotherapy interventions⁵¹ and the expectation that each physiotherapist would treat approximately 20 participants in the progressive-exercise intervention group. This led to an inflation of:

$$f = 1 + (m - 1) \times \text{ICC} = 1 + (20 - 1) \times 0.001 = 1.019, \quad (1)$$

and increased the sample size to the total of 704 participants.

This sample size was based on the assumption that there was no interaction effect and was powered for the two main effect comparisons: (1) progressive exercise compared with best-practice advice and (2) corticosteroid injection compared with no injection. However, this number of participants also provided 80% power and 5% two-sided significance to detect an interaction standardised effect size of 0.35, if an interaction effect did exist. The interaction effect was tested before the main effect comparisons were undertaken. It should be noted that a non-significant interaction effect did not preclude a smaller interaction that this study was not powered to detect. We chose 90% power and 1% two-sided significance to provide more convincing evidence of any treatment effects discovered. No further adjustments to the sample size were made because of multiple testing. The Data Monitoring and Ethics Committee (DMEC) reviewed the sample size assumptions after 338 participants were recruited and no changes were made to the final sample size.

Statistical analysis

A separate SAP³⁷ provides full details of all planned statistical analyses and was finalised prior to any primary outcome analysis. A summary is provided below.

The SAP was reviewed and received input from the TSC and DMEC. Any changes or deviations from the original SAP are described and justified in *Chapter 4* and any additional publications, as appropriate. All statistical analyses were undertaken using Stata® (StataCorp LP, College Station, TX, USA).

The primary statistical analysis was carried out on the basis of intention to treat (ITT), with all randomised participants included and analysed according to their allocated treatment group, irrespective of which treatment they actually received or their compliance with the proposed interventions. The two main effect comparisons for this 2×2 factorial trial were (1) progressive exercise compared with best-practice advice to determine the efficacy of progressive exercise [group A (progressive exercise) + group C (progressive exercise + injection) vs. group B (best-practice advice) + group D (best-practice advice + injection)] and (2) subacromial corticosteroid injection compared with no injection to determine the efficacy of subacromial corticosteroid injection (A + B vs. C + D). This 'factorial analysis' was conducted 'at the margins' of the table (Table 2). The sample size for this type of analysis was calculated under the assumption that there will be no intervention interaction effect (i.e. that progressive exercise would not interact with the steroid injection, such that it would work, work better or work worse only when used together rather than used alone). If a substantial interaction between the two interventions was present, the factorial analysis of the groups would lead to biased results and, therefore, the efficacy of each intervention would need to be drawn from comparisons within the intervention groups (i.e. 'inside-the-table' comparisons). Regardless of being able to detect a significant interaction effect, the results of the trial for the primary outcome, SPADI, meant that estimates were to be presented both 'inside the table' and 'at the margins', together with the size of the interaction.⁵² The success or otherwise of the interventions would be evaluated from the analysis results conducted based on evidence for presence/absence of a treatment interaction.

Interaction

An interaction between the two main effect comparisons was not expected, but the trial was powered to identify a moderate standardised interaction effect of 0.35. The presence of an interaction between the two interventions was formally investigated before testing their effects on the primary outcome. An initial regression model was fitted for the primary outcome to predict the outcome of interest and included the two effects of interest [i.e. (1) individually tailored progressive-exercise programme compared with best-practice advice and (2) subacromial corticosteroid injection compared with no injection] and their interaction.

In the presence of a non-statistically significant treatment interaction (i.e. $p \geq 0.05$), a factorial analysis was planned to determine the success of the trial. The effects for the individually tailored progressive-exercise programme and corticosteroid injection were determined separately from this model as mean differences (MDs) with associated 99% confidence intervals (CIs), as appropriate, adjusted for the relevant covariates. The model used did not include an intervention interaction term.

If a statistically significant treatment interaction (i.e. $p < 0.05$) had been detected then the effect of the individually tailored progressive-exercise programme and corticosteroid injection would have been evaluated from comparisons within the intervention groups, referred to as 'inside-the-table' comparisons (i.e. group A vs. group B to test the effect of the individually tailored progressive exercise programme and group B vs. group D to test for the effect of the corticosteroid injection) (see Table 2). The main effects and their interaction terms would have been included in the analysis model, their regression coefficient with corresponding 95% CI for the interaction terms presented and the reduced statistical power of this model noted.

TABLE 2 Factorial 2×2 analysis diagram

	No corticosteroid injection	Corticosteroid injection	Effect of ProgEx intervention
ProgEx intervention	Group A (ProgEx)	Group C (ProgEx + injection)	A + C vs. B + D
BPA intervention	Group B (BPA)	Group D (BPA + injection)	
Effect of corticosteroid injection	A + B vs C + D		

BPA, best-practice advice; ProgEx, progressive exercise.

Primary outcome analysis

The difference in SPADI between the two intervention groups was estimated overall and at each data collection time point using a repeated measures linear mixed-effects regression model.⁵³ The model was adjusted for the fixed effects of age, sex and baseline SPADI, and random intercepts by centre and observations within participants. Robust standard errors (SEs) for treatment effects from all time points were reported. Clustering by physiotherapist in the progressive-exercise group was accounted for using cluster-robust SEs as part of the mixed-effects model. The final trial results were based on the adjusted model. A non-parametric statistical test (e.g. Mann–Whitney test for comparison of means) with no adjustment and medians and interquartile ranges (IQRs) were reported where approximate normality for the model residual terms was not established. Statistical significance was set at the 1% level and corresponding 99% CIs were reported for the primary outcome. Flooring effects in the SPADI outcome over the 12 months were explored and reported for each treatment group.

Secondary outcome analyses

The intervention effects on secondary outcomes were analysed following the analysis method described for the primary outcome on the basis that the outcomes are clinically similar. If there was no statistically significant evidence of an interaction effect for the primary outcome, then no interaction effect would be assumed for the secondary outcomes. Likewise, if a statistically significant interaction effect was identified for the primary outcome, then the secondary outcomes would be analysed, assuming an interaction effect was present. Continuous secondary outcomes analyses were conducted following similar methods to the outline for the primary outcome analysis, using linear regression for continuous outcomes and logistic/multinomial logistic regression (i.e. logit, mlogit or ologit, as appropriate) for binary and ordinal outcomes. Statistical significance for secondary outcomes was set at 5% and 95% CIs were reported.

Missing data

Missing data were reported and summarised by treatment group. Item-level imputation for the primary outcome SPADI was carried out for items where no more than two out of five items in the pain subscale were missing and no more than three out of eight items in the function subscale were missing, given that no more than 10% of cases had missing data.^{54,55} Missing continuous primary and secondary outcomes were handled as part of the likelihood-based estimation of the repeated measures mixed-effects model, assuming the data were missing at random.⁵⁶ This method took account of missing observations owing to missed visits or a participant leaving the study prematurely. The distribution of missing data was explored to assess the assumption of data being missing at random. Full details are provided in the SAP.³⁷

Sensitivity analysis

Sensitivity analyses were used to assess the robustness of the trial results in the light of the assumptions made about the underlying missing data mechanism. Most analyses assume data to be missing at random or missing completely at random. The sensitivity analysis, therefore, assumed missing not at random, such that missing outcomes were assumed to be worse or better than the observed outcomes.

Prespecified subgroup analysis

Subgroup effects in the following prespecified subgroups were analysed for the primary outcome, utilising subgroup-by-treatment interactions:

- Age: ≤ 64 years vs. ≥ 65 years. (Rationale: increasing age has been shown to be associated with poorer outcome.^{57,58})
- Sex: male vs. female. (Rationale: prevalence is higher in males than in females.¹)
- Smoking status: never smoked vs. former smoker or current smoker. (Rationale: smoking has been shown to be associated with a negative effect on tendon healing.⁵⁹)

- Higher SPADI score at baseline. (Rationale: higher pain and functional disability at baseline may be associated with poorer outcome. We defined a higher SPADI score as ≥ 50 at baseline when the SPADI is converted to the 0 to 100 scale.^{19,57})
- Higher pain self-efficacy (PSEQ-2) score at baseline. (Rationale: higher belief in one's ability to carry out activities despite pain may be associated with better outcome. We define a higher PSEQ-2 score as ≥ 8 at baseline when the PSEQ-2 is converted to the 0–12 scale.)

Supplementary/additional analyses

A complier-average causal effect (CACE) analysis was used to investigate the role of compliance in the treatment effect, given the CACE assumptions described in the SAP. Compliance with intervention was defined in the SAP³⁷ as follows. For the progressive exercise intervention, participants were considered compliant with treatment if they had been signed off for completing treatment or if they receive all six physiotherapy sessions. For corticosteroid injection intervention, participants were considered compliant if they received at least one injection. If no evidence of a statistically significant interaction between the two treatments was identified, then this analysis was planned to be conducted 'at the margins' and using a similar mixed-effects model. If a statistically significant treatment interaction for the primary outcome was identified, the CACE analysis would be conducted 'inside the table'.

Cost-effectiveness analysis

An economic evaluation was integrated within the GRASP trial design. Full details are described in *Chapter 5* and a summary is described here for continuity.

The economic evaluation, in the form of a cost-utility analysis, was conducted from the recommended NHS and Personal Social Services (PSS) perspective.⁶⁰ Individual patient data on the use of health and social services were collected at 8 weeks, 6 months and 12 months post randomisation as part of the follow-up data collection process (see *Table 1*). The cost of delivering each intervention, including physiotherapists' training, materials, delivery of the progressive exercise and advice sessions, and corticosteroid injections, were also estimated. Participants' health-related quality of life was captured through the EQ-5D-5L at baseline and at 8 weeks, 6 months and 12 months post randomisation.

Patient and public involvement

Patient and public involvement (PPI) was central to the design of the GRASP trial and was maintained throughout the trial set-up, implementation and dissemination. PPI representatives were involved in a number of ways. First, as part of the initial trial design, we held a PPI study development meeting, supported by the Research Design Service South Central (Oxford, UK), where the proposed research was presented and discussed with attendees. The views expressed by the patients contributed to the trial design and subsequent trial protocol. In particular, an outcome looking at sleep disturbance was included, as this was deemed to be very important to patients. The PPI representatives also advised keeping the number of self-reported outcomes to a minimum to avoid an undue burden on the participants and recommended using diaries so that the patients could record and monitor their own progress.

Patient and public involvement representatives also attended the GRASP intervention development meeting (see *Chapter 3*) and provided valuable practical input regarding delivery and acceptability of the progressive-exercise and best-practice advice interventions. In addition, PPI representatives were involved in reviewing the participant information sheets and participant questionnaires to ensure that they were accessible and user-friendly. Two PPI representatives were formal members of the GRASP TSC and attended and actively contributed to these meetings, including the final results meeting where data were shared and interpreted. As part of the dissemination process, the PPI representatives also reviewed and advised on the wording of the letter to trial participants, advising them of the GRASP trial results.

Ethics approval and monitoring

Ethics committee approval

The GRASP trial protocol and all related documentation (e.g. informed consent forms, participant information leaflets, patient questionnaires and any proposed advertising material) was approved by the Berkshire B Research Ethics Committee (reference 16/SC/0508) and Integrated Research Application System (ID 199243). The trial was also approved by the UK competent authority the Medicines and Healthcare products Regulatory Agency, as it was classified as a clinical trial of an investigational medicinal product (EudraCT number 2016-002991-28). The trial was conducted in accordance with the principles of the Declaration of Helsinki⁶¹ and the Medical Research Council's GCP guidelines.⁶²

Trial Management Group

A Trial Management Group, consisting of the core trial team, chief investigator and co-applicants, was responsible for the day-to-day running of the trial and met monthly to report on progress and ensure that milestones were met. A trial manager oversaw all aspects of the day-to-day trial management.

Trial Steering Committee

A TSC was responsible for monitoring the trial's progress and providing independent advice. The TSC comprised an independent clinician, two specialist physiotherapists, a statistician, a health economist and two patient representatives.

Data Monitoring and Ethics Committee

A DMEC was responsible for monitoring the trial's progress and providing independent advice. It advised the chairperson of the TSC if, at any time, in its view, the trial should be stopped for ethics reasons, including concerns about participant safety. The DMEC comprised an independent clinician, health service researchers, a specialist physiotherapist and a statistician.

Chapter 3 Intervention description and rationale

Parts of this chapter have been reproduced with permission from Keene *et al.*⁴³ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>. The text below includes minor additions and formatting changes to the original text.

Developing the GRASP trial exercise interventions

The GRASP trial interventions were developed using Medical Research Council guidance for developing and evaluating complex interventions.⁶³ We took into account clinical guidelines, research evidence, current practice variation, deliverability in the NHS (in terms of staffing, resources and time), expert and patient opinion, acceptability to clinicians and patients, and the need to ensure consistency in delivery and reproducibility. The intervention development and descriptions have been reported previously.⁴³

Intervention development

In *Chapter 1*, the lack of evidence for particular exercises, treatment intensities or durations were outlined. With no clear evidence or clinical consensus, advice from clinicians, patient and public representatives and other experts was crucial to the development of the GRASP trial interventions. Twenty-six clinicians, researchers, patients and public representatives attended a GRASP intervention development meeting (June 2016). Delegates discussed and evaluated a comprehensive list of 22 exercise types commonly used in clinical practice and/or reported in trials of shoulder pain treatments (see *Appendix 3, Table 26*). The delegates categorised the exercises into essential exercises, optional exercises or exercises considered not important for managing rotator cuff disorders.

Those selected as essential exercises generally strengthen the posterior rotator cuff muscles (i.e. supraspinatus, infraspinatus and teres minor) and load the shoulder into an elevated position, consistent with current trial evidence.^{17,64} The GRASP trial, therefore, included these exercise types as an essential component of both the progressive-exercise and best-practice advice exercise interventions. Delegates agreed that both exercise interventions should be as practical and simple as possible. Some exercises were considered important for patients with specific presentations or in particular circumstances. These were included as optional exercises in the progressive-exercise intervention. They were not incorporated into the best-practice advice intervention, which prioritised a simple, progressive set of exercises that were likely to benefit most patients and could be easily understood and performed at home without supervision.

Delegates agreed that stretching was not a priority target in rotator cuff disorders and that range of motion could be incorporated into other active exercises. A posterior capsule/soft tissue stretch for the shoulder was included as an option in the progressive-exercise intervention as we recognised that these stretches feature in many exercise programmes evaluated in other clinical trials.¹⁴ Isolated exercises to correct posture towards a theoretical ideal were not included, as there is limited evidence for this approach.⁶⁵ Experts disagree on whether exercises can or should provoke symptoms or should be symptom-free. There is limited evidence for these alternatives, although evidence is building for the acceptability of mild-to-moderate pain symptoms during exercise.^{66,67} The participant information booklet, which was included as part of the GRASP trial intervention materials, and treating physiotherapists advised participants that some pain during the exercises is acceptable, provided that they found it manageable and symptoms resolved to an acceptable level within a few hours.

After the meeting, we developed detailed intervention manuals for the treating physiotherapists that described the key components of the progressive-exercise and best-practice advice interventions. We also developed patient-facing materials, which were reviewed by patient representatives.

Internal pilot

As part of the GRASP trial, we ran an internal pilot from February to June 2017 at three sites, recruiting 42 participants. One of the aims of the internal pilot was to test and refine the recruitment process and explore treatment acceptability. The physiotherapists delivering the GRASP exercise interventions were also asked to provide feedback on the delivery of the intervention. The exercise intervention manuals and training materials were subsequently refined to clarify identified misconceptions. The interventions did not require significant modifications.

The GRASP trial interventions

Table 3 summarises the key components of the GRASP exercise interventions. The interventions were delivered face to face and one to one by UK-registered physiotherapists based at physiotherapy and musculoskeletal services across England.

TABLE 3 Overview of GRASP trial exercise interventions, as per Template for Intervention Description and Replication criteria

TIDieR items ⁶⁸	Progressive exercise	Best-practice advice
Brief name	GRASP	
Why	Physiotherapy-led exercise and advice are commonly used to manage rotator cuff disorders; however, evidence is lacking in terms of how exactly it should be delivered and whether or not patients do better if they receive a corticosteroid injection before starting an exercise programme	
What	Home exercise and advice programme overseen by physiotherapist over six or fewer sessions within 16 weeks	Home exercise and advice programme initiated during a single face-to-face session with a physiotherapist, and then performed unsupervised by participant at home
Materials: participants	Participant information booklet (see Table 4) and exercise instruction sheets with photos	Participant information booklet (see Table 4), incorporating exercise instructions with photos
	Action planner and exercise diary (see Appendix 3, Figure 15)	Action planner and exercise diary (see Appendix 3, Figure 22)
	Resistance bands (if applicable)	Resistance bands
Materials: physiotherapists		Exercise instruction videos available on website or DVD
	Therapist manuals detailing all aspects of the trial and the progressive-exercise intervention, and a quick reference guide for use in the clinic	A therapist manual detailing all aspects of the trial and the best-practice advice intervention
Procedures		At least half a day of training
	Training, including 1 full day (at least 4–5 hours) of face-to-face training delivered by GRASP trial research physiotherapists	
Procedures	Initial appointment	Single face-to-face appointment
	Assess participant as per normal physiotherapy practice	Assess participant as per normal physiotherapy practice

TABLE 3 Overview of GRASP trial exercise interventions, as per Template for Intervention Description and Replication criteria (continued)

TIDieR items ⁶⁸	Progressive exercise	Best-practice advice
	Issue folder containing the progressive-exercise participant information booklet	Issue best-practice advice participant information booklet
	Agree level of exercise that is most appropriate for the participant initially (see Figures 1 and 2)	Explain exercise ladder (see Appendix 3, Figure 21) and agree with participant what level of the ladder is most appropriate initially
	Advice should address barriers to exercise identified during assessment	Educate participants on how to progress and regress their exercises
	Provide education regarding pain during and after exercise	Ensure that the participant knows how to access the exercise videos online or issue DVD (or both)
	Help participant to complete exercise documentation (i.e. the exercise diary and action planner)	Advice should address barriers to exercise identified during assessment
	Make follow-up appointment(s)	Provide education regarding pain during and after exercise
	Complete treatment log	Help participant to complete exercise documentation (i.e. the exercise diary and action planner)
	Appointments 2–6	
	Reassess as per normal physiotherapy practice	Strategies to encourage adherence to exercise were less extensive than in the progressive-exercise intervention, as they need to be feasible to deliver within a single session
	Assist participant to progress/regress exercises	Discharge participant with advice/encouragement to continue with the self-management exercise programme for at least 16 weeks
	Reassure the participant and reinforce key messages from the advice and education	
	Review home exercise programme using the exercise diary	Complete treatment log
	Discuss return to functional activities	
	Review action planner	
	Complete treatment log (after every session)	
Who provides	Physiotherapists already working in NHS musculoskeletal services who have attended the progressive-exercise intervention training	Physiotherapists already working in NHS musculoskeletal services who have attended the best-practice advice intervention training
	The GRASP trial does not exclude physiotherapists based on number of years qualified or experience in treating shoulder conditions	The GRASP trial does not exclude physiotherapists based on number of years qualified or experience treating shoulder conditions
How	Participants receive up to six sessions with a physiotherapist over 16 weeks	Participants receive a single face-to-face session with a physiotherapist lasting up to 60 minutes
	The initial session lasts up to 60 minutes for assessment. It is then followed by up to five 20- to 30-minute sessions	
Where	Physiotherapy sessions are in outpatient clinics based in the NHS	Same as progressive-exercise intervention
	The exercise programme is performed by the participant at home	

continued

TABLE 3 Overview of GRASP trial exercise interventions, as per Template for Intervention Description and Replication criteria (*continued*)

TIDieR items ⁶⁸	Progressive exercise	Best-practice advice
When and how much	<p>The initial appointment is co-ordinated within 14–28 days of randomisation, as per local appointment availability</p> <p>Up to five follow-up sessions arranged within 16 weeks</p> <p>Can be fewer than six sessions if participant has met rehabilitation goals and is self-managing condition</p> <p>Volume of exercise described in <i>Figure 2</i></p>	Same as progressive exercise, but without any follow-up appointments
Tailoring	<p><i>Education and advice</i></p> <p>Focus of education and advice are individualised and based on assessment</p> <p><i>Exercises</i></p> <p>Selection, manipulation of sets, repetitions and/or load is a joint decision-making process</p> <p>Range of motion and position may be modified to accommodate the patient’s comfort and preferences</p>	<p><i>Education and advice</i></p> <p>Focus of education and advice are individualised and based on assessment</p> <p><i>Exercises</i></p> <p>The range of motion through which an exercise is performed, and the load and volume, may be increased or decreased</p>
Modifications	Quick reference guides for each intervention were produced after the pilot phase and contained all key operational procedures for each intervention to supplement the comprehensive manuals	
Intervention fidelity		
How well: training	All aspects of training delivery, content, structure, duration and therapists’ confidence to implement the intervention were evaluated using the post-training feedback forms that were completed anonymously	
How well: physiotherapists	Intervention fidelity is monitored centrally using treatment logs and during site monitoring and quality assurance visits. If performance is found to be below the required standard of protocol adherence, further measures (e.g. further training) will be instituted after discussion with the Trial Management Team and the site	
How well: participants	<p><i>Exercise adherence</i></p> <p>Physiotherapists review the exercise diary at each subsequent session</p> <p>Participants asked to report exercise frequency in postal follow-up questionnaires at 8 weeks, 6 months and 12 months</p>	<p><i>Exercise adherence</i></p> <p>Participants asked to report exercise frequency in postal follow-up questionnaires at 8 weeks, 6 months and 12 months</p>
How well: reporting	Intervention fidelity is reported with main trial results	
TIDieR, Template for Intervention Description and Replication.		

Research physiotherapists from the GRASP trial team provided 1 full day (at least 4–5 hours) of face-to-face training on the progressive-exercise intervention and at least half a day of face-to-face training on the best-practice advice intervention to the relevant delivering physiotherapists. Details on who provided the interventions are provided in *Chapter 4*. Physiotherapists were trained to deliver either the progressive-exercise intervention or the best-practice advice intervention (not both) to reduce the risk of contamination. Training included the trial background, how to deliver the intervention,

the exercises permitted within the trial protocol, behavioural techniques to improve adherence, trial reporting and paperwork, and practical examples using case studies. Physiotherapist manuals were provided, which detailed all aspects of the trial and interventions. GRASP trial team members were available post training to provide support and answer queries.

GRASP trial exercise interventions

Assessment and advice

Appointments were co-ordinated so that participants typically started their first exercise session within 14–28 days of randomisation. The physiotherapist carried out an initial assessment, as per their usual practice, to identify which shoulder movements, in relation to the rotator cuff, were particularly problematic in terms of pain, weakness and restriction, and the associated functional deficits. All GRASP trial participants received a participant information booklet, which contained education and advice relevant to people with a rotator cuff disorder (*Table 4*). All parts of the booklet contained the same information in the progressive-exercise and best-practice advice intervention groups, with the exception of the specifics of the exercise guidance. Advice included use of over-the-counter analgesia, as per BESS guidance.⁶⁹ The treating physiotherapist reinforced the education and advice aspects relevant to that participant. All participants were advised to perform the exercises for at least 4 months and to continue to do so for longer if they were still improving or finding them helpful. Physiotherapists delivering the interventions were trained in questioning techniques based on cognitive-behavioural models⁷⁰ to elicit and address unhelpful beliefs about shoulder pain or exercise that can impede exercise adherence.⁷¹

TABLE 4 Contents of the GRASP trial participant information booklet

Section	Content
Introduction	Summary of common treatments for rotator cuff disorders
What is the rotator cuff?	Description of rotator cuff muscles
What does the rotator cuff do?	Function of rotator cuff muscles
What can go wrong with the rotator cuff?	Possible mechanisms and common symptoms of rotator cuff disorders
What can I do to help my rotator cuff problem?	Introduction to role of self-management advice, includes simple pain education, pain management (including use of heat and cold, medication and pacing)
Maintaining physical fitness	Importance of staying active
Return to usual physical activities	Fear avoidance and deconditioning, and how to address these
Modifying activities	Modifying rather than avoiding activities
Work	Advice on returning to work activities
Sleeping	Sleep positions, pacing to lessen night-time pain
Looking after your mental well-being	Activities to maintain a positive mood and when to seek medical advice
Coping with flare-ups	Planning exercise and activity for times when pain is more severe
Exercise guide	Benefits of exercise and how long to continue with exercise
	Pain during and after exercise
	Guidance on doing GRASP trial exercises with full instructions (e.g. colour photographs and text explaining technique and modifications that can be made)
Note	
Exercise details were specific to the progressive-exercise or best-practice advice intervention.	

Progressive-exercise intervention

Participants received up to six sessions with a physiotherapist over 16 weeks. The initial session was set to last up to 60 minutes for assessment and treatment initiation, followed by up to five 20- to 30-minute follow-up sessions. The physiotherapist and participant decided how frequently to schedule the review appointments within the 16-week time frame. Six sessions over 16 weeks was set to allow the exercise intensity to be progressed and because it was a volume of physiotherapy within the range of feasible delivery in the NHS. It was also deemed to be a sufficient time for a physiological response in the neuromuscular system.⁴⁶ The participant information booklet was provided in a file so that instructions on the progressive exercises selected could be inserted, including detailed guidance and photos for each exercise. The physiotherapist and participant jointly chose one to three exercises to address the problems identified during the assessment (*Figure 1*). We anticipated participants presenting with different problems and pain irritability and, therefore, the exercises were categorised into three difficulty levels (level 1, 2 and 3 exercises), with progressions within each level and different aims and guidelines to match indications for use.




FIGURE 1 Process map of the GRASP trial progressive exercise intervention.

Level 1 exercises: simple shoulder movements

Level 1 exercises aimed to reduce fear, encourage normal movement, improve shoulder mobility and build confidence in exercising independently at home (see *Appendix 3, Figure 17*). The exercises were considered appropriate for participants with irritable and/or severe shoulder pain and/or fear avoidance. The frequency and the number of sets and repetitions for each exercise were agreed between the physiotherapist and participant. Depending on symptom severity, it was recommended that some participants could reasonably move straight to level 2 exercises.

Level 2 exercises: progressive structured resistance training

Level 2 exercises included the essential exercises that target strengthening of the posterior rotator cuff muscles and other optional exercises (see *Appendix 3, Figure 18*). The essential exercises focused on movements commonly affected by a rotator cuff disorder (i.e. resisted external rotation, flexion and abduction of the shoulder).⁶⁴ Resistance exercises for other shoulder movements were optional. If participants were prescribed exercises at level 2, at least one had to be from the essential exercise category.

The American College of Sports Medicine guidance for progressive resistance training recommends two to three sessions of resistance training per week,²⁰ whereas many studies of resistance training in patients with musculoskeletal disorders use daily exercise programmes.^{21,72} We attempted to strike a balance, ensuring that the resistance training was effective, but also regular enough to address other aims, such as building confidence in moving the arm and re-learning motor skills. We asked GRASP trial participants to do their exercises 5 days per week, with 2 non-consecutive recovery days.



Physiotherapists were taught to regulate the exercise intensity using the modified Borg scale of perceived exertion, an 11-point version of the Rating of Perceived Exertion (RPE) scale,⁷³ validated for quantifying the intensity of resistance exercise.⁷⁴ Participants started at a moderate load (3 or 4 on the Borg scale) to enhance motivation and adherence and reduce the likelihood of symptom flare-up. *Figure 2* contains detailed guidance on the scale and how level 2 exercises were initiated, progressed and regressed. Where appropriate, resistance bands or hand weights were incorporated into the exercise, with the level of resistance recommended being guided by the RPE scale feedback from the participant.

Level 3 exercise: patient-specific functional restoration

It was recommended that participants progress to level 3 when their initial problems (e.g. weakness) began to resolve. The physiotherapist altered the exercise programme to be more task specific (e.g. returning to sport) by devising a new exercise in consultation with the participant. Level 3 exercises aimed to modify the essential resistance-training exercises towards the specific movements required to achieve the participant's individual functional goals. The exercise could be high or low load, using many or few repetitions, depending on the participant's needs. It was recognised that not all GRASP trial participants would reach or need this stage of the programme. We anticipated that level 3 exercise instructions would be given face to face and reinforced with written guidance to aid recall.

Optional stretching exercise

Posterior capsule and/or soft tissue stretches of the shoulder (see *Appendix 3, Figure 19*) were included as optional exercises at any stage. We recommend selective use, generally for younger adults engaged in throwing or other overhead athletic or physical activities⁷⁵ who have posterior capsule tightness. We anticipated these exercises to be suitable for participants with low irritability and if they did not provoke symptoms. Although discomfort and stretching sensations were considered acceptable during stretches, we did not anticipate provocation of anterior shoulder pain or reproduction of the participant's specific symptoms. We advised holding stretches for 20–30 seconds, but the physiotherapist and participant decided the number of repetitions and frequency.



(c)

Initial

Once RPE is at 3 or 4, start home exercise with one set of eight repetitions (advising to build up to 12 repetitions as appropriate), once per day, five times per week (with 2 non-consecutive rest days in between)

Repeat for each level 2 exercise in programme up to maximum of three exercises; advise 2 minutes' rest between exercises (and sets)

Progression

If RPE lower than 3 and has successfully progressed to 12 repetitions, exercises may be progressed:

- Add sets up to two or three sets of 8–12 repetitions; rest 2 minutes between sets
- Increase load/resistance to get back to RPE 3 or 4
- Further increase load/resistance to RPE 4–5, or 5–7, if participant is confident
- Increase in sets and load could be done together if the participant and therapist agree

A more difficult exercise should be considered when either:

- The maximum volume of sets and repetitions (3 × 12) at Borg RPE = 7 is achieved
- If change of exercise is deemed appropriate to progress the exercise programme

Regression

If the patient cannot do eight repetitions of a particular exercise at the selected load and target RPE, or can manage this but experiences an unacceptable increase in pain, reduce the load to a level at which they are able to do at least eight repetitions

If they are still unable to do one set of eight repetitions using the lowest load, then you can:

- Remove load altogether
- Reduce repetitions to fewer than eight
- Reduce range of movement or alter the position
- Choose another exercise

FIGURE 2 Guidance for setting level 2 resistance exercises in the GRASP trial. (a) Modified Borg scale; (b) setting the initial exercise; and (c) progression and regression decision guidance.

Exercise progression

During the physiotherapist training, emphasis was placed on the need to progress the exercise interventions as much as possible. To determine that this had in fact occurred, treatment logs completed for each session by the physiotherapists [detailing prescribed exercises, number of sets/repetitions (i.e. volume) and exercise intensity⁷³] were analysed to allow an estimation of treatment progression for the progressive-exercise intervention (see *Chapter 4*). Exercises were categorised and ranked in order of difficulty level (1 = least difficult, 8 = most difficult) according to the following scale:

1. passive movements
2. isometric
3. active assisted
4. active (unassisted)
5. loaded exercises (isotonic) in neutral (0 °)
6. loaded exercises (isotonic) at 90 °(supported)
7. as for 6, but unsupported
8. as for 7, but through range.

Progression of the progressive-exercise intervention was defined as an increase in exercise difficulty, or volume and/or load across attended sessions. Maintained indicates no changes in exercise parameters. Regressed is defined as a decrease in exercise level, or volume and/or load.

Best-practice advice intervention

The best-practice advice intervention was a single face-to-face session with a physiotherapist, lasting up to 60 minutes. With only one session, there was a substantially greater reliance on self-management than in the progressive-exercise intervention. As per the progressive-exercise intervention, participants were given a participant information booklet and the treating physiotherapist reinforced the education and advice aspects that were particularly relevant.

Participants were given a simple set of self-guided exercises, including at least one level of resistance band, to improve shoulder strength and function, which could be progressed and regressed independently at home, depending on their capability. The exercise instructions were given in the participant information booklet and in exercise videos available on the internet and DVDs. We aimed to make the information accessible and appealing to a wide range of individuals by using different media.⁷⁶

This intervention offered a simpler range of exercise options than the progressive-exercise intervention, although the underlying principles remained the same. The physiotherapist and participant chose one or two exercises from the best-practice advice exercise ladder together (see *Appendix 3, Figure 21*).

The exercises on the ladder were arranged with easier exercises on the lower rungs and more difficult exercises on the higher rungs. Participants were recommended to start at the level of exercise that they were capable of undertaking, not necessarily the lowest rung. If two exercises were selected, then these did not need to be from the same rung. The exercises at the lowest level were simple shoulder exercises to reduce fear of movement, encourage normal movement, build shoulder mobility and build confidence in carrying out self-directed exercises. Higher levels introduced a greater extent of resistance exercises for posterior rotator cuff strengthening.

The Borg RPE scale was not used to measure intensity for participants in the best-practice advice group to simplify the programme and maximise independent participant progression. We advised participants that they should find the exercise(s) moderately difficult (i.e. not easy but not extremely hard). They began with one set of eight repetitions at the selected load and aimed to build up to 12 repetitions, exercising once daily for 5 days per week, with 2 non-consecutive rest days. If the exercise(s) became too easy, another set could be added (up to a maximum of three sets). If the expanded set became too easy, the advice was that the exercise(s) should be exchanged for the next level of difficulty.

The next exercise, again, started with one set of eight repetitions and built up in the same way. If the participant encountered difficulties, they were advised to reduce the load and/or number of sets/repetitions or regress to an easier exercise.

Strategies to encourage exercise adherence

Estimates suggest that up to 70% of patients do not adhere to prescribed physiotherapy treatments.²⁵ As part of the GRASP trial interventions, we, therefore, incorporated strategies to promote adherence to the exercise interventions. These strategies were less extensive in the best-practice advice intervention than in the progressive-exercise intervention, as they needed to be feasibly delivered within a single session (see *Appendix 3, Table 27*).

Modifiable behavioural targets were identified from a systematic review of barriers to physiotherapy adherence, including in-treatment exercise adherence, low self-efficacy, depression, anxiety, helplessness, greater perceived barriers to exercise and pain levels during exercise.²⁴ For a summary of the behaviour change techniques used in the GRASP exercise interventions, based on the behaviour change techniques taxonomy,⁷⁷ see *Appendix 3, Table 27*. These techniques were selected based on their evidence base,⁷⁸ successful use in other trials⁷² and recommendations in the NHS Health Trainer Handbook.⁷⁹ Participants were asked to complete an exercise action planner and exercise diary, which were tailored to the interventions (see *Appendix 3, Figures 15, 22 and 23*). Although exercise diaries have questionable reliability for measuring adherence because of issues with real-time compliance and recall bias,⁸⁰ there is evidence to suggest that they promote adherence.⁸¹ We assessed adherence to exercises in the follow-up questionnaires, in which participants reported exercise frequency.

Monitoring, quality assurance and safety

We monitored intervention delivery fidelity using site monitoring visits, quality assurance visits and central monitoring of treatment session logs. Each site was visited annually to ensure that the physiotherapists adhered to the intervention protocol for each exercise arm. A member of the GRASP trial research team attended an appointment session for each trial intervention and completed a standardised checklist covering knowledge of trial procedures, returning trial paperwork, storing trial materials, intervention delivery timing and adherence to intervention protocols. The delivering physiotherapist received feedback at the end of each quality assurance visit. If protocol adherence was below the required standard, further measures (e.g. retraining) were to be instituted after discussion with the trial team and site. Common problems or failings were also shared across sites through regular trial newsletters, e-mails and meetings.

Clinicians delivering the GRASP trial intervention were asked to complete treatment logs at the end of each session. The logs included a checklist that documented the key elements of the session (e.g. exercises prescribed, sets and repetitions, load, injection type and dosage/volume). These were returned to the central GRASP trial team, which reviewed the data for each participant and entered them onto the trial database. For the progressive-exercise intervention, exercise prescription details were checked on arrival. An assessment of progression of exercises over the sessions was not part of the ongoing monitoring. As described above, participants were also allowed to maintain or regress their exercises over the sessions, if clinically appropriate. However, these data were carefully recorded, analysed on completion of the trial and are reported in *Chapter 4*.

Custom-designed reports of treatment log data were generated and regularly reviewed during the conduct of the trial for central monitoring of the intervention delivery, including the timing, number and duration of sessions, injection details (e.g. volume/dosage), content of treatment sessions, participant attendance and paperwork return. Intervention delivery was, therefore, monitored

throughout the trial on a site-by-site and overall basis. Ongoing monitoring during the trial aimed to reveal deviations or discrepancies from the trial protocol so that they could be investigated and, if required, measures taken to address them at an early stage throughout the trial.

Completion of the best-practice advice intervention was defined as attendance at one session. For the progressive-exercise intervention, completion of treatment was defined as attendance at all six treatment sessions, discharged by the treating physiotherapist or referred on for further investigation/treatment (e.g. to orthopaedic consultant). Partial completion was defined as attendance of at least one session but not fulfilling the criteria for full completion described above.

Conclusion

This chapter described the development and details of the GRASP trial interventions for treating rotator cuff disorders tested as part of the trial. The results on how the interventions were implemented and the outcomes from onsite monitoring are detailed in *Chapter 4*.

Chapter 4 Results

Reproduced with permission from Hopewell *et al.*⁸² © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Trial sites

Centre characteristics

Twenty English NHS trusts participated in the GRASP trial (see *Appendix 4, Table 28*). The recruitment period (20 February 2017 to 2 May 2019) at each trust varied from 9 to 26 months, with resulting variation in the number of participants recruited at each site.

Participating clinicians

A total of 223 clinicians across the 20 trial sites were involved in providing the study treatment interventions. Fifty-three physiotherapists and three doctors delivered subacromial corticosteroid injections to 329 (97%) and 10 (3%) participants, respectively. The best-practice advice and progressive-exercise interventions were delivered by 83 and 104 physiotherapists to 324 and 339 participants, respectively (see *Appendix 4, Table 29*). The physiotherapists and doctors worked in hospital physiotherapy, orthopaedic outpatient departments or at satellite clinics (e.g. general practices). Nine physiotherapists at two sites were working for a private company contracted to provide services to NHS patients [Buckinghamshire Musculoskeletal Integrated Care Service (High Wycombe, UK) and Medway Community Healthcare (Rochester, UK)]. The number of physiotherapists involved at each site varied from 3 to 43 (see *Appendix 4, Table 28*). Several physiotherapists provided both the corticosteroid injection and either the best-practice advice or progressive-exercise intervention. Two physiotherapists swapped treatment groups during the trial because of staffing issues at sites and, therefore, delivered both exercise interventions.

The level of experience of each physiotherapist (as determined by Agenda for Change pay banding)⁷² is described in *Appendix 4, Table 29*. Sixty-four per cent (34/53) of physiotherapists delivering injections were band 8. Exercise interventions were predominantly delivered by band 6 and 7 physiotherapists (73% and 80% for best-practice advice and progressive-exercise interventions, respectively).

Participant flow

The overall flow of participants through the study is described in the CONSORT (Consolidated Standards of Reporting Trials) diagram (*Figure 3*). Further details for each stage are provided in the following sections.

Recruitment

Screening

Screening and recruitment took place between February 2017 and April 2019. A total of 2287 patients were screened and assessed to see whether or not they met the GRASP trial eligibility criteria (*Table 5*). A total of 1284 (56%) patients were eligible and 708 agreed to participate. Of those participants who did not meet the eligibility criteria (1003/2287), the most common reasons were owing to another shoulder disorder (e.g. inflammatory arthritis, frozen shoulder, glenohumeral joint instability) or red flags consistent with BESS criteria ($n = 434$, 43%), or had received corticosteroid injection or physiotherapy for shoulder pain in last 6 months ($n = 167$, 17%). Of those participants who were eligible but declined to participate ($n = 576$), the most common reasons given were not interested in taking part in research




FIGURE 3 Participant flow diagram. a, Reasons for not receiving best-practice advice: participant did not attend session (n = 5), withdrawal (n = 4) and other medical condition (n = 3); b, reasons for not receiving injection only: participant declined treatment (n = 2) and contraindications (taking anticoagulants, n = 1; previous reaction to injection, n = 1);

c, reasons for not receiving best-practice advice only: participant did not attend session ($n = 5$), other medical condition ($n = 2$) and received progressive exercise in error ($n = 3$); d, reasons for not receiving injection and best-practice advice: participant did not attend session ($n = 1$), participant declined treatment ($n = 2$), other medical condition ($n = 2$) and previous reaction to injection and received non-GRASP trial treatment ($n = 1$); e, reason for not receiving progressive exercise: participant did not attend session ($n = 3$), received best-practice advice in error ($n = 2$), received injection in error ($n = 1$), received non-GRASP trial treatment ($n = 1$) and withdrawal ($n = 1$); f, reasons for not receiving injection only: participant declined treatment ($n = 5$) and clinician declined treatment ($n = 3$); g, reasons for not receiving progressive exercise only: received best-practice advice in error ($n = 2$), received non-GRASP trial treatment ($n = 3$), other medical condition ($n = 1$) and participant did not attend session ($n = 1$); h, reasons for not receiving injection and progressive exercise: participant did not attend session ($n = 2$) and other medical condition ($n = 1$); and i, 'included in the analysis' is all participants with at least one follow-up time point SPADI outcome and the baseline variables used in the model.

TABLE 5 Number of participants screened by site

Site	Screened (N = 2287), n	Ineligible (N = 1003), n	Declined (N = 576), n	Randomised (N = 708), n
University Hospitals of Derby and Burton NHS Foundation Trust	152	55	51	46
East Lancashire Hospitals NHS Trust	387	193	92	102
Gloucestershire Hospitals NHS Foundation Trust	435	181	134	120
Birmingham Community Healthcare NHS Trust	81	17	35	29
Sandwell and West Birmingham Hospitals NHS Trust	89	23	31	35
Buckinghamshire Musculoskeletal Integrated Care Service	41	22	5	14
East Cheshire NHS Trust	44	17	13	14
Bedfordshire Hospitals NHS Foundation Trust	72	39	10	23
Wirral University Teaching Hospital NHS Foundation Trust	58	30	15	13
Medway Community Healthcare	34	3		31
Bristol Community Health	6	1	1	4
Somerset Partnership NHS Foundation Trust	255	167	39	49
Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust	81	28	20	33
Sherwood Forest Hospitals NHS Foundation Trust	66	14	23	29
Kent Community Health NHS Foundation Trust	62	10	16	36
Northern Devon Healthcare NHS Trust	127	50	41	36
Airedale NHS Foundation Trust	69	36	8	25
North West Boroughs Healthcare NHS Foundation Trust	163	92	31	40
Warrington and Halton Hospitals NHS Foundation Trust	52	25	9	18
Staffordshire and Stoke-on-Trent Partnership NHS Trust	13		2	11

($n = 175$, 30%) or had a treatment preference for not receiving injection ($n = 158$, 27%). For full details see *Appendix 4, Table 30*. The mean age of those who declined to participate was 55 years (median 56 years, IQR 46–65 years) and 53% ($n = 306$) were female.

A total of 708 participants were recruited between March 2017 and May 2019 (see *Appendix 4, Figure 24*). This exceeded the target of 704 participant; four participants were randomised once the target was reached as they were already in the process of joining the study.

Baseline data

Baseline characteristics of participants

The baseline characteristics of participants recruited into the trial are shown in *Table 6* (for more detail see *Appendix 4, Tables 31–33*). Intervention groups were generally well matched in terms of baseline demographic data and primary and secondary outcome measurements. Stratification factors used in the randomisation are shown in *Appendix 4, Table 34*. The majority of participants were white British (89.6%), with similar numbers of men and women (50.7% vs. 49.3%). The overall mean age was 55.5 (SD 13.1) years. The majority of participants reported being married (64.8%) or living with a partner (13.1%). More than two-thirds of participants were classified as either overweight (38.7%) or obese (30.6%). Approximately half (58.9%) reported being in employment, with one-quarter (25.8%) being retired. The majority of participants reported being right-handed (87%) and the numbers were similar in terms of whether the right or left shoulder was affected (49.3% vs. 46.9%). The average duration of rotator cuff symptoms was 4 (median 4, IQR 3–6) months.

TABLE 6 Participant baseline characteristics ('inside the table')

Characteristic	Best-practice advice ($N = 174$)	Injection plus best-practice advice ($N = 178$)	Progressive exercise ($N = 174$)	Injection plus progressive exercise ($N = 182$)
Age (years), mean (SD), n	55.9 (13.1), 174	56.5 (12.4), 178	54.6 (13.7), 174	54.8 (13.2), 182
18–35 years, n (%) ^a	11 (6.3)	13 (7.3)	14 (8.0)	17 (9.3)
≥ 36 years, n (%) ^a	163 (93.7)	165 (92.7)	160 (92.0)	165 (90.7)
Sex, n (%) ^a				
Male	87 (50.0)	89 (50.0)	90 (51.7)	93 (51.1)
Female	87 (50.0)	89 (50.0)	84 (48.3)	89 (48.9)
Ethnicity, n (%)				
White	160 (92.0)	167 (93.8)	154 (88.5)	167 (91.8)
Other	14 (8.0)	11 (6.2)	18 (10.4)	15 (8.2)
Missing	0 (0.0)	0 (0.0)	2 (1.1)	0 (0.0)
Marital status, n (%)				
Married/civil union	118 (67.8)	107 (60.1)	114 (65.5)	120 (65.9)
Living with partner	24 (13.8)	23 (12.9)	22 (12.6)	24 (13.2)
Other	32 (18.4)	48 (27.0)	36 (20.8)	38 (20.9)
Missing	0 (0.0)	0 (0.0)	2 (1.1)	0 (0.0)
Height (m), mean (SD), n	1.7 (0.0), 174	1.7 (0.0), 178	1.7 (0.2), 172	1.7 (0.2), 182
Weight (kg), mean (SD), n	80.9 (16.6), 174	82.9 (17.4), 176	81.2 (18.4), 170	81.7 (18.0), 180

TABLE 6 Participant baseline characteristics ('inside the table') (continued)

Characteristic	Best-practice advice (N = 174)	Injection plus best-practice advice (N = 178)	Progressive exercise (N = 174)	Injection plus progressive exercise (N = 182)
Body mass index (kg/m ²), mean (SD), n	27.9 (5.0), 174	28.7 (5.4), 176	28.0 (5.4), 170	28.1 (4.8), 180
Underweight (< 18.5 kg/m ²), n (%)	3 (1.7)	1 (0.6)	0 (0.0)	0 (0.0)
Normal weight (18.5–24.9 kg/m ²), n (%)	51 (29.3)	51 (28.7)	50 (28.7)	53 (29.1)
Overweight (25–29.9 kg/m ²), n (%)	68 (39.1)	63 (35.4)	73 (42.0)	70 (38.5)
Obese (≥ 30 kg/m ²), n (%)	52 (29.9)	61 (34.3)	47 (27.0)	57 (31.3)
Missing	0 (0.0)	2 (1.1)	4 (2.3)	2 (1.1)
Smoking status, n (%)				
Never smoked	85 (48.9)	100 (56.2)	99 (56.9)	101 (55.5)
Former smoker	66 (37.9)	66 (37.1)	61 (35.1)	63 (34.6)
Current smoker	23 (13.2)	12 (6.7)	12 (6.9)	18 (9.9)
Missing	0 (0.0)	0 (0.0)	2 (1.1)	0 (0.0)
Cigarettes smoked per day (current smoker), median (IQR), n	10 (10, 15), 21	15 (5, 18), 11	13 (8, 18), 12	10 (6, 12), 17
Cigarettes smoked per day (former smoker), median (IQR), n	13.5 (6–20), 66	15.0 (10–20), 66	10.0 (5–20), 60	10.0 (8–20), 63
Symptoms duration, median (IQR), n	4.0 (2–6), 173	4.0 (3–6), 178	4.0 (3–6), 172	4.0 (3–6), 182
Affected shoulder, n (%)				
Left shoulder	89 (51.1)	78 (43.8)	83 (47.7)	82 (45.1)
Right shoulder	78 (44.8)	94 (52.8)	84 (48.3)	93 (51.1)
Both shoulders	7 (4.0)	6 (3.4)	5 (2.9)	7 (3.8)
Missing	0 (0.0)	0 (0.0)	2 (1.1)	0 (0.0)
Hand dominance, n (%)				
Left-handed	13 (7.5)	16 (9.0)	21 (12.1)	21 (11.5)
Right-handed	157 (90.2)	153 (86.0)	148 (85.1)	158 (86.8)
Both	4 (2.3)	9 (5.1)	3 (1.7)	3 (1.6)
Missing	0 (0.0)	0 (0.0)	2 (1.1)	0 (0.0)
Current work status, n (%)				
Retired	44 (25.3)	50 (28.1)	40 (23.0)	49 (26.9)
Semi-retired	13 (7.5)	10 (5.6)	9 (5.2)	7 (3.8)
Employed	84 (48.2)	91 (51.1)	98 (56.3)	82 (45.1)
Other	33 (19.0)	27 (15.2)	25 (14.4)	43 (23.7)
Missing	0 (0.0)	0 (0.0)	2 (1.1)	1 (0.5)
SPADI, mean (SD), n				
Pain subscale	66.0 (17.7), 174	64.2 (18.3), 178	60.7 (17.1), 172	64.6 (17.5), 182
Function subscale	48.1 (23.2), 174	46.3 (22.0), 178	40.3 (21.0), 172	42.6 (21.6), 182
SPADI overall	57.0 (19.2), 174	55.3 (18.9), 178	50.5 (17.5), 172	53.6 (17.8), 182

continued

TABLE 6 Participant baseline characteristics ('inside the table') (continued)

Characteristic	Best-practice advice (N = 174)	Injection plus best-practice advice (N = 178)	Progressive exercise (N = 174)	Injection plus progressive exercise (N = 182)
FABQ-PA, mean (SD), <i>n</i>	15.6 (5.8), 172	15.7 (5.4), 177	14.2 (5.5), 172	14.8 (5.3), 182
PSEQ-2, mean (SD), <i>n</i>	9.6 (2.4), 174	9.5 (2.3), 178	9.8 (2.3), 172	9.7 (2.3), 182
ISI, mean (SD), <i>n</i>	11.0 (6.7), 173	10.4 (6.2), 176	9.5 (5.7), 170	11.1 (6.4), 180
RDA, mean (SD), <i>n</i>	8.0 (2.7), 174	8.2 (2.5), 178	7.6 (2.7), 172	7.7 (2.6), 182
Trial centre, <i>n</i> (%) ^a				
1	12 (6.9)	9 (5.1)	12 (6.9)	13 (7.1)
2	26 (14.9)	26 (14.6)	25 (14.4)	25 (13.7)
3	29 (16.7)	30 (16.9)	31 (17.8)	30 (16.5)
4	8 (4.6)	7 (3.9)	7 (4.0)	7 (3.8)
5	9 (5.2)	8 (4.5)	8 (4.6)	10 (5.5)
6	3 (1.7)	3 (1.7)	4 (2.3)	4 (2.2)
7	3 (1.7)	4 (2.2)	3 (1.7)	4 (2.2)
8	5 (2.9)	6 (3.4)	7 (4.0)	5 (2.7)
9	4 (2.3)	3 (1.7)	4 (2.3)	2 (1.1)
10	7 (4.0)	7 (3.9)	8 (4.6)	9 (4.9)
11	1 (0.6)	1 (0.6)	1 (0.6)	1 (0.5)
12	12 (6.9)	12 (6.7)	13 (7.5)	12 (6.6)
13	8 (4.6)	8 (4.5)	7 (4.0)	10 (5.5)
14	7 (4.0)	9 (5.1)	6 (3.4)	7 (3.8)
15	9 (5.2)	9 (5.1)	8 (4.6)	10 (5.5)
16	9 (5.2)	10 (5.6)	8 (4.6)	9 (4.9)
17	6 (3.4)	7 (3.9)	6 (3.4)	6 (3.3)
18	9 (5.2)	11 (6.2)	9 (5.2)	11 (6.0)
19	2 (1.1)	3 (1.7)	3 (1.7)	3 (1.6)
20	5 (2.9)	5 (2.8)	4 (2.3)	4 (2.2)
a Stratification factor used in randomisation.				

The overall mean baseline SPADI score was 54.1 (SD 18.5) (on a scale of 0–100, with higher values being worse), suggesting a moderate level of disability, with higher levels of shoulder pain (mean SPADI pain subscale 63.9, SD 17.1) compared with impairment of shoulder function (mean SPADI function subscale 44.3, SD 22.1). Overall baseline scores for secondary outcome measures were mean 15.1 (SD 5.5) for FABQ-PA, mean 9.7 (SD 2.3) for PSEQ-2, mean 10.5 (SD 6.3) for ISI and mean 7.9 (SD 2.6) for RDA. Mean baseline values were in the moderate to low range, suggesting that a participant's rotator cuff disorder may not be having considerable impact on sleep and daily activities despite higher levels of pain.

Follow-up

Participants were followed up at 8 weeks and at 6 and 12 months; overall response rates were 91% (641/708), 87% (615/708) and 87% (618/708), respectively. Response rates were generally well balanced across intervention groups. *Appendix 4, Table 35*, shows the number of responses according to type of follow-up (i.e. postal or telephone questionnaire).

Withdrawals

Overall, 26 (3.7%) participants withdrew from the trial: 15 withdrew from the intervention delivery only and 11 withdrew from both the intervention and follow-up questionnaire completion. Numbers were very similar across intervention groups. One participant withdrew completely from the trial and withdrew permission to use their data. Details of the reasons for withdrawal by intervention group are shown in *Table 7*. Two participants died and both deaths were unrelated to the trial intervention(s).

Intervention delivery

Compliance with intervention

Of the 708 participants randomised, the majority received treatment as allocated, with 94% (339/360) of participants randomised to receive subacromial corticosteroid injection prior to either the best-practice advice or progressive-exercise intervention receiving the injection as allocated (*Table 8*).

TABLE 7 Participant withdrawals and reason for withdrawal

Reason for withdrawal	Best-practice advice (N = 174)		Injection plus best-practice advice (N = 178)		Progressive exercise (N = 174)		Injection plus progressive exercise (N = 182)		Overall (N = 708)	
	n	%	n	%	n	%	n	%	n	%
Overall ^a										
Complete withdrawal from use of data	0	0	0	0	1	1	0	0	1	0
Withdrawn from intervention ^a	3	2	4	2	2	1	6	3	15	2
Believes intervention not working	1	1	1	1	0	0	0	0	2	0
Change of diagnosis since randomisation	0	0	3	2	1	1	4	2	8	1
Had treatment preference	1	1	0	0	0	0	0	0	1	0
No reason given	1	1	0	0	0	0	0	0	1	0
Pain has improved	0	0	0	0	1	1	0	0	1	0
Unable to continue with treatment	0	0	0	0	0	0	2	1	2	0
Withdrawn from intervention and future assessments ^a	4	2	3	2	3	2	0	0	11	2
Believes intervention not working	0	0	1	1	1	1	0	0	2	0
Change of diagnosis since randomisation	3	2	0	0	1	1	0	0	4	1
No reason given	1	1	2	1	1	1	0	0	4	1
Missing	0	0	0	0	0	0	0	0	1	0

^a Death (unrelated to the study intervention) was reported for two participants at the 6-month follow-up. One participant withdrew from the intervention and another was classified as withdrawn from intervention and future assessments following notice of their death.

TABLE 8 Intervention received

Intervention received	Best-practice advice ^a (N = 174)	Injection plus best-practice advice ^a (N = 178)	Progressive exercise ^b (N = 174)	Injection plus progressive exercise ^b (N = 182)
Injection received, <i>n</i> (%)		168 (94)		171 (94)
Injection not received, <i>n</i> (%)		10 (6)		11 (6)
Did not attend, <i>n</i> (participants)		1		2
Participant declined, <i>n</i> (participants)		4		4
Clinician declined, <i>n</i> (participants)		5		5
Received extra injection, <i>n</i> (participants)		0		2
Completed exercise treatment, ^c <i>n</i> (%)	162 (93)	162 (91)	138 (79)	139 (76)
Partial exercise completion, ^d <i>n</i> (%)			29 (17)	33 (18)
Received no treatment, <i>n</i> (%)	12 (7)	16 (9)	7 (4)	10 (5)
Did not attend/unable to contact, <i>n</i> (participants)	5	6	3	3
Withdrawal/declined, <i>n</i> (participants)	4	2	1	0
Other condition, <i>n</i> (participants)	3	4	0	2
Received wrong trial intervention, <i>n</i> (participants)	0	3	2	2
Received non-GRASP trial treatment, <i>n</i> (participants)	0	1	1	3
Median number of sessions (IQR)	1 (1–1)	1 (1–1)	4 (3–6)	4 (3–5)
Attendance, <i>n</i> (%)				
Session 1	162 (93)	162 (91)	167 (96)	172 (95)
Session 2			161 (93)	160 (88)
Session 3			144 (83)	136 (75)
Session 4			101 (58)	100 (55)
Session 5			72 (41)	69 (38)
Session 6			44 (25)	38 (21)
Participants receiving additional sessions, <i>n</i> (%)	3 (2)	5 (3)	3 (2)	2 (1)
Additional contact sessions, ^e <i>n</i>	4	6	3	5
Telephone	2	1	0	1
Face to face	2	5	3	4

a Maximum of one session of best-practice advice.

b Up to six sessions of progressive exercise.

c Best-practice advice: attendance at one or more sessions. Progressive exercise: six sessions attended, discharged by clinician as treatment completed (as marked on treatment log), discharged by clinician following patient-initiated follow-up period with no further contact or referred on for further investigation/treatment.

d Defined as attendance at one or more sessions.

e Some participants received more than one additional contact.

For the exercise interventions, there was no difference in attendance rates between those receiving the exercise interventions only and those who received exercise in conjunction with a corticosteroid injection. Overall, 92% (324/352) of participants of those allocated to receive the best-practice advice intervention attended, and 95% (339/356) of participants allocated to receive progressive exercise either partially or fully completed the exercise intervention.

The proportion of participants not attending any treatment sessions was roughly equal between intervention groups. For the progressive-exercise intervention, just over half of participants received four out of a maximum of six sessions, with almost 80% receiving at least three sessions. Note that, participants could be discharged prior to attending six sessions if their symptoms had improved sufficiently.

A small number of participants received extra treatment over and above the interventions defined by the GRASP trial protocol. Two sites reported that two participants received a second subacromial corticosteroid injection in addition to that received as part of their treatment allocation. With regard to the exercise interventions, eight participants allocated to receive best-practice advice received a total of 10 additional sessions. For progressive exercise, five participants received a total of eight additional sessions over and above the six-session maximum. Three of the 13 participants who received additional sessions required further reassurance regarding their condition and/or the exercise programme, four required further session(s) before treatment was concluded satisfactorily, three reported a re-occurrence or suffered re-injury and three reported no improvement in symptoms. There was no sizeable difference in the proportion of participants receiving additional sessions (nor the reasons for further contact) between the four intervention groups.

Timing of delivery of interventions

Appendix 4, Table 36, presents median time from randomisation to first appointments for each intervention group. Subacromial corticosteroid injections prior to receiving the best-practice advice or progressive-exercise interventions were largely delivered within 10 days of randomisation in accordance with the GRASP trial protocol. The first session of the exercise interventions was also delivered within the required time frames for all trial groups, with the majority of participants being seen between 14 and 28 days after randomisation. Participants randomised to injection received their first exercise session 6 days later, on average, than those who were not allocated to receive an injection, possibly because of logistical issues with booking appointments. The progressive-exercise intervention was generally completed within the recommended 16-week time frame, with the median time corresponding to between 13 and 15 weeks for both intervention groups. The initial delay experienced by those who received an injection prior to their exercise sessions is reflected in the longer time to the last session, although the 'actual' exercise treatment period (i.e. first to last exercise session) was almost identical for both progressive-exercise arms.

Content and adherence to interventions

Injecting clinicians and physiotherapists completed a treatment log for each session, detailing the type of treatment provided.

Subacromial corticosteroid injection

Triamcinolone acetonide was the most commonly delivered corticosteroid, accounting for 64% (218/339) of injections delivered overall. The remaining 36% (121/339) of participants received methylprednisolone injection (Table 9). Lidocaine 1% was the most commonly delivered local anaesthetic (294/339, 87%), with only 10% (33/339) receiving 0.5% bupivacaine hydrochloride. Twelve participants received no local anaesthetic (4%), usually because of clinician preference or previous history of adverse reactions. The majority of injections were administered into the posterior subacromial space (278/339, 82%). There were no meaningful differences in injection delivery between the two injection groups. The median dose of corticosteroid prescribed was 40 mg (range of 10–40 mg for methylprednisolone and 20–40 mg for triamcinolone acetonide) and the median volume of local anaesthetic was 4 (range of 0.2–5) ml for 1% lidocaine and 9 (range 2–10) ml for 0.5% bupivacaine hydrochloride, indicating that the injection protocol was adhered to by all injecting therapists.

TABLE 9 Content of subacromial corticosteroid injection

Content of injection ^a	Injection plus progressive exercise (N received injection = 171)	Injection plus best-practice advice (N received injection = 168)	Total (N received injection = 339)
Corticosteroid, n (%), median dose/volume (IQR)			
Methylprednisolone (mg)	60 (35), 40 (32–40)	61 (36), 40 (30–30)	121 (36), 40 (30–40)
Triamcinolone acetonide (mg)	111 (65), 40 (20–20)	107 (64), 40 (20–40)	218 (64), 40 (20–40)
Local anaesthetic, n (%), median dose/volume (IQR)			
1% lidocaine (ml)	148 (87), 4 (2–5)	146 (87), 4 (2–5)	294 (87), 4 (2–5)
0.5% bupivacaine hydrochloride (ml)	18 (11), 9 (9–9)	15 (9), 9 (9–10)	33 (10), 9 (9–9)
None	5 (3)	7 (4)	12 (4)
Shoulder, n (%)			
Right shoulder	91 (53)	90 (54)	181 (53)
Left shoulder	80 (47)	78 (46)	158 (47)
Injection site, n (%)			
Anterior subacromial	13 (7)	14 (8)	27 (8)
Posterior subacromial	142 (83)	136 (81)	278 (82)
Lateral subacromial	15 (9)	15 (9)	30 (9)
Glenohumeral joint	1 (1)	3 (2)	4 (1)
a Per cent of participants who received injection.			

Best-practice advice intervention

Table 10 provides a summary of the treatment logs per session for the best-practice advice intervention. The figures indicate a high level of compliance (as recorded by the treating physiotherapist) with the treatment protocols with regard to provision of exercises, advice, information and treatment compliance strategies. Resisted (isotonic) shoulder external rotation in neutral and active-assisted (wall) shoulder flexion were the most commonly prescribed starting exercises. Ninety-eight per cent (318/324) of participants were prescribed one or two exercises at their treatment session. There were no meaningful differences between those randomised to receive corticosteroid injection plus band and those who received best-practice advice only.

Progressive-exercise intervention

Table 11 (see also Appendix 4, Table 37) provides details of the delivery of the progressive-exercise intervention for each session, as recorded by the treating physiotherapist on the participant treatment log. Similar to the best-practice advice intervention, the figures illustrate a high level of compliance in delivering the various components of the intervention. The most commonly prescribed exercises were from the core exercise section, aimed at strengthening the posterior rotator cuff muscles. All participants in the progressive-exercise intervention received the required number of exercises (i.e. three or less). Level 2 strengthening exercises were the core element of the progressive-exercise intervention and, when these were prescribed, participants were initially expected to perform one set of up to eight repetitions at a load of 3–4 on the modified 10-point Borg scale. Of the 339 participants who attended, 98% (332/339) received these core exercises. In accordance with the trial protocol, data from the treatment logs suggest that on initial presentation, 72% (238/332) of participants

TABLE 10 Content of best-practice advice intervention

Treatment component		Best-practice advice only (N received best-practice advice = 162), n (%) ^a	Injection plus best-practice advice (N received best-practice advice = 162), n (%) ^a	Total (N received best-practice advice = 324), n (%) ^a
Exercises prescribed		162 (100)	162 (100)	324 (100)
Advice/information booklet provided		161 (99)	162 (100)	323 (100)
Exercise diary issued		162 (100)	159 (98)	321 (99)
Action planner completed		160 (99)	160 (99)	320 (99)
Exercise video online/DVD provided		160 (99)	158 (98)	318 (98)
Exercise^b				
1	(a) Shoulder abduction supported by table in sitting	31 (10)	20 (6)	51 (8)
	(b) Shoulder flexion supported by table in sitting	22 (7)	18 (6)	40 (6)
2	(a) Isometric shoulder external rotation	29 (9)	30 (9)	59 (9)
	(b) Isometric shoulder abduction	36 (11)	35 (11)	71 (11)
3	(a) Resisted shoulder external rotation: 0 degrees	89 (28)	82 (26)	171 (27)
	(b) Shoulder flexion up a wall	60 (19)	66 (21)	126 (20)
4	(a) Resisted shoulder external rotation: 90 degrees	16 (5)	32 (10)	48 (8)
	(b) Shoulder raise using a weight	26 (8)	30 (9)	56 (9)
5	(a) Resisted shoulder abduction/external rotation ^c	11 (3)	7 (2)	18 (3)
Total		320 (100)	320 (100)	640 (100)
a Per cent of those who attended best-practice advice.				
b Number of times exercise prescribed. Number of participants attending = 324, but participants usually received more than one exercise.				
c Using resistance band.				

were prescribed one set of exercises, 74% (247/332) were prescribed up to eight repetitions and 83% (277/332) were requested to perform at a load of 3–4 on the Borg scale. Note that 55% (184/332) of participants were prescribed all of these components correctly in combination and in accordance with the protocol. Where the protocol was not adhered to, clinicians nearly always overprescribed by including additional sets and/or repetitions, or by setting higher intensities with target Borg scale scores of > 4. Only 3% (10/332) of participants were underprescribed at the initial session, with all of these relating to lower-target Borg scale scores.

Exercise progression

Appendix 4, Table 38, describes the proportion of participants who were progressed, maintained or regressed, as defined previously in Chapter 3. Two-thirds (227/339) of participants who received the progressive-exercise intervention had their exercise progressed in accordance with the instructions provided in training. A small minority of participants had their exercise programme regressed (39/339, 12%) overall, whereas the remaining participants maintained (73/339; 22%) exercising at the same level as the initial session over the course of their treatment.

TABLE 11 Content of progressive-exercise intervention

Session ^a	Intervention	Attended, n (%)	Exercises prescribed, n (%)	Advice/information booklet provided, n (%)	Exercise diary issued/reviewed, n (%)	Action planner completed/ reviewed, n (%)	Confidence ruler reviewed, n (%)
1	Progressive exercise only	167 (100)	167 (100)	166 (99)	164 (98)	163 (98)	165 (99)
	Injection plus progressive exercise	172 (100)	172 (100)	171 (99)	171 (99)	172 (100)	172 (100)
2	Progressive exercise only	161 (100)	160 (99)	30 (19)	153 (95)	91 (57)	150 (93)
	Injection plus progressive exercise	160 (100)	158 (99)	28 (18)	147 (92)	99 (62)	144 (90)
3	Progressive exercise only	144 (100)	138 (96)	23 (16)	133 (92)	88 (61)	124 (86)
	Injection plus progressive exercise	136 (100)	132 (97)	25 (18)	126 (93)	88 (65)	117 (86)
4	Progressive exercise only	101 (100)	96 (95)	22 (22)	94 (93)	69 (68)	88 (87)
	Injection plus progressive exercise	100 (100)	94 (94)	19 (19)	93 (93)	67 (67)	88 (88)
5	Progressive exercise only	72 (100)	66 (92)	16 (22)	66 (92)	52 (72)	62 (86)
	Injection plus progressive exercise	69 (100)	66 (96)	11 (16)	64 (93)	49 (71)	62 (90)
6	Progressive exercise only	44 (100)	42 (95)	14 (32)	38 (86)	31 (70)	37 (84)
	Injection plus progressive exercise	38 (100)	36 (95)	4 (11)	35 (92)	25 (66)	34 (89)

a Percentage of those who attended session.

Participant-reported adherence to exercise

As part of the participant follow-up questionnaires, participants were asked whether or not they were currently performing the exercises the physiotherapist asked them to complete at home as part of the GRASP trial. A total of 77.8% of participants reported 'yes' at 8 weeks, but this dropped to 49.3% and 32.1% at 6 and 12 months, respectively. Participants were also asked how often they were performing these exercises. *Appendix 4, Table 39*, shows the difference in proportions across intervention groups. At 8 weeks, participants who received progressive exercise were more likely to report performing their exercises 5 days per week than those receiving best-practice advice (60.4% vs. 43.2%) and there was little difference at 6 and 12 months. At 8 weeks and 6 months, participants who received injection were more likely to report performing their exercises 5 days per week than those who received no injection (8 weeks, 57.5% vs. 46.0%; 6 months, 21.4% vs. 12.1%). There was little difference at 12 months.

Quality assurance

As well as monitoring intervention delivery using the treatment logs, annual site visits using a standardised checklist to audit adherence to the GRASP trial protocol were conducted to evaluate the delivery of the interventions. A total of 48 visits involving 45 physiotherapists took place during the trial at 19 of the 20 trial sites. One site was not visited because of the small numbers recruited ($n = 4$). Observation of the treatment sessions indicated that all physiotherapists were following the protocol satisfactorily. Only two physiotherapists swapped treatment groups during the trial, because of staffing issues, and, therefore, delivered both exercise interventions. Feedback regarding suggested areas of improvement was provided after the treatment session. In general, the most common areas discussed were related to improving the assessment of potential barriers to participants' performance of the home exercise programme, linking the performance of the exercises with relevant functional goals and attempting to involve the participant more in the exercise prescription process.

Outcomes and estimations

The primary analysis was ITT and was based on all participants with at least one follow-up time point SPADI outcome and the baseline variables used in the model. From the 708 participants randomised, primary outcome data were available for 90.1% ($n = 638$) of participants at 8 weeks, 86.9% ($n = 615$) of participants at 6 months and 87.1% ($n = 617$) of participants at 12 months. A total of 1869 participant data points contributed to the primary outcome-adjusted analysis model. The number of participants contributing data to each of the secondary outcomes are presented separately.

Primary outcome: shoulder pain and function – SPADI

The primary outcome was shoulder pain and function measured using the SPADI scale over 12 months. There was a considerable overall improvement in SPADI score in each of the four intervention groups from baseline over time. Overall, this represents a 32.2 (SD 23.9)-point improvement on the SPADI scale [overall SPADI score 54.1 (SD 18.4) at baseline and 21.9 (SD 23.4) at 12 months] (*Table 12*). There is no substantial evidence of a floor or ceiling effect in SPADI score, which is considered to be present if $> 15\%$ of the respondents achieved the lowest or highest possible score, respectively.⁸³

Interaction

As per the SAP,³⁷ the presence of an interaction on the primary outcome was formally investigated. A repeated-measures linear mixed-effects regression model was fitted to test the presence of an

TABLE 12 Shoulder Pain and Disability Index summary at each time point by randomised group

Time point	Best-practice advice (N = 174)	Injection plus best-practice advice (N = 178)	Progressive exercise (N = 174)	Injection plus progressive exercise (N = 182)	Overall (N = 708)
Baseline	57.0 (19.0), 174	55.3 (19.0), 178	50.5 (17.4), 172	53.6 (17.8), 182	54.1 (18.5), 706
8 weeks	43.8 (22.6), 149	33.5 (21.6), 163	39.7 (21.6), 157	37.9 (24.0), 169	38.6 (22.8), 638
6 months	28.3 (24.4), 143	28.1 (23.4), 158	24.1 (22.2), 151	26.6 (24.0), 163	26.8 (23.6), 615
12 months	24.0 (24.8), 143	23.9 (23.5), 160	17.9 (21.1), 153	21.7 (24.0), 161	21.9 (23.4), 617
Note Values are mean (SD), <i>n</i> .					

interaction between injection and progressive exercise. The model was adjusted for the fixed effects of age (continuous value), sex, baseline SPADI and time point, with random intercepts by centre, physiotherapist and observations within participant. The physiotherapist treating the largest number of sessions was selected for each participant and included in the model. The interaction coefficient between progressive exercise and injection over 12 months was 2.17 (95% CI -2.96 to 7.31; $p = 0.407$), showing no evidence of a statistically significant interaction effect. Additionally, the interaction was assessed at each time point using a regression model adjusted for similar variables. At 8 weeks, the interaction was 3.41 (95% CI -3.24 to 10.06; $p = 0.314$), at 6 months the interaction was -1.88 (95% CI -9.98 to 6.22; $p = 0.649$) and at 12 months the interaction was 2.25 (95% CI -5.76 to 10.26; $p = 0.581$), showing no evidence of a statistically significant effect. As per the SAP, the analysis at the margins is, therefore, the primary analysis for interpretation (i.e. considering the main effects of injection vs. no injection and progressive exercise vs. best-practice advice). Inside-the-table analysis results are reported in *Appendix 4, Tables 40 and 41*, for completeness.

The results presented here are for the two main effect comparisons:

1. an individually tailored progressive-exercise programme compared with a best-practice advice session with a physiotherapist supported by high-quality materials
2. subacromial corticosteroid injection compared with no injection.

SPADI: progressive exercise compared with best-practice advice

Table 13 presents the unadjusted and adjusted results for SPADI at 8 weeks and at 6 and 12 months. Figure 4 shows an improvement in shoulder pain and function in both intervention groups over time. However, there was no evidence of a statistically significant difference between the progressive-exercise intervention and best-practice advice intervention in shoulder pain and function when analysed over 12 months (adjusted mean SPADI difference between groups -0.66, 99% CI -4.52 to 3.20). There was also no statistically significant difference between progressive exercise and best-practice advice when analysed at 8 weeks and at 6 and 12 months (adjusted MD at 12 months -3.10, 99% CI -7.85 to 1.64).

SPADI: injection compared with no injection

Table 14 presents the unadjusted and adjusted results for SPADI at 8 weeks and at 6 and 12 months. Figure 5 shows an improvement in shoulder pain and function in both groups over time. Injection resulted in an improvement in shoulder pain and function when analysed at 8 weeks compared with no injection (adjusted mean SPADI difference between groups -5.64, 99% CI -9.93 to -1.35).

TABLE 13 Progressive exercise vs. best-practice advice at-the-margins analysis of SPADI

SPADI	n	Best-practice advice			Progressive exercise				Between-group adjusted difference (99% CI)	p-value ^a
		Unadjusted mean (SD)	n	Adjusted mean (SE)	n	Unadjusted mean (SD)	n	Adjusted mean (SE)		
Baseline	352	56.1 (19)			354	52.1 (17.7)				
8 weeks	312	38.4 (22.7)	297	36.96 (1.32)	326	38.7 (22.9)	316	39.50 (1.26)	2.54 (−2.16 to 7.23)	0.164
6 months	301	28.2 (23.8)	288	27.39 (1.33)	314	25.4 (23.1)	307	25.87 (1.27)	−1.52 (−6.26 to 3.22)	0.410
12 months	303	24.0 (24.1)	288	23.67 (1.33)	314	19.9 (22.7)	307	20.57 (1.27)	−3.10 (−7.85 to 1.64)	0.092
Over 12 months	339	30.3 (24.3)	339	29.41 (1.08)	343	28.1 (24.2)	343	28.75 (1.03)	−0.66 (−4.52 to 3.20)	0.659
CACE estimate ^b									−0.27 (−2.69 to 2.16)	0.830

a SPADI analysis adjusted for age, sex and baseline SPADI, with random effects within participant, physiotherapist and centre.

b 95% CI presented.




FIGURE 4 Marginal adjusted mean SPADI values from the repeated measures mixed-effects model and associated 99% CIs for the two treatment groups from baseline to 12 months: best-practice advice vs. progressive exercise.

TABLE 14 Injection vs. no injection at-the-margins analysis of SPADI

SPADI	No injection				Injection				Between-group adjusted difference (99% CI)	p-value ^a
	n	Unadjusted mean (SD)	n	Adjusted mean (SE)	n	Unadjusted mean (SD)	n	Adjusted mean (SE)		
Baseline	346	53.8 (18.6)			360	54.4 (18.4)				
8 weeks	306	41.7 (22.2)	300	41.16 (1.24)	332	35.7 (22.9)	313	35.52 (1.22)	-5.64 (-9.93 to -1.35)	0.001
6 months	294	26.2 (23.4)	289	26.33 (1.26)	321	27.3 (23.7)	306	26.85 (1.23)	0.52 (-3.82 to 4.86)	0.758
12 months	296	20.9 (23.1)	290	21.07 (1.26)	321	22.8 (23.7)	305	23.00 (1.23)	1.93 (-2.41 to 6.27)	0.251
Over 12 months	330	29.7 (24.5)	330	29.63 (1.0)	352	28.7 (24.0)	352	28.53 (0.98)	-1.11 (-4.47 to 2.26)	0.397
CACE estimate ^b									-1.50 (-3.61 to 0.61)	0.164

a SPADI analysis adjusted for age, sex and baseline SPADI, with random effects within participant, physiotherapist and centre.

b 95% CI presented.




FIGURE 5 Marginal adjusted mean SPADI values from the repeated measures mixed-effects model and associated 99% CIs for the two treatment groups from baseline to 12 months: injection vs. no injection.

This difference was not deemed clinically significant where the MCID on the SPADI scale is 8 points on a scale of 0–100. There was no statistically significant difference between injection and no injection when analysed over 12 months (adjusted MD -1.11 , 99% CI -4.47 to 2.26) or when analysed at 6 and 12 months (adjusted MD at 12 months 1.93 , 99% CI -2.41 to 6.27).

Sensitivity analysis

Complier-average causal effect analysis

The primary outcome was analysed in the ITT population. An additional CACE analysis was used to investigate the role of compliance with intervention on the trial effects for the primary outcome. Compliance with intervention was defined in the SAP³⁷ as follows. For the progressive-exercise intervention, participants were considered compliant with treatment if they had been signed off for completing treatment or if they received all six physiotherapy sessions. For the injection intervention, participants were considered compliant if they received at least one injection. Compliance with treatment by intervention group is summarised in *Table 8*. As no evidence of a statistical interaction effect between interventions was identified, the CACE analysis was conducted at the margins for the two main effect comparisons.

Progressive exercise compared with best-practice advice

The proportion of compliers in the progressive-exercise intervention group was 78%. Compliance with the progressive-exercise intervention did not have a significant effect on the primary outcome. The CACE estimate analysis for progressive exercise over 12 months was (mean adjusted difference) -0.27 (95% CI -2.69 to 2.16 ; $p = 0.830$) (see *Table 13*). The model included 1869 participant data points and was adjusted for sex, age, baseline SPADI and centre. The variable for primary physiotherapist was omitted from this analysis because of collinearity.

Injection compared with no injection

The proportion of compliers in the injection treatment group was 94%. Compliance with injection did not have a significant effect on the primary outcome. The CACE estimate analysis for injection over 12 months was mean adjusted difference -1.50 (95% CI -3.61 to 0.61 ; $p = 0.164$) (see *Table 14*). The model included 1869 participant data points and was adjusted for sex, age, baseline SPADI and centre. The variable for primary physiotherapist was, again, omitted because of collinearity.

Secondary outcomes

The results presented here for secondary outcomes are for the two main effect comparisons.

Progressive exercise compared with best-practice advice

Table 15 presents the adjusted analysis results for the comparison of progressive exercise with best-practice advice for each of the secondary outcomes at 8 weeks and at 6 and 12 months (for unadjusted results see Appendix 4, Table 42).

TABLE 15 Analysis of secondary outcomes for progressive exercise vs. best-practice advice at 8 weeks, 6 months and 12 months

Secondary outcome	Best-practice advice		Progressive exercise		Between-group adjusted difference (95% CI)	p-value ^a
	n	Adjusted mean (SE)	n	Adjusted mean (SE)		
SPADI: pain						
8 weeks	300	49.9 (1.4)	316	39.5 (1.3)	2.12 (−1.94 to 6.17)	0.306
6 months	289	32.0 (1.4)	307	25.9 (1.3)	−3.06 (−7.16 to 1.04)	0.144
12 months	290	25.8 (1.4)	307	20.6 (1.3)	−4.01 (−8.11 to 0.09)	0.055
Over 12 months	339	36.0 (1.3)	343	34.5 (1.2)	−1.61 (−4.94 to 1.72)	0.343
SPADI: function						
8 weeks	298	29.40 (1.24)	316	31.77 (1.19)	2.37 (−1.01 to 5.76)	0.169
6 months	288	20.95 (1.26)	307	20.65 (1.21)	−0.30 (−3.72 to 3.12)	0.863
12 months	288	18.74 (1.26)	307	16.12 (1.20)	−2.61 (−6.03 to 0.81)	0.134
Over 12 months	339	23.1 (1.0)	343	22.9 (1.0)	−0.15 (−2.92 to 2.61)	0.913
FABQ-PA						
8 weeks	269	11.62 (0.37)	301	11.94 (0.35)	0.32 (−0.68 to 1.33)	0.531
6 months	266	9.93 (0.37)	281	9.51 (0.36)	−0.42 (−1.44 to 0.60)	0.417
12 months	266	9.29 (0.37)	284	8.32 (0.36)	−0.97 (−1.99 to 0.05)	0.061
Over 12 months	324	10.3 (0.30)	332	9.94 (0.28)	−0.35 (−1.16 to 0.46)	0.396
PSEQ-2						
8 weeks	271	10.25 (0.13)	300	10.19 (0.12)	−0.06 (−0.39 to 0.27)	0.737
6 months	267	10.41 (0.13)	282	10.42 (0.13)	0.01 (−0.33 to 0.34)	0.960
12 months	267	10.59 (0.13)	284	10.70 (0.13)	0.12 (−0.22 to 0.45)	0.492
Over 12 months	325	10.41 (0.10)	332	10.43 (0.10)	0.02 (−0.23 to 0.27)	0.863
ISI						
8 weeks	267	7.46 (0.32)	294	8.09 (0.31)	0.63 (−0.25 to 1.50)	0.159
6 months	264	6.20 (0.32)	281	6.20 (0.31)	−0.01 (−0.89 to 0.88)	0.990
12 months	267	5.92 (0.32)	282	5.40 (0.31)	−0.52 (−1.40 to 0.36)	0.249
Over 12 months	323	6.53 (0.27)	329	6.57 (0.26)	0.04 (−0.69 to 0.77)	0.916
RDA						
8 weeks	270	6.08 (0.14)	297	6.33 (0.13)	0.25 (−0.12 to 0.62)	0.189
6 months	267	5.42 (0.14)	284	5.10 (0.14)	−0.31 (−0.69 to 0.06)	0.101
12 months	268	4.81 (0.14)	285	4.67 (0.14)	−0.14 (−0.51 to 0.24)	0.466
Over 12 months	325	5.44 (0.11)	332	5.38 (0.11)	−0.06 (−0.36 to 0.23)	0.662

continued

continued

TABLE 15 Analysis of secondary outcomes for progressive exercise vs. best-practice advice at 8 weeks, 6 months and 12 months (*continued*)

Secondary outcome	Best-practice advice		Progressive exercise		Between-group adjusted difference (95% CI)	p-value ^a
	n	Adjusted mean (SE)	n	Adjusted mean (SE)		
GIT						
8 weeks	269	7.65 (0.13)	298	7.75 (0.13)	0.11 (−0.25 to 0.47)	0.555
6 months	267	8.16 (0.13)	285	8.69 (0.13)	0.53 (0.17 to 0.90)	0.004
12 months	270	8.57 (0.13)	286	9.08 (0.13)	0.51 (0.14 to 0.87)	0.006
Over 12 months	326	8.12 (0.10)	332	8.50 (0.10)	0.38 (0.10 to 0.66)	0.007

a Outcome analysis adjusted for age, sex and baseline outcome value, with random effects within participant, physiotherapist and centre.

SPADI: shoulder pain subscale


There was an improvement in shoulder pain in both intervention groups over time (*Figure 6*). However, there was no statistically significant difference between the progressive-exercise intervention and best-practice advice in shoulder pain when analysed over 12 months (adjusted mean SPADI pain subscale difference between groups -1.61, 95% CI -4.94 to 1.72) or when analysed at 8 weeks or at 6 and 12 months (adjusted MD at 12 months -4.01, 95% CI -8.11 to 0.09).

SPADI: shoulder function subscale

There was an improvement in shoulder function in both intervention groups over time (*Figure 7*). However, there was no statistically significant difference between the progressive-exercise intervention and best-practice advice in shoulder function when analysed over 12 months (adjusted mean SPADI function subscale difference between groups -0.15, 95% CI -2.92 to 2.61) or when analysed at 8 weeks or at 6 and 12 months (adjusted MD at 12 months -2.61, 95% CI -6.03 to 0.81).

Fear Avoidance Belief Questionnaire – Physical Activity

There was an improvement in fear avoidance behaviour in both intervention groups over time. However, there was no statistically significant difference between the progressive-exercise intervention and the best-practice advice intervention in fear avoidance behaviour when analysed over 12 months (adjusted mean FABQ-PA score difference between groups -0.35, 95% CI -1.16 to 0.46) or when analysed at 8 weeks, 6 months or 12 months (adjusted MD at 12 months -0.97, 95% CI -1.99 to 0.05).

**FIGURE 6** Marginal adjusted mean SPADI pain values from the repeated measures mixed-effects model and associated 95% CIs for the two treatment groups from baseline to 12 months: best-practice advice vs. progressive exercise.




FIGURE 7 Marginal adjusted mean SPADI function values from the repeated measures mixed-effects model and associated 95% CIs for the two treatment groups from baseline to 12 months: best-practice advice vs. progressive exercise.

Pain Self-Efficacy Questionnaire

There was no statistically significant difference between the progressive-exercise intervention and best-practice advice intervention in patient-reported pain self-efficacy when analysed over 12 months (adjusted mean PSEQ-2 score difference between groups 0.02, 95% CI -0.23 to 0.27) or when analysed at 8 weeks, 6 months or 12 months (adjusted MD at 12 months 0.12, 95% CI -0.22 to 0.45). A ceiling effect was noted for this outcome, with most participants reporting higher confidence levels despite experiencing pain.

Insomnia Severity Index

There was an improvement in patient-reported perception of insomnia in both intervention groups over time. However, there was no statistically significant difference between the progressive-exercise intervention and best-practice advice in patient-reported perception of insomnia when analysed over 12 months (adjusted mean ISI difference between groups 0.04, 95% CI -0.69 to 0.77) or when analysed at 8 weeks, 6 months or 12 months (adjusted MD at 12 months -0.52, 95% CI -1.40 to 0.36).

Return to desired activities

There was an improvement in patient-reported RDA in both intervention groups over time. However, there was no statistically significant difference between the progressive-exercise intervention and best-practice advice intervention in patient-reported RDA when analysed over 12 months (adjusted mean RDA difference between groups -0.06, 95% CI -0.36 to 0.23) or when analysed at 8 weeks, 6 months or 12 months (adjusted MD at 12 months -0.14, 95% CI -0.51 to 0.24).

Global Impression of Treatment

Progressive exercise resulted in an improvement in patient-reported GIT success over 12 months (adjusted mean GIT difference between groups 0.38, 95% CI 0.10 to 0.66) and at 6 and 12 months (adjusted MD at 12 months 0.51, 95% CI 0.14 to 0.87), compared with best-practice advice. However, this result was not seen at 8 weeks and the difference was not clinically significant (MCID on the GIT scale is 2 points on an 11-point scale).

Injection compared with no injection

Table 16 presents the adjusted results for the comparison of injection with no injection for each of the secondary outcomes at 8 weeks, 6 months and 12 months (for unadjusted results, see Appendix 4, Table 42).

SPADI: shoulder pain subscale

There was an improvement in shoulder pain in both groups over time (Figure 8). Injection resulted in an improvement in shoulder pain when analysed at 8 weeks, compared with no injection (adjusted mean SPADI pain subscale difference between groups -7.38, 95% CI -11.10 to -3.67). This difference was

RESULTS

TABLE 16 Analysis of secondary outcomes for injection vs. no injection at 8 weeks, 6 months and 12 months

	No injection		Injection		Between-group adjusted difference (95% CI)	p-value ^a
Secondary outcome	n	Adjusted mean (SE)	n	Adjusted mean (SE)		
SPADI: pain						
8 weeks	300	49.9 (1.4)	315	42.9 (1.4)	-7.38 (-11.10 to -3.67)	0.000
6 months	289	32.0 (1.4)	306	32.9 (1.4)	0.89 (-2.88 to 4.66)	0.643
12 months	290	25.8 (1.4)	306	27.8 (1.4)	2.05 (-1.72 to 5.81)	0.286
Over 12 months	339	36.0 (1.3)	343	34.5 (1.1)	-1.55 (-4.46 to 1.37)	0.299
SPADI: function						
8 weeks	301	32.59 (1.18)	313	28.75 (1.16)	-3.84 (-6.95 to -0.73)	0.015
6 months	289	20.69 (1.19)	306	20.89 (1.17)	0.20 (-2.95 to 3.35)	0.900
12 months	290	16.38 (1.19)	305	18.34 (1.17)	1.97 (-1.18 to 5.11)	0.221
Over 12 months	339	23.31 (0.93)	343	22.72 (0.92)	-0.59 (-3.02 to 1.83)	0.631
FABQ-PA						
8 weeks	274	12.02 (0.36)	296	11.59 (0.35)	-0.43 (-1.39 to 0.53)	0.381
6 months	262	9.70 (0.37)	285	9.72 (0.35)	0.03 (-0.95 to 1.01)	0.954
12 months	265	8.55 (0.37)	285	9.01 (0.35)	0.47 (-0.51 to 1.44)	0.349
Over 12 months	316	8.22 (0.10)	340	8.41 (0.10)	0.02 (-0.74 to 0.77)	0.967
PSEQ-2						
8 weeks	275	10.13 (0.13)	296	10.30 (0.12)	0.17 (-0.16 to 0.50)	0.307
6 months	264	10.44 (0.13)	285	10.39 (0.13)	-0.05 (-0.38 to 0.28)	0.773
12 months	266	10.80 (0.13)	285	10.50 (0.13)	-0.30 (-0.63 to 0.03)	0.078
Over 12 months	317	10.45 (0.10)	340	10.40 (0.10)	-0.06 (-0.31 to 0.19)	0.659
ISI						
8 weeks	270	8.57 (0.31)	291	7.07 (0.30)	-1.50 (-2.32 to -0.68)	0.000
6 months	262	6.21 (0.31)	283	6.18 (0.30)	-0.03 (-0.86 to 0.80)	0.947
12 months	265	5.48 (0.31)	284	5.80 (0.30)	0.32 (-0.51 to 1.15)	0.449
Over 12 months	314	6.77 (0.25)	338	6.35 (0.25)	-0.41 (-1.08 to 0.26)	0.227
RDA						
8 weeks	273	6.49 (0.14)	294	5.96 (0.13)	-0.53 (-0.89 to -0.17)	0.004
6 months	266	5.27 (0.14)	285	5.24 (0.14)	-0.03 (-0.39 to 0.34)	0.893
12 months	268	4.63 (0.14)	285	4.84 (0.14)	0.21 (-0.15 to 0.57)	0.258
Over 12 months	317	5.47 (0.11)	340	5.35 (0.11)	-0.12 (-0.40 to 0.16)	0.409
GIT						
8 weeks	273	7.34 (0.13)	294	8.03 (0.13)	0.69 (0.35 to 1.03)	0.000
6 months	267	8.42 (0.13)	285	8.45 (0.13)	0.04 (-0.31 to 0.39)	0.832
12 months	269	8.91 (0.13)	287	8.76 (0.13)	-0.14 (-0.49 to 0.20)	0.416
Over 12 months	317	8.22 (0.10)	347	8.41 (0.10)	0.20 (-0.06 to 0.46)	0.138

^a Outcome analysis adjusted for age, sex and baseline outcome value, with random effects within participant, physiotherapist and centre.




FIGURE 8 Marginal adjusted mean SPADI pain values from the repeated measures mixed-effects model and associated 95% CIs for the two treatment groups from baseline to 12 months: injection vs. no injection.

not clinically significant (MCID on the SPADI scale is 8 points on a scale of 0–100). There was no statistically significant difference between injection and no injection when analysed over 12 months (adjusted MD over 12 months –1.55, 95% CI –4.46 to 1.37) or when analysed at 6 and 12 months (adjusted MD at 12 months 2.05, 95% CI –1.72 to 5.81).

SPADI: shoulder function subscale

There was an improvement in shoulder function in both groups over time (Figure 9). Injection resulted in an improvement in shoulder function when analysed at 8 weeks compared with no injection (adjusted mean SPADI function subscale difference between groups –3.84, 95% CI –6.95 to –0.73). This difference was not clinically significant. There was no statistically significant difference between injection and no injection when analysed over 12 months (adjusted MD over 12 months –0.59, 95% CI –3.02 to 1.83) or when analysed at 6 and 12 months (adjusted MD at 12 months 1.97, 95% CI –1.18 to 5.11).

Fear Avoidance Belief Questionnaire – Physical Activity

There was an improvement in fear avoidance behaviour in both groups over time. However, there was no statistically significant difference between injection and no injection in fear avoidance behaviour when analysed over 12 months (adjusted mean FABQ-PA score difference between groups over 12 months 0.02, 95% CI –0.74 to 0.77) or when analysed at 8 weeks, 6 months or 12 months (adjusted MD at 12 months 0.47, 95% CI –0.51 to 1.44).

Pain Self-Efficacy Questionnaire

There was no statistically significant difference between injection and no injection in patient-reported pain self-efficacy when analysed over 12 months (adjusted mean PSEQ-2 score difference between groups over 12 months –0.06, 95% CI –0.31 to 0.19) or when analysed at 8 weeks, 6 months or




FIGURE 9 Marginal adjusted mean SPADI function values from the repeated measures mixed-effects model and associated 95% CIs for the two treatment groups from baseline to 12 months: injection vs. no injection.

RESULTS

12 months (adjusted MD at 12 months -0.30, 95% CI -0.63 to 0.03). A ceiling effect was noted for this outcome, with most participants reporting higher confidence levels despite experiencing pain.

Insomnia Severity Index

There was an improvement in patient-reported perception of insomnia in both groups over time. Injection resulted in an improvement in patient-reported perception of insomnia when analysed at 8 weeks compared with no injection (adjusted mean ISI difference between groups -1.50, 95% CI -2.32 to -0.68). There was no statistically significant difference between injection and no injection when analysed over 12 months (adjusted MD over 12 months -0.41, 95% CI -1.08 to 0.26) or when analysed at 6 and 12 months (adjusted MD at 12 months 0.32, 95% CI -0.51 to 1.15).

Return to desired activities

There was an improvement in patient-reported RDA in both groups over time. Injection resulted in an improvement in patient-reported RDA when analysed at 8 weeks compared with no injection (adjusted mean RDA difference between groups -0.53, 95% CI -0.89 to -0.17). There was no statistically significant difference between injection and no injection when analysed over 12 months (adjusted MD over 12 months -0.12, 95% CI -0.40 to 0.16) or when analysed at 6 and 12 months (adjusted MD at 12 months 0.21, 95% CI -0.15 to 0.57).

Global Impression of Treatment

Injection resulted in an improvement in patient-reported GIT success when analysed at 8 weeks compared with no injection (adjusted mean GIT difference between groups 0.69, 95% CI 0.35 to 1.03). There was no statistically significant difference between injection and no injection when analysed over 12 months (adjusted MD over 12 months 0.20, 95% CI -0.06 to 0.46) or when analysed at 6 and 12 months (adjusted MD at 12 months -0.14, 95% CI -0.49 to 0.20).

Other outcomes

Participant-reported shoulder condition

As part of the follow-up questionnaires, a total of 23 (3%) participants reported 'yes' to the question 'have you been told you will need to have surgery because of your shoulder problem'. Two, six and 15 participants reported 'yes' at 8 weeks, 6 months and 12 months, respectively, and the numbers were similar across intervention groups. Three participants reported that they had been admitted to hospital as an NHS inpatient because of their shoulder. The type of surgery recorded was surgery to repair rotator cuff tear ($n = 1$; injection plus progressive-exercise intervention), frozen shoulder surgery diagnosed after randomisation ($n = 1$; best-practice advice intervention), subacromial decompression and cuff repair ($n = 1$; injection plus best-practice advice intervention).

Participant-reported injection outside the trial

As part of the follow-up questionnaires, 16 (4%) participants in the injection group and four (1%) participants in the no injection group reported 'yes' to the question 'have you had a steroid injection as a result of pain in your shoulder?' at 8 weeks. Twelve (3%) participants in the injection group and 18 (5%) participants in the no injection group reported 'yes' to the question at 6 months, and 20 (6%) participants in the injection group and six (2%) participants in the no injection group reported 'yes' at 12 months. This excluded the injection(s) participants may have received as part of the GRASP trial.

Harms

There were no SAEs recorded as part of the GRASP trial.

Missing data

There were small numbers of missing data. A total of 641 (90.5%) participants returned the 8-week follow-up questionnaire, 615 (86.9%) returned their 6 month-questionnaire and 618 (87.3%) returned their 12-month questionnaire. Where items were missing within scales, these were dealt with based on published recommendations. SPADI score was imputed as per scoring instructions (see *Chapter 2*); eight (1.1%) SPADI scores were imputed at baseline, six (0.8%) SPADI scores were imputed at 8 weeks, four (0.6%) SPADI scores were imputed at 6 months and two (0.3%) SPADI scores were imputed at 12 months. Missing continuous data for primary and secondary outcomes were accounted for as part of the likelihood-based estimation of the repeated measures linear mixed-effects model, assuming that data were missing at random.

Prespecified subgroup analysis

The following prespecified subgroup analyses were carried out in line with the primary outcome analysis approach: age (≤ 64 years/ ≥ 65 years), sex (male/female), smoking status (never smoked/former smoker or current smoker), higher SPADI score at baseline [SPADI ≥ 50 at baseline (scale 0–100)] and higher pain self-efficacy score at baseline [PSEQ-2 ≥ 8 at baseline (scale 0–12)]. The results presented here for prespecified subgroup analyses are for the two main effect comparisons.

Progressive exercise compared with best-practice advice

There were no statistically significant subgroup differences between the progressive-exercise intervention and best-practice advice intervention in shoulder pain and function when analysed over 12 months (*Figure 10*) or when analysed at 8 weeks, 6 months or 12 months (see *Appendix 4, Figure 25*).




FIGURE 10 Subgroup-adjusted SPADI analysis for progressive exercise over 12 months.

Injection compared with no injection

There were no statistically significant subgroup differences for age, sex, smoking status and pain self-efficacy between injection and no injection interventions in shoulder pain and function when analysed over 12 months (Figure 11) or when analysed at 8 weeks, 6 months or 12 months (see Appendix 4, Figure 28). At 8 weeks, the effect of injection was stronger in participants with a higher baseline SPADI score (adjusted MD -9.67, 99% CI -15.37 to -3.97) than in those who received injection but had a lower baseline SPADI score (adjusted MD -0.36, 99% CI -6.87 to 6.16). This difference was clinically significant (see Appendix 4, Figure 28). There was no statistically significant subgroup difference when analysed over 12 months or when analysed at 6 and 12 months.




FIGURE 11 Subgroup-adjusted SPADI analysis for injection over 12 months.

Chapter 5 Health economics

Introduction

This chapter presents the cost-effectiveness analysis of the GRASP trial. This analysis took an NHS and PSS perspective and tested (using a 2×2 factorial design) four physiotherapy-led interventions: (1) progressive exercise, (2) best-practice advice, (3) progressive exercise preceded by a corticosteroid injection and (4) best-practice advice preceded by a corticosteroid injection. Health-care resource utilisation data and utility data were collected alongside clinical data over the 12-month trial period; these were used to conduct a cost-utility analysis, calculating the cost per quality-adjusted life-year (QALY) gained, as the main aim of treatment is to improve patients' quality of life.

Current guidelines for conducting an economic evaluation within clinical trials have been followed, including guidance for resource use data capture,⁸⁴ which highlighted the need for a health economics analysis plan to incorporate time horizon, frequency of data collection and methods of analysis, as well as other important components, such as resource use measure, perspective and unit costs.⁸⁵ We also followed further guidance on how to conduct economic evaluation alongside randomised trials,⁸⁶ and considerations of the methodological issues around these trials.⁸⁷ In relation to conducting an economic evaluation within a factorial design trial, the challenges and methods discussed by Dakin and Gray⁸⁸ have been taken into account in the GRASP trial analysis.

Methods

Aim

The aim of the GRASP trial's economic evaluation was to address the following question:

What is the cost-effectiveness of individually tailored progressive exercise compared with best-practice advice, with or without corticosteroid injection, in people with a new episode of a rotator cuff disorder?

The within-trial economic analysis was performed using individual patient-level data from the GRASP trial. The analysis uses data from the GRASP trial only and did not combine this trial with any external evidence because, to the best of our knowledge, no study has evaluated exactly the same progressive-exercise intervention evaluated in this study. The analytical approach took the form of a cost-utility analysis. Based on trial evidence, net monetary benefit (NMB) statistics were calculated as QALYs multiplied by willingness-to-pay threshold minus cost to enable comparison between treatment groups.

The economic analysis compared the costs and consequences of each intervention group over the 12-month period following randomisation, with no extrapolation beyond the study period of 12 months, as prespecified in the health economics analysis plan, because there was no statistical difference in clinical outcome between treatment groups at 12 months.⁸⁵

Measurement of resource use and costs

Resource use data for the economic evaluation were collected during the trial period from questionnaires sent to participants (at 8 weeks, 6 months and 12 months after randomisation to the GRASP trial) and from treatment logs completed by the treating physiotherapists at sites. The questionnaire captured both NHS- and PSS-perspective resource use and costs borne by the participant and their family attributable to a rotator cuff disorder. This included the frequency of use of inpatient care, outpatient care and community-based health care (both private and NHS) that was not part of the GRASP trial. It also recorded direct medical costs that were not part of the trial (e.g. medications and steroid injections)

and direct non-medical costs (e.g. help with housework/childcare and travel), the latter being excluded from the base-case economic evaluation. Free-text responses (applicable to all the 'other' options) were reclassified to the appropriate cost category, were removed if deemed unrelated/irrelevant to the trial by clinical experts (e.g. shoulder specialists) or were analysed collectively as 'other' in the descriptive analysis.

Some of the assumptions made when cleaning, analysing or costing the data included (1) if a patient answered 'no' to a prompt question about resource utilisation, then we assumed that the frequency of service use for this category of resources was equal to zero, (2) injections performed outside the GRASP trial were assumed to have been given by a GP within the duration of a typical GP visit and (3) for the self-reported questions on prescribed and over-the-counter medication, when participants failed to specify the duration or reported 'as needed', 'when in pain' or 'occasionally' and similar, we assumed an intake duration of 3 weeks based on clinical expert opinion.

Costing of the interventions

Subacromial corticosteroid injection

Participants randomised to receive corticosteroid injection were given either methylprednisolone or triamcinolone acetonide (median dose of 40 mg) with a local anaesthetic. Injections were mainly given by extended-scope physiotherapists (bands 6–8a); in three cases injections were given by doctors (two orthopaedic consultants and one specialist registrar in orthopaedics). The consultation time varied from 20 minutes to 45 minutes based on the information provided by the physiotherapists. We based the cost of injections on the median injection administration time of 30 minutes, as a median is more robust against outliers and the weighted average cost per hour for each physiotherapist/clinician delivering injections.⁸⁹ Most participants also received local anaesthetic: either 1% lidocaine (up to 5 ml) or 0.5% bupivacaine hydrochloride (up to 10 ml) (see *Appendix 5, Table 43* for unit costs of corticosteroid injection and anaesthetic). The total cost of administering the injection to each participant was calculated by adding the weighted mean administration cost per participant to the mean cost of corticosteroid injections and mean cost of anaesthetic per participant.

Best-practice advice

Participants randomised to best-practice advice received one 45- to 60-minute session with a physiotherapist (band 5–8a), when they were provided with a set of eight 2-week exercise diaries (i.e. a normal A4 printed sheet totalling 16 pages), a three-page document printed on non-carbon copy paper that served as an action planner, an information booklet, one piece of resistance band (with an average of 1 yard per participant) and either a DVD or details of how to access online exercise videos (*Table 17*). The cost of physiotherapists' time was calculated by multiplying the median therapist cost per hour by the median estimate (in minutes) of the exercise session.

Progressive exercise

Participants randomised to progressive exercise received a median of four sessions with a physiotherapist (band 5–8a). The first session lasted between 45 and 60 minutes and the rest generally lasted between 20 and 30 minutes. Participants were given a set of eight 2-week exercise diaries (i.e. a normal A4 printed sheet totalling 16 pages), a three-page document printed on non-carbon copy paper that served as an action planner, an information booklet and at least one piece of resistance band if they were prescribed an exercise that required this (an average of 1 yard per participant) (see *Table 17*). Again, the cost of physiotherapists' time was calculated by multiplying the median therapist cost per hour by the median estimate (in minutes) of the exercise session.

In both the best-practice advice and progressive-exercise interventions, we estimated costs based on median estimates, as they are more robust against outliers. Storage boxes given to study centres were excluded from the costings, as they were deemed to be protocol-driven resources.

TABLE 17 Unit cost of consumables associated with trial per participant

Resource	Best-practice advice	Injection plus best-practice advice	Progressive exercise	Injection plus progressive exercise	Unit type	Unit cost (£)
Exercise diary	✓	✓	✓	✓	Item/set	0.64
Action planner	✓	✓	✓	✓	Item	0.24
TheraBand® 1 yard (TheraBand, Akron, OH, USA)	✓	✓	✓	✓	Item	0.94
DVD or online access to exercise videos	✓	✓	✗	✗	Item	1.20
Information booklet for best-practice advice	✓	✓	✓	✓	Item	2.60
Information booklet for progressive exercise	✗	✗	✓	✓	Item	4.00

Training

We included the cost of training the physiotherapists in how to deliver the best-practice advice and progressive-exercise interventions, as they are not part of standard NHS practice. No training was provided for the injections, as these were delivered as per standard NHS practice and in accordance with the trial protocol.

The cost of training was calculated separately for best-practice advice and progressive exercise by multiplying the mean training time per physiotherapist by the physiotherapist cost per hour (Table 18).

TABLE 18 Assumptions for costing physiotherapist time

Physiotherapist time	Unit	Source
Training for best-practice advice and progressive exercise		
Number of physiotherapists	187 ^a	Therapist diaries
Mean training time (hours) per best-practice advice physiotherapist	3.5	Therapist diaries
Mean training time (hours) per progressive-exercise physiotherapist	4.5	
Physiotherapist cost (£) per hour	35–67	PSSRU p. 143 (band 5–8a) ⁸⁹
Mean cost (£) of training each best-practice advice physiotherapist	168.49	
Mean cost (£) of training each progressive-exercise physiotherapist	177.94	
Mean number of patients treated per best-practice advice physiotherapist	3.9	Therapist diaries
Mean number of patients treated per progressive-exercise physiotherapist	3.6	
Length of session		
First session (minutes)	52.5	Median estimate
Second session (minutes)	25	
Third session (minutes)	25	
Fourth session (minutes)	25	
Fifth session (minutes)	25	
Sixth session (minutes)	25	

PSSRU, Personal Social Service Research Unit.

^a Although there 307 clinicians were recorded for the training, some undertook the training twice, which brings the number of therapists down to 298. However, only 187 physiotherapists both were trained and delivered the exercises.

Training time for therapists to provide the best-practice advice was 3.5 hours and progressive exercise training was 4.5 hours. In the training courses provided as part of the GRASP trial, physiotherapists received an additional hour of training specific to the trial protocol (e.g. completing treatment logs), which was considered to be a protocol-driven resource use and was, therefore, excluded from the analysis. Some sites received refresher training sessions, with each lasting approximately 2.5 hours.

The face-to-face training was delivered by four physiotherapists who were part of the GRASP trial team, but only one physiotherapist attended each training session. We costed the physiotherapist time for delivering the training by multiplying the cost of a grade 7 physiotherapist by the duration of the training session. In total, 298 physiotherapists (bands 5–8a) attended the training programme as part of the trial, of whom 223 delivered the intervention. The cost of the trainers' time was divided by the total number of physiotherapists attending training.

As there is uncertainty about how training would be delivered in routine clinical practice, we have calculated the cost of training physiotherapists to the interventions based on three scenarios (base case, best case and worst case), depending on different hypotheses.

Base-case analysis

The base-case analysis aimed to reflect the NHS cost of face-to-face training as it was delivered in the GRASP trial. It included the time cost for the physiotherapists attending the face-to-face training and the time cost for the physiotherapist delivering the training to the sites (*Table 19*). The cost of refresher training and the trainers' travel costs to each site, venue hire and NHS parking charges were excluded from the analysis. In the base-case analysis, we calculated the total cost of training each physiotherapist

TABLE 19 Cost (£) of intervention per participant

Cost	Best-practice advice (£)	Injection plus best-practice advice (£)	Progressive exercise (£)	Injection plus progressive exercise (£)
Clinician training	43.20	43.20	49.43	49.43
Consumables	5.62	5.62	5.82	5.82
Injections	0	40.1	0	40.1
Physiotherapist time				
Session 1	44.63	44.63	44.63	44.63
Session 2			21.25	21.25
Session 3			21.25	21.25
Session 4			21.25	21.25
Session 5			21.25	21.25
Session 6			21.25	21.25
Total cost by number of sessions attended				
No sessions	0	0	0	0
One session	93.45	133.55	99.88	139.98
Two sessions			121.13	161.23
Three sessions			142.38	182.48
Four sessions			163.63	203.73
Five sessions			184.88	224.98
Six sessions			206.13	246.23

and divided it by the mean number of patients treated per physiotherapist (among physiotherapists receiving this training) to estimate the cost of training as it was delivered in the trial. The total cost of training each physiotherapist was divided by the mean number of participants treated by each physiotherapist in the trial. We estimated the mean number of participants per physiotherapist separately for best-practice advice and progressive exercise, as physiotherapists giving the best-practice advice intervention could treat more people per week than those delivering progressive exercise. The mean numbers of participants treated per physiotherapist in the best-practice advice and the progressive-exercise groups were 3.9 and 3.6, respectively.

Worst-case scenario

This was the same as the base-case analysis, but also included the cost of refresher training, travel, venue hire and NHS parking charges as part of the training delivery cost. Refresher session cost was calculated by multiplying the 2.5-hour training time by the hourly cost of a grade 7 physiotherapist. Travel cost was calculated as the mileage from Oxford to the site and back by car multiplied by a flat cost per mile (£0.45 for the first 10,000 business miles).⁹⁰ Venue hire was calculated based on an average cost of hiring an NHS room of a maximum capacity of 30 people.⁹¹ We also assumed an average of £2 per hour NHS parking charge for the duration of the training. Accommodation charges for overnight stay were not included.

Best-case scenario

The best-case scenario assumes that if the trial interventions were to be implemented in routine clinical practice, the training would be delivered on a free-to-access online platform. The cost of developing the online training materials were based on the team's experience of developing training materials for the NIHR HTA-funded BeST (Back Skills Training) trial for the treatment of low back pain in primary care.⁴⁵ This includes 6 weeks of a full-time grade 8 physiotherapist's time to develop the training materials for the progressive-exercise intervention and 1 month to develop the best-practice advice intervention. It also includes the cost of a grade 7 physiotherapist researcher to maintain it for a 10-year period (spending 30 hours/year). There are approximately 10,000 users per year using the online learning platform [URL: www.futurelearn.com/courses/back-skills-training-programme (accessed 24 May 2021)]. We, therefore, assumed that this researcher would support all 10,000 learners. We included the cost of the physiotherapists treating participants based on having a one-off training session of 3.5 hours for best-practice advice and of 4.5 hours for progressive exercise. We assumed that the training would last 10 years without a refresher session and that each physiotherapist would treat patients for 10 years after being trained. We assumed that each physiotherapist would treat approximately 100 patients per year, based on an assumption of 2.74 new patients per week over 1 year (9.6 patients per week and 3.5 patients per session on average).

The best- and worst-case scenarios have been presented as part of the sensitivity analysis.

We averaged and applied the cost of training for each intervention across all participants randomised, regardless of how many sessions they attended. Other intervention costs were estimated at the individual patient level, based on the recorded number of sessions that they attended. The estimated costs for different numbers of sessions attended of progressive exercise, best-practice advice, progressive exercise preceded by a corticosteroid injection and best-practice advice preceded by a corticosteroid injection are shown in *Table 19*. Following our base-case assumptions, the cost of best-practice advice is £93.45 and best-practice advice plus injection is £133.55. For a progressive-exercise patient attending all six sessions, the cost is £206.13, compared with £246.23 for a patient attending all recommended sessions in the progressive-exercise and injection treatment arm.

Measurement of broader resource use

The unit costs of direct non-medical resource items, such as help with child care, travel to appointments, help with housework and any other additional expenses attributable to having a rotator cuff disorder

incurred by the participant, were obtained directly from the postal follow-up questionnaires and are tabulated in *Appendix 5, Table 44*. However, these costs, private health-care costs and any other non-NHS/PSS costs (e.g. over-the-counter medications) were excluded from the base-case economic evaluation, as they are outside the perspective of this analysis, but are included in the sensitivity analysis presented in *Appendix 5*.

Valuation of resource use

Unit costs of direct medical care that is not part of the trial, such as inpatient care, outpatient care and NHS community care, were sourced from the latest available NHS Reference Costs⁹² (see *Appendix 5, Table 44*). The unit costs of medications related to rotator cuff disorders have been sourced using the latest available *British National Formulary* (BNF)⁹³ (see *Appendix 5, Table 43*). Costs of medications for individual participants were estimated based on their reported doses and frequencies, when these were available, or based on an assumed daily dose using BNF recommendations. When a dose range was reported as 'as required' or when the quantities were not recorded, expert opinion was sought to make reasonable assumptions. The cost of NHS health-care resource use per participant was computed by multiplying the frequency of health resource utilisation reported by the participant by the unit cost of each resource item. In the case of non-NHS costs, participants self-reported the cost of additional expenses. All costs were expressed in 2018/19 Great British pounds. No discounting was applied, as the time horizon of the analysis did not exceed 12 months.

Calculation of utilities and quality-adjusted life-years

Participants' questionnaires contained the EQ-5D-5L questionnaire for self-completion at baseline and at 8 weeks, 6 months and 12 months post randomisation. The EQ-5D-5L instrument⁹⁴ facilitates the generation of a utility score from a person's health-related quality of life while reducing the ceiling effect and being more sensitive than its three-level predecessor.⁹⁵ A utility score refers to the preference of the general population for any particular set of health outcomes. As per the NICE position statement, the responses to the EQ-5D-5L were converted into multiattribute utility scores using the approved 'crosswalk' to the three-level instrument and applying the mapping function developed by van Hout *et al.*,⁹⁶ and the converted responses were valued using the established time trade-off utility algorithm for the UK.⁹⁷ QALYs were calculated as the area under the utility curve of utility scores from baseline, 8-week, 6-month and 12-month data using the trapezoidal rule.⁹⁸ Deceased patients were assigned a utility of zero from the date of death. We assumed that utility remained constant between the last utility measurement and the date of death.

Missing data

Because within-trial health economic evaluations draw on many sources of information on patient characteristics, treatments, outcomes and resource use over the whole trial, incomplete data are a particular issue that require careful attention. Consequently, the base-case analysis imputed missing data using fully conditional multiple imputation under chained equations, using the Stata command 'mi impute chained'. Within multiple imputation under chained equations, regression models were used to impute unobserved costs and utilities at each time point using the baseline covariates [i.e. age, sex and EuroQol-5 Dimensions (EQ-5D)] as predictor variables. The imputation model included a dummy variable for allocation to injection, a dummy variable for allocation to progressive exercise and an interaction term equal to the product of these two variables, following recommended practice for factorial trials.⁸⁸ Different components of costs and EQ-5D utility scores at each time point contributed as both predictors and imputed variables.

Multiple imputation was used to generate 25 data sets (or 'draws') using predictive mean matching, which provides plausible values when costs and utilities are non-normally distributed. In line with recommended practice,⁹⁹ the imputation model was validated by comparing the distributions of the imputed data with the observed data. The imputation was run following the rule of thumb that the number of imputations (M) should be similar to the percentage of incomplete cases (in this case $M = 25$).⁹⁹

Analyses of resource use, costs and outcome data

Cost-effectiveness analysis

The analysis was conducted based on the ITT principle and incremental cost-effectiveness ratios (ICERs) were calculated as the difference in mean costs divided by the difference in mean QALYs between a pair of interventions. The NICE¹⁰⁰ cost-effectiveness threshold of £20,000 per additional QALY was used to identify which of the following treatments represent best value for money (i.e. has the highest NMB): (1) best-practice advice, (2) best-practice advice plus corticosteroid injection, (3) progressive exercise or (4) progressive exercise plus corticosteroid injection.

In addition to calculating and reporting ICERs and NMBs, the results are presented graphically in cost-effectiveness planes, and cost-effectiveness acceptability curves (CEACs) are used to show the probability that each of the four treatment groups has the highest NMB. Measures of uncertainty (SEs and CIs) are also reported around the mean costs and QALYs (95% CIs are presented around ICERs if they are defined). SEs and CEACs were generated using non-parametric bootstrapping with 1000 replicates, as described in the next section. This accommodates sampling (or stochastic) uncertainty and varying levels of willingness to pay for an additional QALY. We made no adjustment for clustering of participants by physiotherapist when analysing costs, QALYs or cost-effectiveness, as the randomisation was carried out on an individual basis, stratified by centre, rather than using cluster randomisation, and the subacromial corticosteroid injections and physiotherapy sessions were delivered in accordance with a standard protocol.

As the GRASP trial is a factorial trial, it was important to consider the interactions [i.e. to examine whether or not the differences in costs, QALYs or NMB between best-practice advice and progressive exercise were affected by the use of corticosteroid injection (or vice versa)]. In the GRASP trial clinical analysis, the primary outcome was analysed at the margins, assuming no interactions and that interaction terms were included in the model only if interactions were significant at the 0.05 level. From the economics point of view, this approach was not appropriate, as health economics findings are interpreted in terms of the absolute magnitude of ICERs, rather than focusing on hypothesis testing, and several mechanisms have been suggested that may introduce large but non-significant interactions for economic end point, but not clinical end point.⁸⁸ It is more important to avoid the bias that may result from ignoring interactions rather than maximising statistical power. We, therefore, compared specific treatment combinations (e.g. best-practice advice, injection only, progressive exercise only and injection plus progressive exercise) incrementally and identified the combination that represents best value for money, rather than making separate decisions on injection and exercise, as the former provides more relevant information for decision-makers if there is any interaction.

For the GRASP trial, the base-case economic analysis was prespecified as regression analysis with an interaction term, although regression analysis without interaction terms has been used as a sensitivity analysis to assess whether or not the assumptions about interactions change the conclusions of the analysis. Benefits of using regression analysis in the context of factorial design trial are that it allows for variation in sample size between groups, adjusts for the effect of the other intervention, facilitates adjustment for baseline utility and can predict the mean outcomes for each cell in the factorial design.

Regression analysis with interaction term (base-case analysis)

Linear regression analyses that predicted both costs and QALYs were calculated for each bootstrap sample on each imputed data set. Randomisation to corticosteroid and randomisation to exercise were included as dummy variables and the base-case analysis also included an interaction between these two variables. The ordinary least squares regression that predicted QALYs also controlled for baseline utility to avoid the bias that would otherwise arise from any imbalance in baseline utility between groups.¹⁰¹ A total of 1000 bootstrap samples were drawn for each imputed data set. Mean costs, QALYs and the NMB in each of the four treatment groups were estimated based on the regression coefficients for each bootstrap of each imputed data set.

We combined uncertainty around missing data with sampling uncertainty using the MI Boot pooled sample approach of Schomaker and Heumann,¹⁰² which has been shown to yield valid inference and to be equivalent to nesting bootstraps within imputations and combining results using Rubin's rule. Pooling bootstraps is simpler to implement than Rubin's rule and facilitates presentation of CEACs. In addition, a simulation study has shown it to give good coverage with ≥ 20 imputations. To implement this in our data set, we averaged across the 25 imputed data sets for the original (non-bootstrapped) sample to get point estimates and estimated 95% CIs as the 2.5th and 97.5th percentiles across all 25,000 bootstraps, adapting the code used previously.¹⁰³ CEACs were estimated across all 25,000 bootstraps. The regression models used to predict cost and QALYs are presented in *Appendix 5, Model 1: regression analysis model with interaction term (base-case analysis)*.

Regression analysis without interaction term (sensitivity analysis)

Regression techniques with an interaction term provide an alternative to at-the-margins analysis, which also assumes no interaction.⁸⁸ The description of the analysis and the model are presented in *Appendix 5, Model 2: regression analysis without interaction term (sensitivity analysis)*.

Results of economic analysis

Completion rate

Among the 708 participants randomised in the trial, 174 were randomised to best-practice advice, 178 were randomised to best-practice advice plus injection, 174 were randomised to progressive exercise and 182 were randomised to progressive exercise plus injection. The completion rates of all health resource items by treatment intervention for each time point are displayed in *Table 20*. In addition, *Table 21* shows the response rate of EQ-5D-5L by follow-up points and treatment group.

Health-care resource use and costs

Information about the use of other relevant NHS services was obtained by participant self-reported data at 8 weeks, 6 months and 12 months. Estimates of health-care use have been presented in *Appendix 5* as follows: from baseline to 8 weeks (see *Appendix 5, Table 45*), from 8 weeks to 6 months (see *Appendix 5, Table 46*) and from 6 to 12 months (see *Appendix 5, Table 47*). These resource quantities were multiplied by the relevant unit cost (see *Appendix 5, Table 44*) to provide estimated mean costs per patient from baseline to 8 weeks (see *Appendix 5, Table 48*), from 8 weeks to 6 months (see *Appendix 5, Table 49*) and from 6 to 12 months (see *Appendix 5, Table 50*).

Prescribed medication usage was recorded at 8 weeks, 6 months and 12 months. Participants were asked to list the drugs that they were currently taking and to report the dose and frequency of use. The yielded estimate of the cost of prescribed medications for each individual over the three time intervals can be seen in *Appendix 5, Table 51*. The mean cost per participant of prescribed medication over the 12-month period was quite low for all treatment groups (£10.89 for best-practice advice compared with £5.36 for best-practice advice plus injection, £2.90 for progressive exercise and £17.57 for progressive exercise plus injection). A summary of all included costs from the NHS and PSS perspective (i.e. intervention cost, NHS service utilisation cost, prescribed medication cost and cost of non-GRASP trial steroid injection) over the trial are given in *Table 22*. It is worth noting that NHS service cost is lower in the progressive-exercise group than in the other intervention groups, which indicates that participants in the progressive-exercise intervention group made less use of primary and secondary health-care services.

Table 23 presents the mean cost and SD of non-NHS costs and any additional expenses, medication and private care that was borne by GRASP trial participants. In terms of employment status, at 8 weeks, 49.44% of participants were in paid employment, of whom 4.66% took time off work. At 6 and 12 months, the percentages were quite similar, with 46.06% and 46.75% of the participants being in paid employment and only 3.81% and 3.67%, respectively, taking time off work. The mean cost of work loss by treatment

TABLE 20 Completion rate (%) of health resource use by treatment interventions and follow-up time points

Type of care	Best-practice advice (N = 174)			Injection plus best-practice advice (N = 178)			Progressive exercise (N = 174)			Injection plus progressive exercise (N = 182)		
	Yes, n (%)	No, n (%)	Missing, n (%)	Yes, n (%)	No, n (%)	Missing, n (%)	Yes, n (%)	No, n (%)	Missing, n (%)	Yes, n (%)	No, n (%)	Missing, n (%)
Baseline to 8 weeks												
Primary care (NHS community-based services)	16 (9.20)	113 (64.94)	45 (25.86)	8 (4.49)	142 (79.78)	28 (15.73)	22 (12.64)	124 (71.26)	28 (16.09)	11 (6.04)	151 (82.97)	20 (10.99)
Secondary care (NHS outpatient services)	6 (3.45)	123 (70.69)	45 (25.86)	6 (3.37)	144 (80.90)	28 (15.73)	10 (5.75)	136 (78.16)	28 (16.09)	3 (1.65)	160 (87.91)	19 (10.44)
Private care	2 (1.15)	127 (72.99)	45 (25.86)	1 (0.56)	150 (84.27)	27 (15.17)	3 (1.72)	143 (82.18)	28 (16.09)	0	162 (89.01)	20 (10.99)
Injection utilisation	1 (0.57)	129 (74.14)	44 (25.29)	7 (3.93)	144 (80.90)	27 (15.17)	3 (1.72)	144 (82.76)	27 (15.52)	10 (5.49)	153 (84.07)	19 (10.44)
Non-medical expenses	5 (2.87)	124 (71.26)	45 (25.86)	5 (2.81)	145 (81.46)	28 (15.73)	15 (8.62)	131 (75.29)	28 (16.09)	18 (9.89)	144 (79.12)	20 (10.99)
8 weeks to 6 months												
Primary care (NHS community-based services)	16 (9.20)	111 (63.79)	47 (27.01)	15 (8.43)	132 (74.16)	31 (17.42)	18 (10.34)	122 (70.11)	34 (19.54)	16 (8.79)	134 (73.63)	32 (17.58)
Secondary care (NHS outpatient services)	7 (4.02)	120 (68.97)	47 (27.01)	9 (5.06)	137 (76.97)	32 (17.98)	8 (4.60)	132 (75.86)	34 (19.54)	2 (1.10)	148 (81.32)	32 (17.58)
Private care	8 (4.60)	120 (68.97)	46 (26.44)	6 (3.37)	141 (79.21)	31 (17.42)	8 (4.60)	132 (75.86)	34 (19.54)	4 (2.20)	146 (80.22)	32 (17.58)
Injection utilisation	9 (5.17)	121 (69.54)	44 (25.29)	6 (3.37)	141 (79.21)	31 (17.42)	9 (5.17)	131 (75.29)	34 (19.54)	6 (3.30)	143 (78.57)	33 (18.13)
Non-medical expenses	8 (4.60)	121 (69.54)	45 (25.86)	6 (3.37)	141 (79.21)	31 (17.42)	12 (6.90)	128 (73.56)	34 (19.54)	13 (7.14)	137 (75.27)	32 (17.58)
6–12 months												
Primary care (NHS community-based services)	17 (9.77)	116 (66.67)	41 (23.56)	22 (12.36)	128 (71.91)	28 (15.73)	14 (8.05)	126 (72.41)	34 (19.54)	24 (13.19)	128 (70.33)	30 (16.48)
Secondary care (NHS outpatient services)	10 (5.75)	123 (70.69)	41 (23.56)	15 (8.43)	135 (75.84)	28 (15.73)	9 (5.17)	132 (75.86)	33 (18.97)	15 (8.24)	137 (75.27)	30 (16.48)
Private care	8 (4.60)	125 (71.84)	41 (23.56)	3 (1.69)	147 (82.58)	28 (15.73)	8 (4.60)	133 (76.44)	33 (18.97)	9 (4.95)	143 (78.57)	30 (16.48)
Injection utilisation	12 (6.90)	121 (69.54)	41 (23.56)	8 (4.49)	142 (79.78)	28 (15.73)	9 (5.17)	132 (75.86)	33 (18.97)	12 (6.59)	138 (75.82)	32 (17.58)
Non-medical expenses	8 (4.60)	125 (71.84)	41 (23.56)	8 (4.49)	142 (79.78)	28 (15.73)	6 (3.45)	135 (77.59)	33 (18.97)	10 (5.49)	142 (78.02)	30 (16.48)

TABLE 21 Response rate (%) of EQ-5D-5L by follow-up time point and treatment

Time point	Best-practice advice (N = 174)		Injection plus best-practice advice (N = 178)		Progressive exercise (N = 174)		Injection plus progressive exercise (N = 182)	
	n	Missing, n (%)	n	Missing, n (%)	n	Missing, n (%)	n	Missing, n (%)
8 weeks	132	42 (24.14)	151	27 (15.17)	147	27 (15.52)	164	18 (9.89)
6 months	134	40 (22.99)	151	27 (15.17)	143	31 (17.82)	154	28 (15.38)
12 months	138	36 (20.69)	158	20 (11.24)	144	30 (17.24)	154	28 (15.38)

TABLE 22 Health-care cost (£) over the 12-month follow-up (available cases, without imputation of missing data)

Type of care	Best-practice advice (N = 174)		Injection plus best-practice advice (N = 178)		Progressive exercise (N = 174)		Injection plus progressive exercise (N = 182)	
	n ^a	Mean cost (£) (SD)	n ^a	Mean cost (£) (SD)	n ^a	Mean cost (£) (SD)	n ^a	Mean cost (£) (SD)
Intervention	167	43.20 (0)	164	43.20 (0)	166	49.43 (29.50)	171	49.43 (30.94)
NHS services	174	60.44 (311.76)	178	61.29 (312.85)	174	39.33 (103.79)	182	61.19 (317.38)
Prescriptions	123	10.89 (64.31)	145	5.36 (18.19)	138	2.90 (8.44)	148	17.57 (74.96)
Corticosteroid injections, not as part of GRASP trial ^a	103	10.67 (28.81)	127	8.65 (23.55)	120	10.46 (33.64)	132	12.29 (34.12)
Total cost (NHS and PSS)	103	193.31 (414.85)	119	203.23 (146.97)	116	236.95 (151.67)	124	308.68 (407.61)

a Number column refers to the participants who answered the question 'did you use X resource use?' at each time point [i.e. 103 out of 174 participants in the best-practice advice group responded to the question if they had an injection outside the GRASP trial, of whom one participant (0.57%) had an injection (see Table 21)].

TABLE 23 Non-NHS costs (£) over the 12 months (available cases, without imputation of missing data)

Non-NHS cost	Best-practice advice (N = 174)		Injection plus best-practice advice (N = 178)		Progressive exercise (N = 174)		Injection plus progressive exercise (N = 182)	
	n ^a	Mean cost (£) (SD)	n ^a	Mean cost (£) (SD)	n ^a	Mean cost (£) (SD)	n ^a	Mean cost (£) (SD)
Time off work	174	107.58 (576.68)	178	105.17 (658.46)	174	36.98 (309.12)	182	102.86 (704.33)
Additional expenses	109	36.99 (189.04)	134	13.62 (94.41)	131	33.58 (209.86)	143	280.49 (3202.68)
Medication (out of pocket)	115	13.34 (30.97)	132	15.71 (29.64)	127	20.11 (49.82)	139	17.74 (38.90)
Private care	174	22.07 (131.22)	178	16.98 (161.47)	174	15.95 (79.78)	182	18.62 (100.24)
Total cost (societal)	101	229.78 (926.49)	123	185.68 (818.29)	119	110.30 (412.65)	133	441.39 (3448.15)

a The number column refers to the participants who answered the question 'did you use X resource use?' at each time point.

allocation for the 12-month period is also shown in *Table 23*. *Table 23* further indicates that the non-NHS cost of 'additional expenses' and 'total cost (societal)' was higher in the injection and progressive-exercise intervention groups than in the other intervention groups. Utilisation of corticosteroid injections outside the GRASP trial is presented in *Appendix 5, Table 52*. The use of corticosteroid injections outside the trial varied slightly across treatment groups and follow-up periods, but, overall, was very low, with the largest number of participants receiving injection ($n = 12$) recorded between 6 and 12 months from the best-practice advice group. In addition, < 1% of participants reported paying for an injection privately. Similarly, physiotherapy sessions taken outside the GRASP trial have been recorded and presented in *Appendix 5, Tables 44–47*. The number of physiotherapy sessions taken outside the trial was, overall, very small across all treatment groups and follow-up periods, and varied slightly.

Utility and quality-adjusted life-years

Utility scores were estimated using validated EQ-5D-5L questionnaires completed by participants at baseline, 8 weeks, 6 months and 12 months. The summary statistics of the unadjusted and adjusted EQ-5D utility scores for all observed cases across all time points by treatment interventions are presented in *Table 24* and *Appendix 5, Table 53*. EQ-5D-5L scores at 12 months were higher than the baseline scores in all treatment groups. Baseline EQ-5D was markedly higher in the group randomised to progressive exercise only. Consequently, unadjusted EQ-5D utilities and QALYs should be interpreted with caution.

TABLE 24 Utility and QALY estimates: EQ-5D-5L scores (available cases with and without imputation and adjustment for baseline utility)

Utility and QALY estimate	Best-practice advice		Injection plus best-practice advice		Progressive exercise		Injection plus progressive exercise	
	<i>n</i> ^a	Mean (SD)	<i>n</i> ^a	Mean (SD)	<i>n</i> ^a	Mean (SD)	<i>n</i> ^a	Mean (SD)
Available cases without imputation and no adjustment for baseline utility								
Baseline	174	0.65 (0.20)	178	0.64 (0.18)	172	0.69 (0.15)	181	0.64 (0.18)
8 weeks	132	0.68 (0.20)	151	0.73 (0.17)	147	0.70 (0.15)	164	0.69 (0.20)
6 months	134	0.74 (0.20)	151	0.75 (0.16)	143	0.78 (0.16)	154	0.72 (0.23)
12 months	138	0.77 (0.20)	158	0.77 (0.16)	144	0.81 (0.16)	154	0.75 (0.22)
QALYs	101	0.73 (0.17)	132	0.75 (0.12)	124	0.76 (0.28)	137	0.73 (0.18)
Imputation and no adjustment for baseline utility								
Baseline	174	0.65 (0.20)	178	0.64 (0.18)	174	0.69 (0.15)	182	0.64 (0.18)
8 weeks	174	0.69 (0.20)	178	0.72 (0.17)	174	0.69 (0.15)	182	0.68 (0.21)
6 months	174	0.73 (0.20)	178	0.75 (0.17)	174	0.76 (0.17)	182	0.72 (0.23)
12 months	174	0.76 (0.21)	178	0.77 (0.16)	174	0.81 (0.16)	182	0.76 (0.21)
QALYs	174	0.72 (0.18)	178	0.75 (0.13)	174	0.77 (0.28)	182	0.74 (0.17)
Imputation and adjustment for baseline utility								
QALYs	174	0.74 (0.15)	178	0.74 (0.15)	174	0.77 (0.12)	182	0.72 (0.17)
a The number column refers to the participants who answered the question 'did you use X resource use?' at each time point.								

Cost-effectiveness results

Base-case results

Table 25 presents the costs and QALYs associated with the four interventions under investigation. This analysis evaluated the impact of exercise treatment and injection and interactions between these two interventions inside the table, while imputing missing values and adjusting for age, sex and baseline utility.

When all randomised patients were included in the analysis and missing values were imputed using multiple imputation, patients receiving best-practice advice accrued an average of 0.737 (95% CI 0.710 to 0.763) QALYs and an NHS cost of £195 over the 12-month period (see Table 25). In the base-case analysis, adding injection to best-practice advice gained 0.021 QALYs ($p = 0.184$) and increased the cost by £10 per participant ($p = 0.747$) compared with best-practice advice alone. Progressive exercise alone was £52 ($p = 0.247$) more expensive per participant than best-practice advice, while gaining 0.019 QALYs ($p = 0.220$). However, there was a non-significant interaction for cost ($p = 0.397$), which meant that when injection was added to progressive exercise it generated an additional cost of £60 per participant (i.e. £50 more than the difference between best-practice advice and injection only). There was also a non-significant qualitative interaction for QALYs ($p = 0.106$), whereby adding injection to best-practice advice increased QALYs, but adding injection to progressive exercise reduced QALYs; the groups receiving injection alone or progressive exercise alone accrued more QALYs than the group receiving best-practice advice, whereas the group that received both of these treatments had lower QALYs than either of the groups receiving only one treatment. Best-practice advice plus injection cost £475.59 more per QALY gained than best-practice advice alone. Progressive exercise alone and progressive exercise plus injection were both strongly dominated by best-practice advice plus injection, being both more costly and accruing fewer QALYs.

The 2013 NICE cost-effectiveness threshold of £20,000 per additional QALY¹⁰⁰ was used to identify which treatments represent best value for money (i.e. has highest NMB). The interactions for cost and QALYs combine to give a qualitative, but non-significant interaction for NMB ($p = 0.100$). Best-practice advice plus injection had a 54.93% probability of being the most cost-effective treatment at a ceiling

TABLE 25 Regression analysis with an interaction term, including imputation of missing values and adjustment for baseline utility, sex and age (base-case analysis)

Regression analysis	Total costs (£), mean (SE)	QALYs, mean (SE)	NMB (£), ^a mean (SE)
BPA	195 (54)	0.737 (0.013)	14,538 (290)
IBPA	205 (20)	0.757 (0.011)	14,939 (227)
ProgEx	247 (23)	0.756 (0.012)	14,865 (255)
IProgEx	307 (30)	0.742 (0.012)	14,524 (263)
Injection simple effect (IBPA – BPA)	10 (44) ($p = 0.747$)	0.021 (0.015) ($p = 0.184$)	402 (322) ($p = 0.212$)
ProgEx simple effect (ProgEx – BPA)	52 (44) ($p = 0.247$)	0.019 (0.016) ($p = 0.220$)	327 (323) ($p = 0.309$)
Interaction (BPA – IBPA – ProgEx + IProgEx): ProgEx by injection	50 (57) ($p = 0.397$)	–0.035 (0.022) ($p = 0.106$)	–743 (455) ($p = 0.100$)

BPA, best-practice advice; IBPA, injection plus best-practice advice; IProgEx, injection plus progressive exercise; ProgEx, progressive exercise.

^a NMB calculated at a ceiling ratio of £20,000 per QALY.

Notes

Values represent the mean (SE) for each group for males of age 55.46 years and a baseline utility of 0.653. As there was assumed to be no interaction between baseline variables and treatments, the simple effects for each treatment and the interaction between treatments are assumed to be the same for all participant subgroups, although the absolute costs and absolute QALYs may be higher or lower, depending on participants' sex, age and baseline utility.

ratio of £20,000 per QALY (Figure 12). Progressive exercise alone had the second highest NMB and had a 35.64% probability of being cost-effective at a ceiling ratio of £20,000 per QALY.

Sensitivity analyses

The analysis ignoring the interaction between exercise treatment and injection also found it to be cost-effective to adopt injection, but not progressive exercise, although there remained substantial uncertainty around this conclusion (see *Appendix 5, Table 54*). In this analysis, progressive exercise (with/without injection) had a statistically significant effect on cost ($p = 0.012$), with an increase of £78 per participant compared with no progressive exercise (with/without injection), but gained < 0.001 QALYs ($p = 0.984$). Progressive exercise, therefore, cost £438,089 per QALYs gained compared with no progressive exercise. Injection (with/without progressive exercise) non-significantly increased cost (£35 per participant; $p = 0.239$) while offering a negligible QALY gain (0.003; $p = 0.818$), but was, nonetheless, expected to be cost-effective compared with no injection (with/without progressive exercise), costing £15,110 per QALY gained.

Appendix 5, Table 55, presents an extension to the NHS and PSS perspective taken by the base-case analysis to further consider the societal perspective, which included expenses borne by participants in the study, over-the-counter medication cost, income loss and cost of private care. In this analysis, adding injection to best-practice advice gained 0.02 QALYs ($p = 0.183$) and decreased the cost by £34 per participant ($p = 0.813$). Progressive exercise alone was £60 ($p = 0.247$) less expensive per participant than best-practice advice, while offering a gain of 0.019 QALYs ($p = 0.229$). When injection was added to progressive exercise, it increased costs by £374 per participant, as there was a very large non-significant qualitative interaction for QALYs (£408; $p = 0.106$). The interactions for cost and QALYs combined to give a qualitative and borderline statistically significant interaction for NMB ($p = 0.049$). Best-practice advice plus injection was expected to be the most cost-effective treatment (with a 47.55% probability of being cost-effective), followed by progressive exercise only (with a 44.87% probability of being cost-effective).

As described above, we extended the base-case analysis by considering the maximum cost of delivering the training for best-practice advice and progressive exercise (e.g. travel cost, venue hire, parking) while calculating the treatment cost of the intervention. In this analysis, the total cost of training was £139.44 per participant for best-practice advice and £166.69 per participant for progressive exercise. The results of the worst-case cost-effectiveness analysis are shown in *Appendix 5, Table 56*. QALY gains from the interventions are virtually identical to the base-case analysis (differing only from Monte Carlo error due to bootstrapping) and differences between treatment groups were not statistically significant.




FIGURE 12 The CEAC for the comparison between treatment groups (base-case analysis). The frontier indicated which treatment is economically preferred at different threshold values for cost-effectiveness.

The total training cost per participant was £416.54 higher than in the base case, although the incremental cost of progressive exercise compared with best-practice advice alone increased by only £41 compared with the base case. At a £20,000 per QALY ceiling ratio, best-practice advice plus injection remained the most cost-effective treatment, with a 53.59% probability of being cost-effective. Progressive exercise and progressive exercise plus injection were dominated (i.e. more costly and less effective) by best-practice advice plus injection.

Finally, we conducted a sensitivity analysis that assumed that study interventions would be implemented in routine clinical practice with the training delivered on an online platform. The best-case analysis results are presented in *Appendix 5, Table 57*. The total cost of training was £2.35 per participant for best-practice advice and £3.02 for progressive exercise, which is, respectively, £40.85 and £46.41 less expensive per participant than the base case. At a £20,000 per QALY ceiling ratio, best-practice advice plus injection remained the most cost-effective treatment, with a 53.6% probability of being cost-effective. Progressive exercise and progressive exercise plus injection were dominated (i.e. more costly and less effective) by best-practice advice plus injection.

Discussion

The GRASP trial economic analysis evaluated the cost-utility of best-practice advice alone, best-practice advice preceded by a corticosteroid injection, progressive exercise alone and progressive exercise preceded by a corticosteroid injection, and compared alternative methodological approaches for conducting economic evaluation alongside factorial trials.

At a £20,000 per QALY ceiling ratio, a corticosteroid injection followed by best-practice advice was expected to be the most cost-effective treatment for people with a new episode of a rotator cuff disorder, regardless of the analytical approach adopted, although there was substantial uncertainty around this conclusion. There were no significant differences in costs or QALYs and there was a 36% chance that progressive exercise alone is the most cost-effective strategy. In addition, the strength of evidence in favour of best-practice advice plus injection did not vary considerably between the base-case analysis, ignoring interactions, and the two sensitivity analyses varying the assumptions about training cost. Across these analyses, NMBs for best-practice advice plus injection ranged from £14,783 to £14,986.

Although missing data are usually an issue in economic analysis and may introduce bias into the health economics results, the rate of complete response to the health-care resource use questions and EQ-5D questionnaire was reasonably high in the GRASP trial. Regardless, robust multiple imputation models have been applied and included all treatment indicators.

One of the advantages of conducting a factorial design trial is that it enables us to compare four treatment options within a single trial and explore whether or not there are interactions between treatments. We observed interactions for both costs and QALYs, which were very large compared with the main effect of treatment and meant that adding injections to best-practice advice increased mean QALYs, whereas adding injections to progressive exercise decreased mean QALYs. The opposite trend was observed for costs when a societal perspective was taken, which translated to a statistically significant interaction for NMB. We are not aware of a clinical mechanism that may explain these interactions and these interactions (only one of which was statistically significant) may have arisen by chance. Furthermore, even relatively small interactions will change the direction of clinical effect in studies such as this where the simple effect of treatment is very small. As randomised controlled trials, in general, are not powered based on economic end points but rather clinical outcomes, there is an ongoing argument that the economic evaluations are very likely underpowered. This argument is more prominent in a factorial design setting and increases the degree of uncertainty around the economic estimates in particular. We followed recent methodological work in prespecifying that the economic evaluation would include an interaction term regardless of statistical significance.⁸⁸ In the base-case

analysis, interactions between treatments were not statistically significant, suggesting that the standard statistical approach would have been to conduct an at-the-margins approach. Only when the broader societal perspective was taken together with the base-case NHS perspective did the interactions for cost and QALYs combine to give a qualitative and statistically significant interaction for NMB. However, our sensitivity analysis demonstrated that the conclusion that best-practice advice plus injection was the most cost-effective treatment remained unchanged in the sensitivity analysis omitting the interaction term. Dakin and Gray⁸⁸ have discussed the challenges associated with the economic evaluations conducted alongside factorial trials, but further research is needed in this area.

The current economic evaluation used the newly developed EQ-5D-5L to capture the health-related quality of life for patients with a new episode of a rotator cuff disorder. It is regarded as more sensitive in capturing health changes than its predecessor (i.e. the EuroQol-5 Dimensions, three-level version). Nonetheless, as a generic measure of health, it is not disease specific and, hence, not expected to capture all the treatment benefits. The economic analysis showed a negligible and non-statistically significant QALY difference between the treatment groups, which is also consistent with the primary clinical outcome (i.e. SPADI) in this trial.

Finally, our economic evaluation included data from the GRASP trial only. Although there are no previous data on the specific progressive exercise regimen used in this study, there have been a number of previous studies of injections.³⁰ In principle, future analyses could use methods such as Bayesian bootstrapping^{88,104,105} to combine evidence from the GRASP trial with previous evidence on the efficacy of injection compared with no injection.

Chapter 6 Discussion

This chapter provides an overview of the aims of the GRASP trial and summarises the main findings, before considering its internal and external validity. The interpretation of the findings are then considered in the context of data from other similar trials in this area.

Interpretation

Aim and overview of trial findings

Shoulder pain in the UK is very common, with the most common attribution being the rotator cuff, which accounts for around 70% of new episodes of shoulder pain presenting in primary care.² The majority of shoulder pain is managed in primary care or at primary care interface services by physiotherapists and GPs. Current treatments aim to improve pain and function with standard care that includes rest, advice, analgesia, physiotherapist-prescribed exercise and corticosteroid injection; however, there are no NICE clinical guidelines for this area.⁴ Prior to the GRASP trial, limited evidence existed regarding the most clinically effective and cost-effective form of physiotherapist-prescribed exercise and delivery mechanism associated with the best outcomes for people with a rotator cuff disorder. There was also uncertainty around the long-term benefits and harms associated with corticosteroid injection. In the GRASP trial, we aimed to assess the clinical effectiveness and cost-effectiveness of whether or not (1) an individually tailored progressive, home exercise programme prescribed and supervised by a physiotherapist provided greater improvement in shoulder pain and function over 12 months (measured using the SPADI score) compared with a best-practice advice session with a physiotherapist and provision of high-quality self-management materials, and (2) subacromial corticosteroid injection provided greater improvement in shoulder pain and function over 12 months compared with no injection.

For the primary outcome, there was no evidence of a difference in the SPADI scores over 12 months between participants randomised to receive the progressive-exercise intervention and those who received best-practice advice. Likewise, there was no evidence when analysed at the 8-week and 6- and 12-month time points. In both intervention groups, shoulder pain and function did improve over time, although SPADI scores at 12 months showed that the condition did not resolve completely, as most participants still reported some symptoms. There was also no difference between groups for secondary outcome measures, with the exception of progressive exercise, which resulted in an improvement in patient-reported GIT over 12 months and at the 6- and 12-month time points. There were no significant subgroup differences in shoulder pain and function across the different time points when assessed for age, sex, baseline smoking status, SPADI and pain self-efficacy.

Over 12 months, there was no evidence of a difference in SPADI scores between participants randomised to receive corticosteroid injection and those receiving no injection, nor when analysed at the 6- and 12-month time points. There was a small difference in SPADI scores at 8 weeks, in favour of injection, but this was just below the threshold for a clinically important difference in the SPADI. There were no differences between groups for secondary outcome measures, with the exception of corticosteroid injection at 8 weeks, which resulted in a small improvement in shoulder pain, shoulder function, sleep disturbance, RDA and GIT. Prespecified subgroup analysis showed that the effect of corticosteroid injection was stronger at 8 weeks in people with a higher baseline SPADI score (i.e. $\text{SPADI} \geq 50$) than in those who received injection but had a lower baseline SPADI score. No differences were observed for other prespecified subgroup analyses.

At 8 weeks and 6 months, participants who received injections were more likely to report performing their exercises 5 days per week, in accordance with the advice from the treating physiotherapist, than participants who did not receive injections. This suggests that, although the effect of corticosteroid injection is short lived, it may facilitate engagement with prescribed home exercises. There were no SAEs recorded as part of the trial as a result of either corticosteroid injection or physiotherapy.

A cost-utility analysis investigated the impact of progressive exercise, injection and the interaction between progressive-exercise treatment and injection, accounting for missing values and adjusting for baseline imbalance. There were no statistically significant differences between the treatment groups in terms of costs or QALYs over the 12-month period. More specifically, the addition of injection to best-practice advice produced a negligible and non-statistically significant QALY gain, with a small extra cost. Progressive exercise was more expensive per participant than best-practice advice, but, again, with a negligible and non-statistically significant QALY gain. Progressive exercise alone and progressive exercise plus injection were both strongly dominated by best-practice advice plus injection, being more costly and accruing fewer QALYs. Among the treatments under investigation, the one expected to provide the best value for money was the best-practice advice session with a physiotherapist and injection, although there is substantial uncertainty around this conclusion. Although the benefits of corticosteroid injection were limited both in size and to the early phase of recovery, this combination of interventions dominated in terms of their cost-effectiveness.

Generalisability

Internal validity and methodology

The GRASP trial was a pragmatic multicentre superiority 2×2 factorial randomised controlled trial. Given the factorial design, we first formally tested for an interaction effect. In the absence of any significant interaction, we were able to assess the effects of our two main comparisons: (1) progressive-exercise programme compared with best-practice advice session and (2) subacromial corticosteroid injection compared with no injection. In accordance with the sample size estimation (see *Chapter 4*), data from 704 participants were required to detect a standardised effect size of 0.33 (equivalent to 8 points on the SPADI total score) with 90% power and 1% two-sided statistical significance, allowing for 20% loss to follow-up at 12 months and potential for a small clustering effect by physiotherapist.³⁶ The DMEC reviewed the sample size assumptions after 338 participants had been recruited and did not recommend any changes to the final sample size. We recruited a total of 708 participants and had a lower than estimated loss to follow-up rate of 13% at 12 months, and so the trial was adequately powered to detect a statistically and clinically important difference between interventions. Measurements for the primary and secondary outcomes were collected by postal questionnaires at 8 weeks, 6 months and 12 months. When postal questionnaires were returned to the GRASP trial office, data were checked and if missing data were identified, either for part or a whole outcome measure, then the participant was contacted and information collected by telephone. As a result, we had limited missing outcome data from the completed questionnaires.

Randomisation was generated using the centralised computer randomisation service provided by OCTRU. Randomisation was stratified by site, age and sex using variable block size, ensuring that participants were balanced across interventions groups and minimising the chances of research staff anticipating treatment allocation prior to randomisation. It was not possible to blind participants and treating physiotherapists because of the nature of the interventions being tested. Both the primary and secondary outcomes were patient reported and collected using postal questionnaires. There was potential for bias as participants were aware of treatment allocation, but this reflects the difficulty of achieving and maintaining blinding in pragmatic rehabilitation trials of this nature.⁷² In the small number of cases where outcome data were collected by telephone (e.g. participants who did not respond to postal reminders), the researcher was blinded to the treatment allocated and participants were asked not to disclose which intervention they had received.

Physiotherapists were trained to deliver either the best-practice advice intervention or the progressive-exercise intervention to minimise possible contamination between treatment groups. Only two physiotherapists swapped treatment groups during the trial, because of staffing issues at sites, and

so ended up delivering both interventions. According to the results of the GIT questionnaire, the interventions were generally well received by the participants. Interventions were also delivered with high levels of fidelity by the physiotherapists, as determined by quality assurance visits conducted at site and review of treatment logs. Attendance rates were 94% for injection, 95% for progressive exercise (either partially or full completed) and 92% for best-practice advice. These attendance rates are above those normally expected for NHS outpatient physiotherapy, with non-attendance rates estimated to be 10.4% according to recent NHS Hospital Episode Statistics data.⁴¹ There was no difference in attendance rates between those receiving the physiotherapist-delivered exercise interventions and those who received physiotherapist-delivered exercise interventions in conjunction with a corticosteroid injection.

Despite some initial concerns from physiotherapists raised during site training regarding the adequacy of a single contact with a physiotherapist to start a self-guided exercise programme, very few participants in the best-practice advice intervention required an additional contact session during the trial. Most participants in the progressive-exercise intervention group attended a median of four sessions (out of a maximum of six sessions) before being discharged. Progression of exercises, defined as an increase in exercise difficulty or volume and/or load, was regarded as key to achieving the overload and subsequent physiological response in the neuromuscular system to improve muscle function. Treatment logs provided evidence that 67% of participants in the progressive-exercise group had exercise progression between their first and last session, 22% maintained the initial exercise dose during treatment and only 12% had to regress their exercise dose over the sessions. The maintenance or regression of the level of exercise over the sessions was consistent with the tailoring and modification of the exercise programme allowed in the intervention protocol in the trial. The intervention was designed to enable therapists to adapt the programme according to the participant's response to exercising the shoulder.

A small proportion of participants (3.8%) withdrew from the GRASP trial. This was either withdrawal from the intervention only or withdrawal from both the intervention and future follow-up assessment. The most common reason was a change in diagnosis since randomisation, and not dissatisfaction with treatment. Numbers were balanced across intervention groups. Participants were advised that they may seek other forms of treatment/medication outside the GRASP trial. This information was collected as part of the participant follow-up questionnaires. There were no significant differences in medication type or other health-care resources usage across the intervention groups, suggesting that the effects seen in terms of any improvement in shoulder pain and function were due to the trial interventions.

External validity and generalisability of study findings

The GRASP trial recruited participants from 20 primary care-based musculoskeletal services and their related physiotherapy services in the NHS. We had originally planned for eight sites; however, slower than anticipated recruitment meant that we increased our overall number of sites. The advantage of this was a greater range of centres in terms of geography and size, making it more representative of the NHS as a whole.

The training provided to the staff in these centres was relatively brief, with most NHS physiotherapy staff having expertise in delivering the best-practice advice intervention, with limited additional training. The best-practice advice intervention places emphasis on strategies to optimise self-management, with participants receiving a single face-to-face session rather than four to six sessions, as would be more typical of standard NHS physiotherapy treatment for this condition. As a result, we believe that the implementation of the best-practice advice intervention in the NHS would be straightforward and would involve relatively small training costs. No additional training was required for the subacromial corticosteroid injection, as this was delivered in accordance with current NHS practice and predominantly by extended-scope physiotherapists with the appropriate post-registration qualification in injection therapy.

We believe that the participants recruited into the GRASP trial are representative of patients referred to NHS primary care-based musculoskeletal and physiotherapy services with a new episode of shoulder pain due to a rotator cuff disorder, in terms of their age and sex. Screening log data showed that the age and sex of patients who declined to take part in the trial were similar to those who did take part. However, one of the main reasons that participants declined to take part in the trial was because they were not interested in taking part in research (30%) or that they had a treatment preference for not wanting to receive corticosteroid injection (27%), as opposed to 7% having a treatment preference for wanting to receive injection. The extent to which this is representative of clinical practice outside a trial setting is unclear.

The mean age of participants recruited into the GRASP trial was 55.5 years, with a similar proportion of men and women. This is consistent with data from a large epidemiological study of rotator cuff pathology¹⁰⁶ using The Health Improvement Network database (a large UK primary care database) in which the highest incidence of rotator cuff pathology was found in those aged between 55 and 59 years, with no significant difference between men and women. This study also showed that people in the lowest socioeconomic group (with the Townsend deprivation score used as a measure of material deprivation) had the highest disease incidence.¹⁰⁶ This is reflected in the findings of the GRASP trial, in which, despite around half of participants reporting being in employment, their reported household income was low.

Our population was predominantly white British (89.7%) and this figure is higher than the population in England as a whole (78.7%).¹⁰⁷ The prevalence of rotator cuff disorder in ethnic minority groups is not well known or understood and so it is difficult to infer what influence this may have on the generalisability of our results. More than two-thirds of participants included in the GRASP trial were considered to be overweight or obese based on their body mass index. Again, the effect of obesity on the prevalence of rotator cuff disorders is not well known, including the extent to which it can contribute to symptoms¹⁰⁸ and ability to exercise effectively. There is some evidence that obesity can lead to poorer outcomes after surgery to repair a rotator cuff tear.¹⁰⁹

The mean duration of symptoms for participants included in the GRASP trial was 4 months. Our eligibility criteria meant that we specifically wanted to target those participants with a new episode of shoulder pain attributable to a rotator cuff and who had not received corticosteroid injection or physiotherapy for shoulder pain in the last 6 months. The overall mean SPADI baseline score was 54.1 (on a scale of 0–100), with higher reported levels of shoulder pain (mean 63.9) than impairment of shoulder function (mean 44.3). Irrespective of the allocated intervention, participant shoulder pain and function improved over time, although overall SPADI scores at 12 months (mean 21.9) show that symptoms did not resolve completely. These findings are consistent with a large epidemiological study of the prevalence of people consulting for shoulder pain in UK primary care, whereby 13.6% of people with shoulder pain continued to consult beyond 2 years from initial presentation.¹ The SELF trial, which compared the effectiveness of usual physiotherapy treatment with a programme of self-management, also found that rotator cuff symptoms had not resolved completely when measured using the SPADI scale at 12 months.⁶⁷

Overall evidence: comparison with other literature

Exercise intervention

Findings from a Cochrane review published in 2016, before the start of the GRASP trial, highlighted the lack of evidence about the long-term clinical effectiveness and cost-effectiveness of physiotherapy for the treatment of rotator cuff disorders, despite its widespread provision.¹⁴ Evidence from several small trials with short-term follow-up also raised uncertainty about which types of exercise and delivery mechanisms were associated with best outcomes.^{15,16}

We searched MEDLINE, EMBASE and Cumulative Index to Nursing and Allied Health Literature (CINHAL) to identify new evidence relevant to the GRASP trial (date of last search: June 2020).

From an initial 2354 records, we identified seven trials^{67,110–115} published between 2013 and 2020, comparing the effects of supervised exercise with unsupervised exercise, or no intervention, in people with a rotator cuff disorder (excluding those who required surgery). Most of the trials concluded that there was little or no difference between supervised and unsupervised exercise. The populations were comparable to the GRASP trial, with the exception of the trial by Krischak *et al.*,¹¹⁰ which evaluated people with atraumatic full-thickness rotator cuff tears. All trials were small, with the exception of the trial by Contreras *et al.*¹¹³ ($n = 271$) and the SUPPORT trial¹¹⁵ [which had 64 participants in each group (2×2 factorial trial) and 256 participants in total]. Only two^{67,115} of the seven trials reported on the effect of exercise on shoulder pain and function at 12 months, two reported medium-term follow-up data (24 or 26 weeks^{111,113}) and the remaining three trials reported outcomes at ≤ 6 weeks (see *Appendix 6, Table 58*). This reinforces the importance of the GRASP trial findings in terms of their definitive nature and length of follow-up.

Corticosteroid injection

At the time of planning the GRASP trial, there was systematic review evidence that, in comparison with placebo, corticosteroid injections had short-term benefit for treating tendinopathy, although there was some uncertainty regarding its use for rotator cuff disorders. There were also concerns about the longer-term safety of corticosteroid injection and its effect on the tendon.³⁰

We searched MEDLINE, EMBASE, the Allied and Complementary Medicine Database (AMED), CINHAL, the Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry to identify new evidence relevant to the GRASP trial (date of last search: June 2020).⁹¹ From an initial 794 records, we identified one small trial¹¹⁶ that compared the effects of corticosteroid injection with no injection in people with a rotator cuff tear and found no difference in shoulder pain and function when analysed at 3 or 6 months, measured using the Constant–Murley score (MD at 6 months -1.9 , 95% CI -10.89 to 7.09 ; patients, $n = 40$).

We identified an additional 10 trials^{7,90,117–124} that compared the effects of corticosteroid injection with placebo injection (see *Appendix 6, Table 59*), of which four^{7,118,121,122} were judged as suitable for inclusion in a meta-analysis. The remaining studies could not be included because of either incomplete or incompatible outcome data. Three trials,^{118,121,122} with a total of 215 patients, compared subacromial corticosteroid injection with placebo injection for combined shoulder pain and function in the short term (i.e. ≤ 8 weeks), with results favouring corticosteroid over placebo [standardised mean difference (SMD) -0.51 , 95% CI -1.02 to 0.00 ; $I^2 = 69\%$; $n = 3$; patients, $n = 215$; rated as having moderate-quality evidence]. Two of the trials^{118,122} also reported outcome data for medium-term follow-up (i.e. 3–6 months), in which no difference was apparent (SMD 0.08 , 95% CI -0.24 to 0.39 ; $I^2 = 0\%$; $n = 2$; patients, $n = 151$; rated as having moderate-quality evidence). With regard to shoulder pain only, three trials reported short-term outcomes^{118,121,122} and two reported medium-term outcomes.^{118,122} The results mirrored those seen for combined shoulder pain and function, which favoured corticosteroid injection over placebo in the short term (SMD -0.35 , 95% CI -0.65 to -0.05 ; $I^2 = 17\%$; $n = 3$; patients, $n = 215$; rated as having moderate quality evidence), but not the medium term (SMD 0.05 , 95% CI -0.27 to 0.37 ; $I^2 = 0\%$; $n = 2$; patients, $n = 151$; rated as having moderate-quality evidence). Two trials^{7,122} reported on shoulder functional improvement in the short and medium term and, again, there was a short-term benefit favouring corticosteroid injection (SMD -0.33 , 95% CI -0.67 to 0.00 ; $I^2 = 0\%$; $n = 2$; patients, $n = 143$; rated as having moderate-quality evidence), but there was no difference seen in medium-term functional outcomes (SMD -0.24 , 95% CI -0.59 to 0.10 ; $I^2 = 0\%$; $n = 2$; patients, $n = 131$; rated as having moderate-quality evidence). No trials provided outcome data beyond 6-month follow-up and none reported any SAEs as a result of injection.

These findings reinforce the importance of the results of the GRASP trial in terms of the short-term benefit of subacromial corticosteroid injection, a benefit which is not maintained at 6- and 12-month follow-up.

Chapter 7 Conclusion

This chapter provides interpretation of the GRASP trial findings for clinical practice and policy, and provides recommendations for future research.

In adults with a new episode of shoulder pain (i.e. within the last 6 months) attributable to a rotator cuff disorder, there was no difference in the primary outcome (SPADI) or other prespecified secondary outcomes between participants randomised to receive (1) progressive exercise compared with best-practice advice, or (2) subacromial corticosteroid injection compared with no injection, when analysed over 12 months. Irrespective of allocated intervention, participants' shoulder pain and function improved over time, although SPADI scores at 12 months show that the condition did not resolve completely, as participants still reported some symptoms. Participants randomised to receive subacromial corticosteroid injection reported an improvement in shoulder pain and function at 8 weeks, but injection provided modest short-term benefit only. The greatest benefit of injection was seen in the subgroup of participants who reported higher SPADI scores at baseline; however, as this is based on subgroup analysis, this should be viewed with caution. No SAEs were reported as a result of the intervention(s). The cost-utility analysis, performed as part of the GRASP trial, suggests that, at a £20,000 per QALY ceiling ratio, a corticosteroid injection followed by best-practice advice is likely to be the most cost-effective treatment combination for people with a new episode of a rotator cuff disorder. There are no significant differences in costs or QALYs.

Implications for health care

Early and effective management of rotator cuff disorders in primary care and primary care interface musculoskeletal services is vital, given their associated disability and commonality. Consequences of poor initial management may lead to an increased likelihood of recurrent or persistent problems in older age and the subsequent need for surgery. This is particularly important given recent evidence from the NIHR HTA-funded CSAW trial¹²⁵ and updated Cochrane review⁹³ that showed a lack of benefit from subacromial decompression surgery, which is often used after non-operative interventions have failed.

The GRASP trial shows that a single face-to-face session with a physiotherapist is likely to be more cost-effective and is not significantly different in terms of clinical outcomes than a comprehensive physiotherapy intervention of up to six face-to-face sessions. This is particularly important given the incidence of rotator cuff disorders and the need to develop cost-effective and pragmatic methods of dealing with this high-volume condition. Subacromial corticosteroid injection provides a modest short-term benefit and is associated with an increased level of engagement in exercise. The greatest benefit was observed in those with higher levels of pain and functional impairment at baseline.

Physiotherapists delivering the best-practice advice intervention attended a short face-to-face training session where focus was on strategies to promote self-management and independent progression of exercise, adherence to exercise and addressing barriers to exercise. The exercises prescribed were those within the range that physiotherapists deliver in usual practice. We are exploring the use of an online training module where physiotherapists can access the best-practice advice intervention training virtually. This has proved very successful in implementation of physiotherapy interventions from other musculoskeletal trials.⁴⁵ In addition, the materials provided to participants in terms of the best-practice advice booklet, exercise DVD and website are in English and, therefore, there is a need to explore translation of these materials into other languages. There may also be some people for whom a single session is not appropriate, for example those with low levels of literacy or inability to engage with self-management care, in which case additional physiotherapy sessions may be required.

Implications for research

There is a case to extend follow-up beyond 12 months, as some participants still reported pain and impaired shoulder function at 12 months. There is a need to better understand the natural history of rotator cuff disorders, including whether symptoms resolve over an extended period of time or persist in the longer term. Part of this investigation could involve studies examining the natural course of rotator cuff disorders and could include a randomised trial that compares the effects of no physiotherapy with best-practice advice.

Although subacromial corticosteroid injection provided short-term benefit, there are still concerns regarding long-term harm due to its possible effects on tendon structure.¹²⁶ Very few participants reported having undergone surgery related to their rotator cuff disorder during the 12-month follow-up period. Twelve months may be too early to measure this effectively, as participants may still be undergoing other forms of non-operative treatment. Therefore, longer-term follow-up would be beneficial.

Finally, screening data from trial sites as part of the recruitment process showed that some people had a clear preference not to receive corticosteroid injection and, therefore, declined to take part in the trial. The reason for this strong treatment preference is not clear and would warrant further investigation to establish the reasons why.

Acknowledgements

GRASP trial management team

Sally Hopewell (co-chief investigator), Lucy Cureton (trial manager), Adam Pritchard (trial administrator), Peter Heine (Research Physiotherapist), David J Keene (lead physiotherapist), Ioana R Marian (statistician), Melina Dritsaki (health economist) and Sarah E Lamb (co-chief investigator).

We would like to thank Debbie Brown (Research Physiotherapist) for her assistance with development of the GRASP trial exercise interventions, Hessam Soutakbar (Research Physiotherapist) for his assistance with GRASP trial exercise intervention site training and monitoring and Jacqueline Thompson for her assistance with GRASP trial participant telephone follow-up. We would also like to thank Emma Searle (MSc student; Université Paris Descartes, Paris, France) for her help with updating the literature search.

Principal investigators and research teams by site

We are grateful to the participants, principal investigators and their research teams at our GRASP trial collaborating sites.

University Hospitals of Derby and Burton NHS Foundation Trust

Marcus Bateman (principal investigator).

East Lancashire Hospitals NHS Trust

Alison Hallett (principal investigator) and Helen Thompson.

Gloucestershire Hospitals NHS Foundation Trust

Elaine Willmore (principal investigator).

Birmingham Community Healthcare NHS Trust

Lucy McCann (principal investigator) and Jonathan Price.

Sandwell and West Birmingham Hospitals NHS Trust

Neil Smith (principal investigator).

Buckinghamshire Musculoskeletal Integrated Care Service

Harry Kardamilas (principal investigator).

East Cheshire Hospitals NHS Trust

Matt Hurst (principal investigator).

Bedfordshire Hospitals NHS Foundation Trust

Tim Andrews (principal investigator) and Lori Wells.

Wirral University Teaching Hospital NHS Foundation Trust

Chole De Matas (principal investigator).

Medway Community Healthcare

Arun Jaykumar (principal investigator).

Bristol Community Health

Sean Grove (principal investigator).

Somerset Partnership NHS Foundation Trust

Corinne Birch (principal investigator).

Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust

Julie Bury (principal investigator).

Sherwood Forest Hospitals NHS Foundation NHS Foundation Trust

James Blacknall (principal investigator).

Kent Community Health NHS Foundation Trust

Sally Jessep (principal investigator) and Llewelyn Boucher.

Northern Devon Healthcare NHS Trust

Robert Sandbach (principal investigator).

Airedale NHS Foundation Trust

Stacey Lalande (principal investigator).

North West Boroughs Healthcare NHS Foundation Trust

Gill Dickson (principal investigator).

Staffordshire and Stoke on Trent Partnership NHS Foundation Trust

Treena Larkin (principal investigator).

Warrington and Halton Hospitals NHS Foundation Trust

Carole Cummings (principal investigator).

Trial Steering Committee

Dr Neal Millar (chairperson, Clinical Senior Research Fellow), Dr Chris Metcalfe (Reader in Medical Statistics), Professor Rebecca Kearney (Research Physiotherapist), Dr Melinda Cairns (Consultant Physiotherapist), Dr Sue Jowett (Reader in Health Economics), Mr Richard Goodier (patient representative) and Dr Jean Millar (patient representative).

Data Monitoring and Ethics Committee

Professor Mike Clarke (chairperson, Independent Methodologist), Dr Brennan Kahan (Independent Statistician), Dr Alison Rushton (Independent Physiotherapist) and Dr Jessica Watson (Independent GP Registrar).

Other acknowledgements

The GRASP trial was conducted as part of the portfolio of trials in the registered United Kingdom Clinical Research Collaboration OCTRU at the University of Oxford. It has followed their standard operating procedures, ensuring compliance with the principles of GCP and the Declaration of Helsinki, and any applicable regulatory requirements.

This research is funded by the NIHR HTA programme (15/26/06). The funder had no role in the design of the study, the collection, analysis and interpretation of data, and in writing the manuscript.

Contributions of authors

Sally Hopewell (<https://orcid.org/0000-0002-6881-6984>) (Associate Professor, University of Oxford) was the co-chief investigator; led the funding application, study conception and design; provided overall study supervision; and prepared and reviewed the report.

David J Keene (<https://orcid.org/0000-0001-7249-6496>) (University Research Lecturer, University of Oxford) contributed to study design; led on physiotherapy expertise-based design; advised on overall study conduct, review and preparation; and reviewed the report.

Peter Heine (<https://orcid.org/0000-0003-2530-1216>) (Research Physiotherapist, University of Oxford) conducted site physiotherapist training, quality assessment visits and site monitoring; conducted physiotherapy intervention analysis; and contributed to preparation and review of the report.

Ioana R Marian (<https://orcid.org/0000-0002-0692-8112>) (Trial Statistician, University of Oxford) conducted the clinical analysis and contributed to preparation and review of the report.

Melina Dritsaki (<https://orcid.org/0000-0002-1673-3036>) (Health Economist, University of Oxford) conducted the health economic evaluation and contributed to preparation and review of the report.

Lucy Cureton (<https://orcid.org/0000-0003-0082-8468>) (Trial Manager, University of Oxford) contributed to overall study conduct and preparation and review of the report.

Susan J Dutton (<https://orcid.org/0000-0003-4573-5257>) (Associate Professor, University of Oxford) was responsible for overseeing the statistical aspects of the study, contributed to study design and advised on expertise-based design, overall study conduct and review of statistical aspects, and preparation and review of the report.

Helen Dakin (<https://orcid.org/0000-0003-3255-748X>) (University Research Lecturer, University of Oxford) was responsible for overseeing the health economic evaluation and contributed to overall study design, and preparation and review of the report.

Andrew Carr (<https://orcid.org/0000-0001-5940-1464>) (Professor of Orthopaedic Surgery, University of Oxford) contributed to study design and advised on clinical aspects of trial, overall study conduct and review of the report.

Willie Hamilton (<https://orcid.org/0000-0003-1611-1373>) (Professor of Primary Care Diagnostics, University of Exeter) contributed to study design and advised on clinical aspects of trial, overall study conduct and review of the report.

Zara Hansen (<https://orcid.org/0000-0001-8915-7765>) (Post-Doctoral Researcher, University of Oxford) contributed to study design and advised on clinical aspects of trial, overall study conduct and review of the report.

Anju Jaggi (<https://orcid.org/0000-0001-8413-2622>) (Consultant Physiotherapist, Royal National Orthopaedic Hospital) contributed to study design and advised on clinical aspects of trial, overall study conduct and review of the report.

Chris Littlewood (<https://orcid.org/0000-0002-7703-727X>) (Professor of Musculoskeletal Research, Manchester Metropolitan University) contributed to study design and advised on clinical aspects of trial, overall study conduct and review of the report.

Karen Barker (<https://orcid.org/0000-0001-9363-0383>) (Professor of Physiotherapy, University of Oxford) contributed to study design and advised on clinical aspects of trial, overall study conduct and review of the report.

Alastair Gray (<https://orcid.org/0000-0003-0239-7278>) (Professor of Health Economics, University of Oxford) contributed to study design and advised on health economic aspects of trial, overall study conduct and review of the report.

Sarah E Lamb (<https://orcid.org/0000-0003-4349-7195>) (Professor, University of Exeter) was the co-chief investigator, led the funding application, study conception and design, provided overall study supervision, and prepared and reviewed the report.

Publication

Hopewell S, Keene DJ, Marian IR, Dritsaki M, Heine O, Cureton L, *et al.* Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 × 2 factorial, randomised controlled trial [published online ahead of print 12 July 2021]. *Lancet* 2021.

Data-sharing statement

Direct access to research data was granted to authorised representatives of the sponsor, regulatory authorities or the host institution for monitoring and/or auditing of the study to ensure compliance with regulations. Summary results data will be included on the EudraCT database (URL: <https://eudract.ema.europa.eu/>) within 12 months of the end of the trial. General release will be 5 years after the end of the trial to allow the investigators sufficient time to complete and report additional analyses of the data set. All data requests should be submitted to the corresponding author.

Patient data

This work uses data provided by patients and collected by the NHS as part of their care and support. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people's patient records, to understand more about disease, develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone's privacy, and it's important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You can find out more about the background to this citation here: <https://understandingpatientdata.org.uk/data-citation>.

References

1. Linsell L, Dawson J, Zondervan K, Rose P, Randall T, Fitzpatrick R, Carr A. Prevalence and incidence of adults consulting for shoulder conditions in UK primary care; patterns of diagnosis and referral. *Rheumatology* 2006;**45**:215–21. <https://doi.org/10.1093/rheumatology/kei139>
2. Mitchell C, Adebajo A, Hay E, Carr A. Shoulder pain: diagnosis and management in primary care. *BMJ* 2005;**331**:1124–8. <https://doi.org/10.1136/bmj.331.7525.1124>
3. Whittle S, Buchbinder R. In the clinic. Rotator cuff disease. *Ann Intern Med* 2015;**162**:ltc1–15. <https://doi.org/10.7326/AITC201501060>
4. The Royal College of Surgeons. *Commissioning Guide: Subacromial Shoulder Pain*. 2014. URL: www.rcseng.ac.uk/library-and-publications/rcs-publications/docs/subacromial-shoulder-pain/ (accessed 24 May 2021).
5. National Institute for Health and Care Excellence. *Shoulder Pain*. 2017. URL: <http://cks.nice.org.uk/shoulder-pain#!scenario:1> (accessed 2 March 2021).
6. Hermans J, Luime JJ, Meuffels DE, Reijman M, Simel DL, Bierma-Zeinstra SM. Does this patient with shoulder pain have rotator cuff disease? The Rational Clinical Examination systematic review. *JAMA* 2013;**310**:837–47. <https://doi.org/10.1001/jama.2013.276187>
7. Holt TA, Mant D, Carr A, Gwilym S, Beard D, Toms C, *et al*. Corticosteroid injection for shoulder pain: single-blind randomized pilot trial in primary care. *Trials* 2013;**14**:425. <https://doi.org/10.1186/1745-6215-14-425>
8. Urwin M, Symmons D, Allison T, Brammah T, Busby H, Roxby M, *et al*. Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivation. *Ann Rheum Dis* 1998;**57**:649–55. <https://doi.org/10.1136/ard.57.11.649>
9. Chartered Society for Physiotherapy. *An Audit of Physiotherapy Services in England*. 2012. URL: www.csp.org.uk/system/files/documents/2018-11/stretched-to-the-limit-2012.pdf (accessed 24 May 2021).
10. Roach KE, Budiman-Mak E, Songsiridej N, Lertratanakul Y. Development of a shoulder pain and disability index. *Arthritis Care Res* 1991;**4**:143–9. <https://doi.org/10.1002/art.1790040403>
11. Williams JW, Holleman DR, Simel DL. Measuring shoulder function with the Shoulder Pain and Disability Index. *J Rheumatol* 1995;**22**:727–32.
12. Hanratty CE, McVeigh JG, Kerr DP, Basford JR, Finch MB, Pendleton A, Sim J. The effectiveness of physiotherapy exercises in subacromial impingement syndrome: a systematic review and meta-analysis. *Semin Arthritis Rheum* 2012;**42**:297–316. <https://doi.org/10.1016/j.semarthrit.2012.03.015>
13. Littlewood C, Ashton J, Chance-Larsen K, May S, Sturrock B. Exercise for rotator cuff tendinopathy: a systematic review. *Physiotherapy* 2012;**98**:101–9. <https://doi.org/10.1016/j.physio.2011.08.002>
14. Page MJ, Green S, McBain B, Surace SJ, Deitch J, Lyttle N, *et al*. Manual therapy and exercise for rotator cuff disease. *Cochrane Database Syst Rev* 2016;**6**:CD012224. <https://doi.org/10.1002/14651858.CD012224>
15. Bennell K, Wee E, Coburn S, Green S, Harris A, Staples M, *et al*. Efficacy of standardised manual therapy and home exercise programme for chronic rotator cuff disease: randomised placebo controlled trial. *BMJ* 2010;**340**:c2756. <https://doi.org/10.1136/bmj.c2756>

16. Littlewood C, Malliaras P, Mawson S, May S, Walters SJ. Self-managed loaded exercise versus usual physiotherapy treatment for rotator cuff tendinopathy: a pilot randomised controlled trial. *Physiotherapy* 2014;**100**:54–60. <https://doi.org/10.1016/j.physio.2013.06.001>
17. Ingwersen KG, Christensen R, Sørensen L, Jørgensen HR, Jensen SL, Rasmussen S, *et al.* Progressive high-load strength training compared with general low-load exercises in patients with rotator cuff tendinopathy: study protocol for a randomised controlled trial. *Trials* 2015;**16**:27. <https://doi.org/10.1186/s13063-014-0544-6>
18. Abdulla SY, Southerst D, Côté P, Shearer HM, Sutton D, Randhawa K, *et al.* Is exercise effective for the management of subacromial impingement syndrome and other soft tissue injuries of the shoulder? A systematic review by the Ontario Protocol for Traffic Injury Management (OPTIMA) Collaboration. *Man Ther* 2015;**20**:646–56. <https://doi.org/10.1016/j.math.2015.03.013>
19. Littlewood C, Malliaras P, Chance-Larsen K. Therapeutic exercise for rotator cuff tendinopathy: a systematic review of contextual factors and prescription parameters. *Int J Rehabil Res* 2015;**38**:95–106. <https://doi.org/10.1097/MRR.0000000000000113>
20. Kraemer WJ, Adams K, Cafarelli E, Dudley GA, Dooly C, Feigenbaum MS, *et al.* American College of Sports Medicine position stand. Progression models in resistance training for healthy adults. *Med Sci Sports Exerc* 2002;**34**:364–80. <https://doi.org/10.1097/00005768-200202000-00027>
21. Heine PJ, Williams MA, Williamson E, Bridle C, Adams J, O'Brien A, *et al.* Development and delivery of an exercise intervention for rheumatoid arthritis: strengthening and stretching for rheumatoid arthritis of the hand (SARAH) trial. *Physiotherapy* 2012;**98**:121–30. <https://doi.org/10.1016/j.physio.2011.03.001>
22. Green S, Buchbinder R, Hetrick S. Acupuncture for shoulder pain. *Cochrane Database Syst Rev* 2005;**2**:CD005319. <https://doi.org/10.1002/14651858.CD005319>
23. Green S, Buchbinder R, Hetrick S. Physiotherapy interventions for shoulder pain. *Cochrane Database Syst Rev* 2003;**2**:CD004258. <https://doi.org/10.1002/14651858.CD004258>
24. Jack K, McLean SM, Moffett JK, Gardiner E. Barriers to treatment adherence in physiotherapy outpatient clinics: a systematic review. *Man Ther* 2010;**15**:220–8. <https://doi.org/10.1016/j.math.2009.12.004>
25. Sluijs EM, Kok GJ, van der Zee J. Correlates of exercise compliance in physical therapy. *Phys Ther* 1993;**73**:771–82. <https://doi.org/10.1093/ptj/73.11.771>
26. UK BEAM Trial Team. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: effectiveness of physical treatments for back pain in primary care. *BMJ* 2004;**329**:1377. <https://doi.org/10.1136/bmj.38282.669225.AE>
27. Knox CR, Lall R, Hansen Z, Lamb SE. Treatment compliance and effectiveness of a cognitive behavioural intervention for low back pain: a complier average causal effect approach to the BeST data set. *BMC Musculoskelet Disord* 2014;**15**:17. <https://doi.org/10.1186/1471-2474-15-17>
28. Arroll B, Goodyear-Smith F. Corticosteroid injections for painful shoulder: a meta-analysis. *Br J Gen Pract* 2005;**55**:224–8.
29. Buchbinder R, Green S, Youd JM. Corticosteroid injections for shoulder pain. *Cochrane Database Syst Rev* 2003;**1**:CD004016. <https://doi.org/10.1002/14651858.CD004016>
30. Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. *Lancet* 2010;**376**:1751–67. [https://doi.org/10.1016/S0140-6736\(10\)61160-9](https://doi.org/10.1016/S0140-6736(10)61160-9)

31. Crawshaw DP, Helliwell PS, Hensor EM, Hay EM, Aldous SJ, Conaghan PG. Exercise therapy after corticosteroid injection for moderate to severe shoulder pain: large pragmatic randomised trial. *BMJ* 2010;**340**:c3037. <https://doi.org/10.1136/bmj.c3037>
32. Rhon DI, Boyles RB, Cleland JA. One-year outcome of subacromial corticosteroid injection compared with manual physical therapy for the management of the unilateral shoulder impingement syndrome: a pragmatic randomized trial. *Ann Intern Med* 2014;**161**:161–9. <https://doi.org/10.7326/M13-2199>
33. Hay EM, Thomas E, Paterson SM, Dziedzic K, Croft PR. A pragmatic randomised controlled trial of local corticosteroid injection and physiotherapy for the treatment of new episodes of unilateral shoulder pain in primary care. *Ann Rheum Dis* 2003;**62**:394–9. <https://doi.org/10.1136/ard.62.5.394>
34. National Institute for Health and Care Excellence. *Patient Group Directions. Medicines Practice Guideline [MPG2]*. URL: www.nice.org.uk/guidance/mpg2 (accessed 20 May 2021).
35. Roddy E, Zwierska I, Hay EM, Jowett S, Lewis M, Stevenson K, et al. Subacromial impingement syndrome and pain: protocol for a randomised controlled trial of exercise and corticosteroid injection (the SUPPORT trial). *BMC Musculoskelet Disord* 2014;**15**:81. <https://doi.org/10.1186/1471-2474-15-81>
36. Hopewell S, Keene DJ, Maia Schlüssel M, Dritsaki M, Dutton S, Carr A, et al. Clinical and cost-effectiveness of progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of rotator cuff disorders: protocol for a 2 x 2 factorial randomised controlled trial (the GRASP trial). *BMJ Open* 2017;**7**:e018004. <https://doi.org/10.1136/bmjopen-2017-018004>
37. Marian IR, Hopewell S, Keene DJ, Cureton L, Lamb SE, Dutton SJ. Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of rotator cuff disorders: statistical analysis plan for the Getting it Right: Addressing Shoulder Pain (GRASP) 2 x 2 factorial multicentre randomised controlled trial. *Trials* 2020;**21**:767. <https://doi.org/10.1186/s13063-020-04704-5>
38. Brooks R. EuroQol: the current state of play. *Health Policy* 1996;**37**:53–72. [https://doi.org/10.1016/0168-8510\(96\)00822-6](https://doi.org/10.1016/0168-8510(96)00822-6)
39. Mintken PE, Cleland JA, Whitman JM, George SZ. Psychometric properties of the Fear-Avoidance Beliefs Questionnaire and Tampa Scale of Kinesiophobia in patients with shoulder pain. *Arch Phys Med Rehabil* 2010;**91**:1128–36. <https://doi.org/10.1016/j.apmr.2010.04.009>
40. Nicholas MK, McGuire BE, Asghari A. A 2-item short form of the Pain Self-efficacy Questionnaire: development and psychometric evaluation of PSEQ-2. *J Pain* 2015;**16**:153–63. <https://doi.org/10.1016/j.jpain.2014.11.002>
41. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. *Sleep Med* 2001;**2**:297–307. [https://doi.org/10.1016/S1389-9457\(00\)00065-4](https://doi.org/10.1016/S1389-9457(00)00065-4)
42. Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. *J Man Manip Ther* 2009;**17**:163–70. <https://doi.org/10.1179/jmt.2009.17.3.163>
43. Keene DJ, Soutakbar H, Hopewell S, Heine P, Jaggi A, Littlewood C, et al. Development and implementation of the physiotherapy-led exercise interventions for the treatment of rotator cuff disorders for the 'Getting it Right: Addressing Shoulder Pain' (GRASP) trial. *Physiotherapy* 2020;**107**:252–66. <https://doi.org/10.1016/j.physio.2019.07.002>
44. Electronic Medicines Compendium. *Electronic Medicines Compendium*. URL: www.medicines.org.uk/emc/ (accessed 20 May 2021).

45. Lamb SE, Hansen Z, Lall R, Castelnuovo E, Withers EJ, Nichols V, *et al.* Group cognitive behavioural treatment for low-back pain in primary care: a randomised controlled trial and cost-effectiveness analysis. *Lancet* 2010;**375**:916–23. [https://doi.org/10.1016/S0140-6736\(09\)62164-4](https://doi.org/10.1016/S0140-6736(09)62164-4)
46. American College of Sports Medicine. American College of Sports Medicine position stand. Progression models in resistance training for healthy adults. *Med Sci Sports Exerc* 2009;**41**:687–708. <https://doi.org/10.1249/MSS.0b013e3181915670>
47. Jones R, Jenkins F. *Safe and Effective Staffing Levels for the Allied Health Professions: A Practical Guide*. Bristol: Otmoor Publishing Ltd; 2014.
48. Page MJ, McKenzie JE, Green SE, Beaton DE, Jain NB, Lenza M, *et al.* Core domain and outcome measurement sets for shoulder pain trials are needed: systematic review of physical therapy trials. *J Clin Epidemiol* 2015;**68**:1270–81. <https://doi.org/10.1016/j.jclinepi.2015.06.006>
49. Great Britain. *Data Protection Act 2018*. London: The Stationery Office; 2018.
50. Breckenridge JD, McAuley JH. Shoulder Pain and Disability Index (SPADI). *J Physiother* 2011;**57**:197. [https://doi.org/10.1016/S1836-9553\(11\)70045-5](https://doi.org/10.1016/S1836-9553(11)70045-5)
51. Lamb SE, Williamson EM, Heine PJ, Adams J, Dosanjh S, Dritsaki M, *et al.* Exercises to improve function of the rheumatoid hand (SARAH): a randomised controlled trial. *Lancet* 2015;**385**:421–9. [https://doi.org/10.1016/S0140-6736\(14\)60998-3](https://doi.org/10.1016/S0140-6736(14)60998-3)
52. Kahan BC. Bias in randomised factorial trials. *Stat Med* 2013;**32**:4540–9. <https://doi.org/10.1002/sim.5869>
53. Brown H, Prescott R. *Applied Mixed Models in Medicine*. 3rd edn. Chichester: John Wiley & Sons, Ltd; 2014. <https://doi.org/10.1002/9781118778210>
54. Eekhout I, de Vet HC, Twisk JW, Brand JP, de Boer MR, Heymans MW. Missing data in a multi-item instrument were best handled by multiple imputation at the item score level. *J Clin Epidemiol* 2014;**67**:335–42. <https://doi.org/10.1016/j.jclinepi.2013.09.009>
55. Shirley Ryan AbilityLab. *Shoulder Pain and Disability Index*. 2015. URL: www.sralab.org/rehabilitation-measures/shoulder-pain-and-disability-index#chronic-pain (accessed 4 October 2019).
56. Sullivan TR, White IR, Salter AB, Ryan P, Lee KJ. Should multiple imputation be the method of choice for handling missing data in randomized trials? *Stat Method Med Res* 2018;**27**:2610–26. <https://doi.org/10.1177/0962280216683570>
57. Chester R, Shepstone L, Daniell H, Sweeting D, Lewis J, Jerosch-Herold C. Predicting response to physiotherapy treatment for musculoskeletal shoulder pain: a systematic review. *BMC Musculoskelet Disord* 2013;**14**:203. <https://doi.org/10.1186/1471-2474-14-203>
58. Tempelhof S, Rupp S, Seil R. Age-related prevalence of rotator cuff tears in asymptomatic shoulders. *J Shoulder Elbow Surg* 1999;**8**:296–9. [https://doi.org/10.1016/S1058-2746\(99\)90148-9](https://doi.org/10.1016/S1058-2746(99)90148-9)
59. Carbone S, Gumina S, Arceri V, Campagna V, Fagnani C, Postacchini F. The impact of preoperative smoking habit on rotator cuff tear: cigarette smoking influences rotator cuff tear sizes. *J Shoulder Elbow Surg* 2012;**21**:56–60. <https://doi.org/10.1016/j.jse.2011.01.039>
60. National Institute for Health and Care Excellence. *Guide to the Methods of Technology Appraisal* 2013. 2013. URL: www.nice.org.uk/article/pmg9/chapter/Foreword (accessed 2 March 2021).
61. World Medical Association. *WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects*. URL: www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ (accessed 15 July 2021).

62. Medical Research Council. *Good Research Practice: Principles and Guidelines*. URL: <https://mrc.ukri.org/research/policies-and-guidance-for-researchers/good-research-practice/> (accessed 15 July 2021).
63. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M, Medical Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;**337**:a1655. <https://doi.org/10.1136/bmj.a1655>
64. Edwards P, Ebert J, Joss B, Bhabra G, Ackland T, Wang A. Exercise rehabilitation in the non-operative management of rotator cuff tears: a review of the literature. *Int J Sports Phys Ther* 2016;**11**:279–301.
65. Ratcliffe E, Pickering S, McLean S, Lewis J. Is there a relationship between subacromial impingement syndrome and scapular orientation? A systematic review. *Br J Sports Med* 2014;**48**:1251–6. <https://doi.org/10.1136/bjsports-2013-092389>
66. Klintberg IH, Cools AM, Holmgren TM, Holzhausen AC, Johansson K, Maenhout AG, et al. Consensus for physiotherapy for shoulder pain. *Int Orthop* 2015;**39**:715–20. <https://doi.org/10.1007/s00264-014-2639-9>
67. Littlewood C, Bateman M, Brown K, Bury J, Mawson S, May S, Walters SJ. A self-managed single exercise programme versus usual physiotherapy treatment for rotator cuff tendinopathy: a randomised controlled trial (the SELF study). *Clin Rehabil* 2016;**30**:686–96. <https://doi.org/10.1177/0269215515593784>
68. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ* 2014;**348**:g1687. <https://doi.org/10.1136/bmj.g1687>
69. Kulkarni R, Gibson J, Brownson P, Thomas M, Rangan A, Carr AJ, Rees JL. Subacromial shoulder pain. *Shoulder Elbow* 2015;**7**:135–43. <https://doi.org/10.1177/1758573215576456>
70. Shawe-Taylor M, Rigby J. Cognitive behaviour therapy: its evolution and basic principles. *J R Soc Promot Health* 1999;**119**:244–6. <https://doi.org/10.1177/146642409911900408>
71. Moseley GL, Butler DS. Fifteen years of explaining pain: the past, present, and future. *J Pain* 2015;**16**:807–13. <https://doi.org/10.1016/j.jpain.2015.05.005>
72. Williams MA, Williamson EM, Heine PJ, Nichols V, Glover MJ, Dritsaki M, et al. Strengthening And stretching for Rheumatoid Arthritis of the Hand (SARAH). A randomised controlled trial and economic evaluation. *Health Technol Assess* 2015;**19**(19). <https://doi.org/10.3310/hta19190>
73. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc* 1982;**14**:377–81. <https://doi.org/10.1249/00005768-198205000-00012>
74. McGuigan MR, Foster C. A new approach to monitoring resistance training. *Strength Cond J* 2004;**26**:42–7. <https://doi.org/10.1519/00126548-200412000-00008>
75. McClure P, Balaicuis J, Heiland D, Broersma ME, Thorndike CK, Wood A. A randomized controlled comparison of stretching procedures for posterior shoulder tightness. *J Orthop Sports Phys Ther* 2007;**37**:108–14. <https://doi.org/10.2519/jospt.2007.2337>
76. Hill AM, McPhail S, Hoffmann T, Hill K, Oliver D, Beer C, et al. A randomized trial comparing digital video disc with written delivery of falls prevention education for older patients in hospital. *J Am Geriatr Soc* 2009;**57**:1458–63. <https://doi.org/10.1111/j.1532-5415.2009.02346.x>
77. Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W, et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. *Ann Behav Med* 2013;**46**:81–95. <https://doi.org/10.1007/s12160-013-9486-6>

78. Peek K, Sanson-Fisher R, Mackenzie L, Carey M. Interventions to aid patient adherence to physiotherapist prescribed self-management strategies: a systematic review. *Physiotherapy* 2016;**102**:127–35. <https://doi.org/10.1016/j.physio.2015.10.003>
79. Michie SRN, Fussell A, Hardeman W, Johnston M, Newman S, Yardley L. *Improving Health: Changing Behaviour*, NHS Health Trainer Handbook 2008 18 November 2016. URL: <https://uwe-repository.worktribe.com/output/1011599/improving-health-changing-behaviour-nhs-health-trainer-handbook> (accessed 21 June 2021).
80. Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient compliance with paper and electronic diaries. *Control Clin Trials* 2003;**24**:182–99. [https://doi.org/10.1016/S0197-2456\(02\)00320-3](https://doi.org/10.1016/S0197-2456(02)00320-3)
81. Abraham C, Michie S. A taxonomy of behavior change techniques used in interventions. *Health Psychol* 2008;**27**:379–87. <https://doi.org/10.1037/0278-6133.27.3.379>
82. Hopewell S, Keene DJ, Marian IR, Dritsaki M, Heine O, Cureton L, et al. Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 × 2 factorial, randomised controlled trial [published online ahead of print 12 July 2021]. *Lancet* 2021. [https://doi.org/10.1016/S0140-6736\(21\)00846-1](https://doi.org/10.1016/S0140-6736(21)00846-1)
83. McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? *Qual Life Res* 1995;**4**:293–307. <https://doi.org/10.1007/BF01593882>
84. Ridyard CH, Hughes DA. Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK Health Technology Assessment program. *Value Health* 2010;**13**:867–72. <https://doi.org/10.1111/j.1524-4733.2010.00788.x>
85. Dritsaki M, Dakin H, Hopewell S, Lamb SE. *Clinical and Cost Effectiveness of Progressive Exercise Compared to Best Practice Advice, With or Without Corticosteroid Injection, for the Treatment of Rotator Cuff Disorders: A 2 × 2 Factorial Randomised Controlled Trial – Health Economics Analysis Plan*. URL: <https://ora.ox.ac.uk/objects/uuid:e33a9c3c-2b7f-4c5a-969f-d31729652c9c> (accessed 21 October 2020).
86. Petrou S, Gray A. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. *BMJ* 2011;**342**:d1548. <https://doi.org/10.1136/bmj.d1548>
87. Hughes D, Charles J, Dawoud D, Edwards RT, Holmes E, Jones C, et al. Conducting economic evaluations alongside randomised trials: current methodological issues and novel approaches. *PharmacoEconomics* 2016;**34**:447–61. <https://doi.org/10.1007/s40273-015-0371-y>
88. Dakin H, Gray A. Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations. *Stat Med* 2017;**36**:2814–30. <https://doi.org/10.1002/sim.7322>
89. Curtis L, Burns A. *Unit Costs of Health and Social Care* 2019. Canterbury: Personal Social Services Research Unit, University of Canterbury; 2019. www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2019/ (accessed 16 September 2020).
90. Withrington RH, Girgis FL, Seifert MH. A placebo-controlled trial of steroid injections in the treatment of supraspinatus tendonitis. *Scand J Rheumatol* 1985;**14**:76–8. <https://doi.org/10.3109/03009748509102022>
91. Searle E, Nicolson P, Hopewell S. *Comparative Effectiveness of Subacromial Corticosteroid Injection Versus Other Non-Surgical Interventions for Improving Pain and Function in People with a Rotator Cuff Disorder: A Systematic Review and Meta-Analysis*. MSc thesis. Paris: Descartes University; 2020.

92. NHS Improvement. *NHS Reference Costs 2017*. URL: <https://webarchive.nationalarchives.gov.uk/20200501111106/https://improvement.nhs.uk/resources/reference-costs/> (accessed 25 May 2021).
93. Karjalainen TV, Jain NB, Page CM, Lähdeoja TA, Johnston RV, Salamh P, *et al.* Subacromial decompression surgery for rotator cuff disease. *Cochrane Database Syst Rev* 2019;**1**:CD005619. <https://doi.org/10.1002/14651858.CD005619.pub3>
94. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, *et al.* Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;**20**:1727–36. <https://doi.org/10.1007/s11136-011-9903-x>
95. Rabin R, Oemar M, Oppe M, Janssen B, Herdman M. *EQ-5D-5L User Guide. Basic Information on How to Use the EQ-5D-5L Instrument*. Rotterdam: EuroQol Group; 2011.
96. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, *et al.* Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. *Value Health* 2012;**15**:708–15. <https://doi.org/10.1016/j.jval.2012.02.008>
97. Dolan P. Modeling valuations for EuroQol health states. *Med Care* 1997;**35**:1095–108. <https://doi.org/10.1097/00005650-199711000-00002>
98. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. *Methods for the Economic Evaluation of Health Care Programmes*. 3rd edn. New York, NY: Oxford University Press; 2005.
99. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. *Stat Med* 2011;**30**:377–99. <https://doi.org/10.1002/sim.4067>
100. National Institute for Health and Care Excellence. *Judging Whether Public Health Interventions Offer Value for Money*. URL: www.nice.org.uk/advice/lgb10/chapter/judging-the-cost-effectiveness-of-public-health-activities (accessed 16 September 2020).
101. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. *Health Econ* 2005;**14**:487–96. <https://doi.org/10.1002/hec.944>
102. Schomaker M, Heumann C. Bootstrap inference when using multiple imputation. *Stat Med* 2018;**37**:2252–66. <https://doi.org/10.1002/sim.7654>
103. Dakin H, Farmer A, Gray A, Holman RR. Economic evaluation of factorial trials: cost-utility analysis of the atorvastatin in factorial with omega EE90 risk reduction in diabetes 2 × 2 × 2 factorial trial of atorvastatin, omega-3 fish oil, and action planning. *Econ Eval* 2020;**23**:134–08. <https://doi.org/10.1016/j.jval.2020.05.018>
104. Lubsen J, Pocock SJ. Factorial trials in cardiology: pros and cons. *Eur Heart J* 1994;**15**:585–8. <https://doi.org/10.1093/oxfordjournals.eurheartj.a060552>
105. Sadatsafavi M, Marra C, Aaron S, Bryan S. Incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods. *Trials* 2014;**15**:201. <https://doi.org/10.1186/1745-6215-15-201>
106. White JJ, Titchener AG, Fakis A, Tambe AA, Hubbard RB, Clark DI. An epidemiological study of rotator cuff pathology using The Health Improvement Network database. *Bone Joint J* 2014;**96**:350–3. <https://doi.org/10.1302/0301-620X.96B3.32336>
107. Office for National Statistics. *Ethnicity*. URL: www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/ethnicity (accessed 21 June 2021).
108. Gumina S, Candela V, Passaretti D, Latino G, Venditto T, Mariani L, Santilli V. The association between body fat and rotator cuff tear: the influence on rotator cuff tear sizes. *J Shoulder Elbow Surg* 2014;**23**:1669–74. <https://doi.org/10.1016/j.jse.2014.03.016>

109. Warrender WJ, Brown OL, Abboud JA. Outcomes of arthroscopic rotator cuff repairs in obese patients. *J Shoulder Elbow Surg* 2011;**20**:961–7. <https://doi.org/10.1016/j.jse.2010.11.006>
110. Krischak G, Gebhard F, Reichel H, Friemert B, Schneider F, Fisser C, et al. A prospective randomized controlled trial comparing occupational therapy with home-based exercises in conservative treatment of rotator cuff tears. *J Shoulder Elbow Surg* 2013;**22**:1173–9. <https://doi.org/10.1016/j.jse.2013.01.008>
111. Granviken F, Vasseljen O. Home exercises and supervised exercises are similarly effective for people with subacromial impingement: a randomised trial. *J Physiother* 2015;**61**:135–41. <https://doi.org/10.1016/j.jphys.2015.05.014>
112. Asensio-García MDR, Bernabeú-Casas RC, Palazón-Bru A, Tomás-Rodríguez MI, Nouni-García R. Effectiveness of a group physiotherapy intervention in nontraumatic, inoperable painful shoulder: a randomized clinical trial. *Am J Phys Med Rehabil* 2018;**97**:110–15. <https://doi.org/10.1097/PHM.0000000000000817>
113. Contreras J, Liendo R, Díaz C, Díaz M, Osorio M, Guzmán R, et al. [Effectiveness of a self-administered rehabilitation program for shoulder pain syndrome in primary health care.] *Rev Med Chil* 2018;**146**:959–67. <https://doi.org/10.4067/s0034-98872018000900959>
114. Türkmen E, Analay Akbaba Y, Altun S. Effectiveness of video-based rehabilitation program on pain, functionality, and quality of life in the treatment of rotator cuff tears: a randomized controlled trial. *J Hand Ther* 2020;**33**:288–95. <https://doi.org/10.1016/j.jht.2019.08.004>
115. Roddy E, Ogollah RO, Oppong R, Zwierska I, Datta P, Hall A, et al. Optimising outcomes of exercise and corticosteroid injection in patients with subacromial pain (impingement) syndrome: a factorial randomised trial. *Br J Sport Med* 2021;**55**:262–71. <https://doi.org/10.1136/bjsports-2019-101268>
116. Gialanella B, Prometti P. Effects of corticosteroids injection in rotator cuff tears. *Pain Med* 2011;**12**:1559–65. <https://doi.org/10.1111/j.1526-4637.2011.01238.x>
117. Adebajo AO, Nash P, Hazleman BL. A prospective double blind dummy placebo controlled study comparing triamcinolone hexacetonide injection with oral diclofenac 50 mg TDS in patients with rotator cuff tendinitis. *J Rheumatol* 1990;**17**:1207–10.
118. Alvarez CM, Litchfield R, Jackowski D, Griffin S, Kirkley A. A prospective, double-blind, randomized clinical trial comparing subacromial injection of betamethasone and xylocaine to xylocaine alone in chronic rotator cuff tendinosis. *Am J Sports Med* 2005;**33**:255–62. <https://doi.org/10.1177/0363546504267345>
119. Alvarez-Nemegyei J, Bassol-Perea A, Rosado Pasos J. [Efficacy of the local injection of methylprednisolone acetate in the subacromial impingement syndrome. A randomized, double-blind trial.] *Reumatol Clin* 2008;**4**:49–54. [https://doi.org/10.1016/S1699-258X\(08\)71799-6](https://doi.org/10.1016/S1699-258X(08)71799-6)
120. Blair B, Rokito AS, Cuomo F, Jarolem K, Zuckerman JD. Efficacy of injections of corticosteroids for subacromial impingement syndrome. *J Bone Joint Surg Am* 1996;**78**:1685–9. <https://doi.org/10.2106/00004623-199611000-00007>
121. Hong JY, Yoon SH, Moon DJ, Kwack KS, Joen B, Lee HY. Comparison of high- and low-dose corticosteroid in subacromial injection for periarticular shoulder disorder: a randomized, triple-blind, placebo-controlled trial. *Arch Phys Med Rehabil* 2011;**92**:1951–60. <https://doi.org/10.1016/j.apmr.2011.06.033>
122. Penning LI, de Bie RA, Walenkamp GH. The effectiveness of injections of hyaluronic acid or corticosteroid in patients with subacromial impingement: a three-arm randomised controlled trial. *J Bone Joint Surg Br* 2012;**94**:1246–52. <https://doi.org/10.1302/0301-620X.94B9.28750>

123. Petri M, Dobrow R, Neiman R, Whiting-O'Keefe Q, Seaman WE. Randomized, double-blind, placebo-controlled study of the treatment of the painful shoulder. *Arthritis Rheum* 1987;**30**:1040–5. <https://doi.org/10.1002/art.1780300911>
124. Vecchio PC, Hazleman BL, King RH. A double-blind trial comparing subacromial methylprednisolone and lignocaine in acute rotator cuff tendinitis. *Br J Rheumatol* 1993;**32**:743–5. <https://doi.org/10.1093/rheumatology/32.8.743>
125. Beard DJ, Rees JL, Cook JA, Rombach I, Cooper C, Merritt N, *et al.* Arthroscopic subacromial decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trial. *Lancet* 2018;**391**:329–38. [https://doi.org/10.1016/S0140-6736\(17\)32457-1](https://doi.org/10.1016/S0140-6736(17)32457-1)
126. Dean BJ, Carr AJ. The effects of glucocorticoid on tendon and tendon derived cells. *Adv Exp Med Biol* 2016;**920**:239–46. https://doi.org/10.1007/978-3-319-33943-6_23
127. NHS. NHS Electronic Drug Tariff. 2020. URL: www.drugtariff.nhsbsa.nhs.uk/#/00770298-DC/DC00770293/Home (accessed 25 May 2021).
128. NHS Improvement. NHS Reference Costs 2019. URL: www.england.nhs.uk/national-cost-collection/ (accessed 25 May 2021).
129. Curtis L, Burns A. *Unit Costs of Health and Social Care* 2010. Canterbury: Personal Social Services Research Unit, University of Kent; 2010. URL: www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2010/ (accessed 25 May 2021).
130. Curtis L, Burns A. *Unit Costs of Health and Social Care* 2015. Canterbury: Personal Social Services Research Unit, University of Kent; 2015. URL: www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2015/ (accessed 25 May 2021).
131. Murgia M. NHS to trial artificial intelligence app in place of 111 helpline. *Financial Times*, 4 January 2017.
132. WhatClinic. *Orthopaedic Clinics UK*. URL: www.whatclinic.com/orthopaedic/uk (accessed 25 May 2021).
133. The Physiotherapy Centre. *Prices*. 2020. URL: www.thephysiotherapycentre.org.uk/prices (accessed 23 June 2021).
134. Private Healthcare UK. *How Much Does a Private Ultrasound Cost in the UK?* URL: www.privatehealth.co.uk/conditions-and-treatments/ultrasound/costs/ (accessed 25 May 2021).
135. Office for National Statistics. *Employee Earnings in the UK: 2019*. URL: www.ons.gov.uk/releases/employeeearningsintheuk2019 (accessed 23 June 2021).
136. Department of Health and Social Care (DHSC). *Social Care – Charging for Care and Support*. London: DHSC; 2017.

Appendix 1 Chapter 1 appendix

Diagnosis of Shoulder problems in Primary Care:

Guidelines on treatment and referral




FIGURE 13 The BESS diagnostic algorithm.⁴ Reproduced with permission (Professor Jonathan L Rees, Nuffield Orthopaedic Centre, 2021, personal communication).

Appendix 2 Chapter 2 appendix

Amendment number	Protocol version number	Date issued	Author(s) of changes	Details of changes made
1	Version 2.0	20 March 2017	Sally Hopewell	<p>Clarification of eligibility criteria to include those predominantly seeking treatment for one shoulder</p> <p>Clarification of timelines for injection and physiotherapy referral</p> <p>Minor clarifications on physiotherapy intervention content, including revision of <i>Figure 2</i></p> <p>Correction to month of recruitment</p> <p>Addition of PROMPTS (personalised text message versus standard text message prompts for increasing response to postal questionnaires) substudy</p>
4	Version 3.0	13 September 2017	Sally Hopewell	<p>Minor clarification regarding methods of data collection and management</p> <p>Minor change of wording regarding injection delivery</p>
12	Version 4.0	14 May 2018	Sally Hopewell	Addition of monetary incentive at 12-month follow-up
16	Version 5.0	2 January 2019	Sally Hopewell	<p>Addition of text reminder at 12 months</p> <p>Change to wording regarding duration of recruitment</p>



GRASP Injection Referral Form and Treatment Log



PART 1: GRASP Injection Referral Form (to be completed by the research clinician)

Appointments should be scheduled so that the participant receives their injection within 10 days of randomisation.

PARTICIPANT ID:										DATE OF REFERRAL:									
G	R	-								D	D	M	M	Y	Y	Y	Y		

PARTICIPANT DETAILS

Full name:
 Date participant randomised:
 Date of birth:
 NHS Number:
 Participant address:

Phone 1: Phone 2:
 Email:

REFERRED BY (name): Position:

PART 2: GRASP Injection Treatment Log (to be completed by the injecting therapist).

The therapist should follow usual local procedure for their Trust when administering the corticosteroid injection.

PARTICIPANT ID:										DATE OF INJECTION:									
		-								D	D	M	M	Y	Y	Y	Y		

Name of injecting therapist:

- Corticosteroid injected (tick): ☐ Methylprednisolone acetate ☐ Triamcinolone acetonide
- Dose of corticosteroid injected *(mg):
- Choice of local anaesthetic injected (tick): ☐ 1% lidocaine ☐ 0.5% Bupivacaine hydrochloride
- Volume of local anaesthetic injected * (mls):
- Corticosteroid and local anaesthetic given as (tick): ☐ Combined injection ☐ Separate injection
- Which shoulder is injected (tick): ☐ Left ☐ Right
- Site of injection (tick): ☐ Anterior subacromial space ☐ Posterior subacromial space
- ☐ Other (specify):
- Participant given local injection advice leaflet (tick): ☐
- Participant given advice on what to do if adverse event occurs (tick): ☐

If injection not given please contact GRASP Trial Office as soon as possible on: 01865 737432.

Injection not given (tick): ☐ Reason injection not given:

*Choice of corticosteroid injection can be either Methylprednisone acetate (up to 40mg) or Triamcinolone acetonide (up to 40mg). Choice of local anaesthetic can be either 1% lidocaine (up to 5ml) or 0.5% Bupivacaine hydrochloride (up to 10ml)

ONE FULL COPY RETAINED IN GRASP INVESTIGATOR SITE FILE, ONE FULL COPY IN PATIENT NOTES,
PART 2 ONLY TO BE SENT TO THE GRASP TRIAL OFFICE – REDACT AS NECESSARY

FIGURE 14 Injection referral form and treatment log. OCTRU logo reproduced with permission (Vicki Barber, Oxford Clinical Trials Research Unit, 2021, personal communication).

Appendix 3 Chapter 3 appendix

TABLE 26 Categories of exercise considered by the delegates of the GRASP trial intervention development meeting

Exercise category	Included in intervention	
	Best-practice advice	Progressive exercise
Pectoralis major and anterior capsule stretch		
Posterior shoulder/capsule stretch		✓
Other shoulder stretches		
Scapular stability exercises and 'setting' (isolated positional changes of the scapula prior to shoulder movement)		
Scapular retraction		✓
Scapular protraction		
Scapular elevation/depression		
Press-ups		✓
External shoulder rotation (low challenge exercises)	✓	✓
External shoulder rotation (in shoulder elevation < 90°)	✓	✓
External shoulder rotation (in shoulder elevation ≈ 90°)	✓	✓
External shoulder rotation (in shoulder elevation > 90°)	✓	✓
Internal shoulder rotation (low challenge exercises)		
Internal shoulder rotation (in shoulder elevation < 90°)		
Internal shoulder rotation (in shoulder elevation ≈ 90°)		
Pendulum exercise		
Assisted shoulder flexion	✓	✓
Active shoulder flexion (unresisted)	✓	✓
Shoulder extension		
Shoulder adduction		
Shoulder abduction	✓	✓
Resisted functional movement		✓
Thoracic extension		

TABLE 27 Behavioural strategies to address barriers to exercise, highlighting common and discrete components to each exercise intervention

Behaviour change technique	Progressive exercise	Best-practice advice
Education and persuasion	Information on benefits of exercise provided face to face and in participant information booklet	Information on benefits of exercise provided face to face and in participant information booklet
Training	Exercises demonstrated, instructions provided in written form, exercises practised within the session and at home independently, and exercises reviewed at each appointment and feedback provided	Exercises demonstrated, instructions provided in written and video form (web and/or DVD), and exercises practised within the session and at home independently

continued

TABLE 27 Behavioural strategies to address barriers to exercise, highlighting common and discrete components to each exercise intervention (continued)

Behaviour change technique	Progressive exercise	Best-practice advice
Graded tasks	Focus on starting with a manageable amount of exercise (up to three exercises). Use of modified Borg scale to set resistance exercise [initially at lower levels and then increase difficulty, volume and load (see Figure 3)]	Focus on starting with a manageable amount of exercise (one or two exercises). Participants to increase volume and load according to set progression advice
Equipment provision to enable exercise	Resistance band issued if appropriate. Advice on what can be used for hand weights	All participants issued resistance band to enable exercise performance. Advice on what can be used for hand weights
Problem-solving	Over the sessions, therapists facilitate participant problem-solving and encourage the participant to lead the decision-making about progression/regression of programme. Barriers to exercise (e.g. belief or practicalities) are reviewed and ways to overcome these are discussed. An exercise plan is agreed collaboratively	Therapists encourage participant problem-solving within the session. A starting point on exercise ladder is agreed collaboratively
Action planning	An action planner document is to be completed (i.e. where and when exercises will be carried out), including contingency plans, prompts/cues for when to do the exercises, a plan of what to do if pain increases and information on when and where the exercise diary will be completed. See also <i>Behavioural contract</i> and <i>Confidence ruler</i>	An action planner document is to be completed (i.e. where and when exercises will be carried out), including contingency plans, prompts/cues for when to do the exercises, a plan of what to do if pain increases and information on when and where the exercise diary will be completed
Goal-setting	Agree a long- and a short-term goal (which are specific, measurable, achievable, relevant and timed) and reinforce link between goal and exercise plan	Agree a long-term goal (which is specific, measurable, achievable, relevant and timed) and reinforce link between goal and exercise plan
Review goals	Goals reviewed and adjusted at each session	Not applicable
Confidence ruler	Use the confidence ruler (from 0 to 10) to assess participant's confidence in undertaking agreed exercise plan. If the participant selects ≤ 7 , discuss reasons and adapt programme (see <i>Graded tasks</i>) or address barriers (see <i>Problem-solving</i>)	Not applicable
Feedback on exercise performance from physiotherapist	Within and between sessions, review action planners and diaries at each session, and review discrepancies in plan and performance	In session only
Therapist feedback on outcome of exercise	Progress in physical performance and symptoms highlighted after reassessment at each session	Not applicable
Self-monitoring of exercise	Exercise diary to complete each day	Same as <i>Progressive exercise</i>
Behavioural contract	Therapist and participant sign action planner document. Participant commits to undertaking exercises and bringing documents to be reviewed at next appointment. Therapist to review exercise diary	Not applicable
Reduce negative emotions	Simple advice on managing low mood in the information booklet. Provide reassurance about condition and capacity to exercise	Same as <i>Progressive exercise</i>



GRASP Progressive Exercise Action Planner



Participant Name:

Date started:

My confidence: On a scale of 0 to 10, how confident am I that I can carry out my exercise programme?
(circle)

Not confident 0 --- 1 --- 2 --- 3 --- 4 --- 5 --- 6 --- 7 --- 8 --- 9 --- 10 Very confident

My long term goal is: *(for example to return to gardening or work)*

My short term goal is: *(for example be to be able to lift a saucepan or drive)*

It is important to think about when and how you will do your exercises.

When it is (time or other cue), I will do my exercises. If I cannot do them at this time I will do them:

I will remind myself to do my exercises by:

If my pain increases with the exercises then I will:
.....

Exercise diary: It is important to measure and record your progress, so that you can see when you are succeeding, as well as to work out what you can change if your plan is not working.

When will I record it?

.....

Where will I complete my diary?

.....

Patient: I will do my exercises, record my progress (Exercise Diary) and bring my exercise diary to the next meeting.

Date:

Signature:

Physiotherapist: I will discuss your exercise diary with you and how you got on when you bring it back at the next meeting.

Date:

Signature:

At your next appointment. This form will be reviewed at your next physiotherapy session along with your exercise diary. If any parts have changed or needs to change, a new planner can be completed.

FIGURE 15 Progressive exercise intervention: action planner. OCTRU logo reproduced with permission (Vicki Barber, Oxford Clinical Trials Research Unit, 2021, personal communication).



GRASP Progressive Exercise
Diary



Participant Name:

Date started:


Please add the number or times you repeat an exercise and the number of sets into the boxes for each exercise each day.

If you have not done your exercises as it is a planned rest day mark the box with a cross (x), if you forgot, mark it with a zero (0).


Day	Exercise:		Exercise:		Exercise:	
	Repetitions	Sets	Repetitions	Sets	Repetitions	Sets
1						
2						
3						
4						
5						
6						
7						
8						
9						
10						
11						
12						
13						
14						

FIGURE 16 Progressive exercise intervention: exercise diary. OCTRU logo reproduced with permission (Vicki Barber, Oxford Clinical Trials Research Unit, 2021, personal communication).

1a Shoulder flexion in sitting, supported by table



1b Shoulder abduction in sitting, supported by table




1c Shoulder flexion in standing, supported by table



1d Shoulder abduction in standing, supported by table



1e Shoulder flexion in supine



1f Assisted shoulder flexion, using wall




FIGURE 17 Progressive exercise intervention: level 1 simple shoulder movement exercises. Exercises can be modified in a number of ways: (1) the range of motion through which an exercise is performed may be increased or decreased; and (2) the position may be modified, for example some exercises may be carried out in lying, sitting or standing positions to accommodate the patient's comfort and preferences.


2a Isometric external rotation




2b Isometric abduction




2c External rotation with band



2d Abduction with a band




2e Shoulder flexion using wall




2f Arm raise using a weight or resistance band




2g External rotation with band, arm elevated and supported



2h External rotation with band, arm elevated and unsupported



2i Arm elevation with resisted external rotation



2j Abduction and elevation with band




FIGURE 18 Progressive exercise intervention: level 2 essential resistance exercises. Exercises can be modified in a number of ways: (1): the range of motion through which an exercise is performed may be increased or decreased; and (2) the position may be modified, for example some exercises may be carried out in lying, sitting or standing positions to accommodate the patient's comfort and preferences.


2k Isometric internal rotation



2l Internal rotation with band



2m Internal rotation with band, arm elevated (supported)



2n Internal rotation with band, arm elevated (unsupported)



2o Adduction from elevation with band



2p Prone shoulder lift



2q Prone arm lift, elbow flexed



2r Prone arm lift, elbow extended



2s 4-point kneeling, arm elevation



2t Press-ups on knees



2u Full press-up



FIGURE 19 Progressive exercise intervention: level 2 optional resistance exercises. Exercises can be modified in a number of ways: (1) the range of motion through which an exercise is performed may be increased or decreased; and (2) the position may be modified, for example some exercises may be carried out in lying, sitting or standing positions to accommodate the patient's comfort and preferences.

S1 Sleeper stretch



S2 Cross body stretch



FIGURE 20 Progressive exercise intervention: level 2 optional resistance exercises. To be used selectively and only for younger adults engaged in throwing or other overhead athletic or physical activities⁷⁵ who have posterior capsule tightness.




FIGURE 21 Best-practice advice intervention: exercise progression ladder.



GRASP Best Practice Exercise Diary



Participant Name:

Please add the number of times you repeat an exercise and the number of sets into the boxes for each exercise each day.

If you have not done your exercises as it is a planned rest day (2 days out of 7) mark the box with a cross (x) if you forgot, mark it with a zero (0).

Day	Exercise:		Exercise:	
	Repetitions	Sets	Repetitions	Sets
1				
2				
3				
4				
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				

Date started:

FIGURE 22 Best-practice advice intervention: exercise diary. OCTRU logo reproduced with permission (Vicki Barber, Oxford Clinical Trials Research Unit, 2021, personal communication).



GRASP Best Practice Action Planner



Participant Name:

<p>My long term goal is: <i>(for example to return to gardening or work)</i></p>
<p>It is important to think about when and how you will do your exercises.</p> <p>When it is (time or other cue), I will do my exercises. If I cannot do them at this time I will do them:</p> <p>I will remind myself to do my exercises by:</p> <p>If my pain increases with the exercises then I will:</p> <p>.....</p>
<p>Exercise diary: It is important to measure and record your progress, so that you can see when you are succeeding, as well as to work out what you can change if your plan is not working.</p> <p>When will I record it?</p> <p>.....</p> <p>Where will I complete my diary?</p> <p>.....</p>

FIGURE 23 Best-practice advice intervention: action planner. OCTRU logo reproduced with permission (Vicki Barber, Oxford Clinical Trials Research Unit, 2021, personal communication).

Appendix 4 Chapter 4 appendix

TABLE 28 Characteristics of participating NHS trusts

Site	Start date	Months of recruitment ^a	Number of clinicians ^b
University Hospitals of Derby and Burton NHS Foundation Trust	20 February 2017	26	18
East Lancashire Hospitals NHS Trust	2 March 2017	26	17
Gloucestershire Hospitals NHS Foundation Trust	12 April 2017	24	43
Birmingham Community Healthcare NHS Trust	13 April 2017	24	13
Sandwell and West Birmingham Hospitals NHS Trust	19 May 2017	23	13
Buckinghamshire Musculoskeletal Integrated Care Service	26 May 2017	23	3
Bedfordshire Hospitals NHS Foundation Trust	8 June 2017	22	7
East Cheshire NHS Trust	10 July 2017	21	8
Wirral University Teaching Hospital NHS Foundation Trust	18 August 2017	20	6
Medway Community Healthcare	10 August 2017	20	6
Bristol Community Health	29 September 2017	19	4
Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust	27 November 2017	17	9
Somerset Partnership NHS Foundation Trust	23 November 2017	17	13
Sherwood Forest Hospitals NHS Foundation Trust	20 December 2017	16	4
Kent Community Health NHS Foundation Trust	19 January 2018	15	10
Northern Devon Healthcare NHS Trust	8 February 2018	14	17
Airedale NHS Foundation Trust	20 February 2018	14	7
North West Boroughs Healthcare NHS Foundation Trust	29 March 2018	13	10
Staffordshire and Stoke-on-Trent Partnership NHS Trust	26 April 2018	12	6
Warrington and Halton Hospitals NHS Foundation Trust	16 July 2018	9	9
Total		26	223

^a Recruitment ended 2 May 2019.
^b The number of clinicians who delivered trial interventions.

TABLE 29 Characteristics of participating physiotherapists

Participating physiotherapist	Agenda for Change grade, n (%)					Total ^b
	Band 5	Band 6	Band 7	Band 8a	Other ^a	
Injectors	0 (0)	6 (11)	13 (23)	34 (61)	3 (5)	56 (100)
Best-practice advice	17 (20)	38 (46)	22 (27)	6 (7)	0 (0)	83 (100)
Progressive exercise	16 (15)	55 (53)	28 (27)	5 (5)	0 (0)	104 (100)

^a Two orthopaedic consultants and one specialist registrar in orthopaedics.
^b Some physiotherapists provided both injection and exercise interventions. Two physiotherapists delivered both exercise interventions.

TABLE 30 Reasons participants were ineligible or declined to participate

Reason	Total, n (%)
Ineligible, <i>n</i>	1003
History of significant shoulder trauma (e.g. dislocation, fracture, full-thickness tear requiring surgery)	94 (9)
Neurological disease affecting shoulder	23 (2)
Other shoulder disorder (e.g. inflammatory arthritis, frozen shoulder, glenohumeral joint instability) or red flags consistent with BESS criteria	434 (43)
Received corticosteroid injection or physiotherapy for shoulder pain in last 6 months	167 (17)
Contraindications to corticosteroid injection	31 (3)
Symptoms > 6 months	132 (13)
Did not speak English	32 (3)
Other reason	28 (3)
Other (neither declined nor ineligible)	3 (0.3)
Unable to contact	59 (6)
Declined, <i>n</i>	576
Not interested in taking part in research	175 (30)
Does not want to be randomised	39 (7)
Already has treatment preference for receiving injection	38 (7)
Already has treatment preference for not receiving injection	158 (27)
Does not want to be randomised to receive progressive-exercise intervention	6 (1)
Does not want to be randomised to receive best-practice advice intervention	8 (1)
Unable to attend treatment sessions	71 (12)
Leaving the area	9 (2)
Prefer not to say	20 (3)
Other/no information	52 (9)




FIGURE 24 Predicted vs. actual recruitment rate per month.

TABLE 31 Baseline characteristics detailed (inside the table)

Characteristic	Best-practice advice (N = 174)		Injection plus best-practice advice (N = 178)		Progressive exercise (N = 174)		Injection plus progressive exercise (N = 182)	
	n	%	n	%	n	%	n	%
Ethnicity								
White British	158	90.8	162	91.0	152	87.4	163	89.6
White other	2	1.1	5	2.8	2	1.1	4	2.2
Mixed	1	0.6	0	0.0	2	1.1	3	1.6
Indian	4	2.3	3	1.7	3	1.7	4	2.2
Pakistani	4	2.3	2	1.1	7	4.0	2	1.1
Bangladeshi	1	0.6	0	0.0	0	0.0	1	0.5
Black or black British	3	1.7	3	1.7	4	2.3	4	2.2
Chinese	0	0.0	0	0.0	0	0.0	0	0.0
Other	0	0.0	3	1.7	1	0.6	1	0.5
Prefer not to say	1	0.6	0	0.0	1	0.6	0	0.0
Missing	0	0.0	0	0.0	2	1.1	0	0.0
Marital status								
Married/civil union	118	67.8	107	60.1	114	65.5	120	65.9
Living with partner	24	13.8	23	12.9	22	12.6	24	13.2
Unmarried (never married)	10	5.7	11	6.2	14	8.0	17	9.3
Separated/divorced	13	7.5	29	16.3	13	7.5	13	7.1
Widow/widower	7	4.0	6	3.4	8	4.6	6	3.3
Prefer not to say	2	1.1	2	1.1	1	0.6	2	1.1
Missing	0	0.0	0	0.0	2	1.1	0	0.0
Current work status								
Retired	44	25.3	50	28.1	40	23.0	49	26.9
Semi-retired	13	7.5	10	5.6	9	5.2	7	3.8
Employed	84	48.3	91	51.1	98	56.3	82	45.1
Self-employed	19	10.9	14	7.9	12	6.9	17	9.3
Unemployed	2	1.1	5	2.8	5	2.9	9	4.9
Permanently sick or disabled	4	2.3	1	0.6	1	0.6	4	2.2
Looking after home or family	6	3.4	6	3.4	4	2.3	8	4.4
Other	2	1.1	1	0.6	3	1.7	5	2.7
Missing	0	0.0	0	0.0	2	1.1	1	0.5
Level of education								
None or primary education	2	1.1	4	2.2	4	2.3	6	3.3
Secondary	92	52.9	92	51.7	74	42.5	89	48.9
Higher professional or university education	80	46.0	82	46.1	94	54.0	87	47.8
Missing	0	0.0	0	0.0	2	1.1	0	0.0

TABLE 31 Baseline characteristics detailed (inside the table) (continued)

Characteristic	Best-practice advice (N = 174)		Injection plus best-practice advice (N = 178)		Progressive exercise (N = 174)		Injection plus progressive exercise (N = 182)	
	n	%	n	%	n	%	n	%
Household income								
< £10,000	36	20.7	27	15.2	22	12.6	27	14.8
Between £10,000 and £19,999	39	22.4	60	33.7	46	26.4	52	28.6
Between £20,000 and £29,000	41	23.6	26	14.6	36	20.7	30	16.5
Between £30,000 and £39,999	21	12.1	23	12.9	20	11.5	23	12.6
Between £40,000 and £49,999	12	6.9	12	6.7	8	4.6	14	7.7
≥ £50,000	12	6.9	10	5.6	19	10.9	10	5.5
Prefer not to answer	13	7.5	20	11.2	20	11.5	25	13.7
Missing	0	0.0	0	0.0	3	1.7	1	0.5
State benefits								
Yes	37	21.3	36	20.2	30	17.2	41	22.5
No	136	78.2	139	78.1	140	80.5	139	76.4
Prefer not to say	1	0.6	3	1.7	2	1.1	1	0.5
Missing	0	0.0	0	0.0	2	1.1	1	0.5
Benefits received								
Attendance Allowance	1	0.6	2	1.1	0	0.0	0	0.0
Carer's Allowance	6	3.4	2	1.1	2	1.1	2	1.1
Child Benefit	16	9.2	14	7.9	14	8.0	14	7.7
Child Tax Credit	8	4.6	9	5.1	8	4.6	3	1.6
Council Tax Benefit	7	4.0	5	2.8	4	2.3	2	1.1
Disability Living Allowance	5	2.9	6	3.4	3	1.7	7	3.8
Employment and Support Allowance	2	1.1	4	2.2	2	1.1	8	4.4
Income Support	3	1.7	1	0.6	2	1.1	3	1.6
Housing Benefit	5	2.9	3	1.7	3	1.7	4	2.2
Jobseeker's Allowance	2	1.1	1	0.6	0	0.0	1	0.5
Working Tax Credit	4	2.3	7	3.9	5	2.9	5	2.7
Other	10	5.7	9	5.1	8	4.6	9	4.9

TABLE 32 Participant demographics at baseline: categorical outcomes (at the margins)

Participant demographic	Progressive exercise				Injection				Overall	
	Best-practice advice		Progressive exercise		No		Yes			
	n	%	n	%	n	%	n	%	n	%
Ethnicity										
White British	320	90.9	315	88.5	310	89.1	325	90.3	635	89.7
White other	7	2.0	6	1.7	4	1.1	9	2.5	13	1.8
Mixed	1	0.3	5	1.4	3	0.9	3	0.8	6	0.8
Indian	7	2.0	7	2.0	7	2.0	7	1.9	14	2.0
Pakistani	6	1.7	9	2.5	11	3.2	4	1.1	15	2.1
Bangladeshi	1	0.3	1	0.3	1	0.3	1	0.3	2	0.3
Black or black British	6	1.7	8	2.2	7	2.0	7	1.9	14	2.0
Chinese	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Other	3	0.9	2	0.6	1	0.3	4	1.1	5	0.7
Missing	0	0.0	2	0.6	2	0.6	0	0.0	2	0.3
Marital status										
Married/civil union	225	63.9	234	65.7	232	66.7	227	63.1	459	64.8
Living with partner	47	13.4	46	12.9	46	13.2	47	13.1	93	13.1
Unmarried (never married)	21	6.0	31	8.7	24	6.9	28	7.8	52	7.3
Separated/divorced	42	11.9	26	7.3	26	7.5	42	11.7	68	9.6
Widow/widower	13	3.7	14	3.9	15	4.3	12	3.3	27	3.8
Prefer not to say	4	1.1	3	0.8	3	0.9	4	1.1	7	1.0
Missing	0	0.0	2	0.6	2	0.6	0	0.0	2	0.3
Body mass index (kg/m²)										
Underweight (< 18.5)	4	1.1	0	0.0	3	0.9	1	0.3	4	0.6
Normal weight (18.5–24.9)	102	29.0	103	28.9	101	29.0	104	28.9	205	29.0
Overweight (25–29.9)	131	37.2	143	40.2	141	40.5	133	36.9	274	38.7
Obese (≥ 30)	113	32.1	104	29.2	99	28.4	118	32.8	217	30.6
Missing	2	0.6	6	1.7	4	1.1	4	1.1	8	1.1
Smoking status										
Never smoked	185	52.6	200	56.2	184	52.9	201	55.8	635	89.7
Former smoker	132	37.5	124	34.8	127	36.5	129	35.8	13	1.8
Current smoker	35	9.9	30	8.4	35	10.1	30	8.3	6	0.8
Missing	0	0.0	2	0.6	2	0.6	0	0.0	2	0.3

TABLE 32 Participant demographics at baseline: categorical outcomes (at the margins) (continued)

Participant demographic	Progressive exercise				Injection				Overall	
	Best-practice advice		Progressive exercise		No		Yes			
	n	%	n	%	n	%	n	%	n	%
Affected shoulder										
Left shoulder	167	47.4	165	46.3	172	49.4	160	44.4	332	46.9
Right shoulder	172	48.9	177	49.7	162	46.6	187	51.9	349	49.3
Both shoulders	13	3.7	12	3.4	12	3.4	13	3.6	25	3.5
Missing	0	0.0	2	0.6	2	0.6	0	0.0	2	0.3
Hand dominance										
Left handed	29	8.2	42	11.8	34	9.8	37	10.3	71	10.0
Right handed	310	88.1	306	86.0	305	87.6	311	86.4	616	87.0
Both	13	3.7	6	1.7	7	2.0	12	3.3	19	2.7
Missing	0	0.0	2	0.6	2	0.6	0	0.0	2	0.3
Current work status										
Retired	94	26.7	89	25.0	84	24.1	99	27.5	183	25.8
Semi-retired	23	6.5	16	4.5	22	6.3	17	4.7	39	5.5
Employed	175	49.7	180	50.6	182	52.3	173	48.1	355	50.1
Self-employed	33	9.4	29	8.1	31	8.9	31	8.6	62	8.8
Unemployed	7	2.0	14	3.9	7	2.0	14	3.9	21	3.0
Permanently sick or disabled	5	1.4	5	1.4	5	1.4	5	1.4	10	1.4
Looking after home or family	12	3.4	12	3.4	10	2.9	14	3.9	24	3.4
Other	3	0.9	8	2.2	5	1.4	6	1.7	11	1.6
Missing	0	0.0	3	0.8	2	0.6	1	0.3	3	0.4
Level of education										
None or primary education	6	1.7	10	2.8	6	1.7	10	2.8	16	2.3
Secondary	184	52.3	163	45.8	166	47.7	181	50.3	347	49.0
Higher professional or university education	162	46.0	181	50.8	174	50.0	169	46.9	343	48.4
Missing	0	0.0	2	0.6	2	0.6	0	0.0	2	0.3
Household income										
≤ £10,000	63	17.9	49	13.8	58	16.7	54	15.0	112	15.8
Between £10,000 and £19,999	99	28.1	98	27.5	85	24.4	112	31.1	197	27.8
Between £20,000 and £29,000	67	19.0	66	18.5	77	22.1	56	15.6	133	18.8
continued										

continued

TABLE 32 Participant demographics at baseline: categorical outcomes (at the margins) (continued)

		Progressive exercise				Injection					
		Best-practice advice		Progressive exercise		No		Yes			
Participant demographic		n	%	n	%	n	%	n	%	n	%
	Between £30,000 and £39,999	44	12.5	43	12.1	41	11.8	46	12.8	87	12.3
	Between £40,000 and £49,999	24	6.8	22	6.2	20	5.7	26	7.2	46	6.5
	≥ £50,000	22	6.3	29	8.1	31	8.9	20	5.6	51	7.2
	Prefer not to answer	33	9.4	45	12.6	33	9.5	45	12.5	78	11.0
	Missing	0	0.0	4	1.1	3	0.9	1	0.3	4	0.6
State benefits											
	Yes	73	20.7	71	19.9	67	19.3	77	21.4	114	20.3
	No	275	78.1	279	78.4	276	79.3	278	77.2	554	78.2
	Prefer not to say	4	1.1	3	0.8	3	0.9	4	1.1	7	1.0
	Missing	0	0.0	3	0.8	2	0.6	1	0.3	3	0.4
Benefits received											
	Attendance Allowance	3	0.9	0	0.0	1	0.3	2	0.6	3	0.4
	Carer's Allowance	8	2.3	4	1.1	8	2.3	4	1.1	12	1.7
	Child Benefit	30	8.5	28	7.9	30	8.6	28	7.8	58	8.2
	Child Tax Credit	17	4.8	11	3.1	16	4.6	12	3.3	28	4.0
	Council Tax Benefit	12	3.4	6	1.7	11	3.2	7	1.9	18	2.5
	Disability Living Allowance	11	3.1	10	2.8	8	2.3	13	3.6	21	3.0
	Employment and Support Allowance	6	1.7	10	2.8	4	1.1	12	3.3	16	2.3
	Income Support	4	1.1	5	1.4	5	1.4	4	1.1	9	1.3
	Housing Benefit	8	2.3	7	2.0	8	2.3	7	1.9	15	2.1
	Jobseeker's Allowance	3	0.9	1	0.3	2	0.6	2	0.6	4	0.6
	Working Tax Credit	11	3.1	10	2.8	9	2.6	12	3.3	21	3.0
	Other	19	5.4	17	4.8	18	5.2	18	5.0	36	5.1

TABLE 33 Participant demographic characteristics at baseline: continuous outcomes (at the margins)

Characteristic	Progressive exercise		Injection		Overall (N = 708)
	Best-practice advice (N = 352)	Progressive exercise (N = 356)	No (N = 348)	Yes (N = 360)	
Height (m), mean (SD), <i>n</i>	1.7 (0.0), 352	1.7 (0.0), 354	1.7 (0.0), 346	1.7 (0.2), 360	1.7 (0.0), 706
Weight (kg), mean (SD), <i>n</i>	81.9 (17.0), 350	81.5 (18.2), 350	81.1 (17.6), 344	82.3 (17.6), 356	81.7 (17.6), 700
Body mass index (kg/m ²), mean (SD), <i>n</i>	28.3 (5.2), 350	28.0 (5.2), 350	27.9 (5.2), 344	28.4 (5.2), 356	28.2 (5.2), 700
Age (years), mean (SD), <i>n</i>	56.2 (12.7), 352	54.7 (13.5), 356	55.3 (13.4), 348	55.6 (12.8), 360	55.5 (13.1), 708
Cigarettes smoked per day (current smoker), median (IQR), <i>n</i>	10 (9–15), 32	10 (6–15), 29	10 (10–15), 33	10 (6–15), 28	10 (8–15), 61
Cigarettes smoked per day (former smoker), median (IQR), <i>n</i>	15.0 (7–20), 132	10.0 (5–20), 123	12.0 (5–20), 126	10.0 (8–20), 129	12.0 (6–20), 255
Symptoms duration, median (IQR), <i>n</i>	4.0 (2–6), 351	4.0 (3–6), 354	4.0 (3–6), 345	4.0 (3–6), 360	4.0 (3–6), 705
SPADI, mean (SD), <i>n</i>					
Pain subscale	65.1 (18.0), 352	62.7 (17.4), 354	63.3 (17.6), 346	64.4 (17.9), 360	63.9 (17.7), 706
Function subscale	47.2 (22.6), 352	41.5 (21.3), 354	44.2 (22.4), 346	44.5 (21.9), 360	44.3 (22.1), 706
SPADI overall	56.1 (19.0), 352	52.1 (17.7), 354	53.8 (18.6), 346	54.4 (18.4), 360	54.1 (18.5), 706
FABQ-PA, mean (SD), <i>n</i>	15.6 (5.6), 349	14.5 (5.4), 354	14.9 (5.7), 344	15.2 (5.3), 359	15.1 (5.5), 703
PSEQ-2, mean (SD), <i>n</i>	9.6 (2.4), 352	9.8 (2.3), 354	9.7 (2.3), 346	9.6 (2.3), 360	9.7 (2.3), 706
ISI, mean (SD), <i>n</i>	10.7 (6.4), 349	10.3 (6.1), 350	10.2 (6.3), 343	10.7 (6.3), 356	10.5 (6.3), 699
RDA, mean (SD), <i>n</i>					
Overall	8.1 (2.6), 352	7.7 (2.6), 354	7.8 (2.7), 346	7.9 (2.5), 360	7.9 (2.6), 706
Recreational	3.0 (1.0), 352	2.8 (1.0), 354	2.9 (1.0), 346	2.9 (1.0), 360	2.9 (1.0), 706
Social life	2.5 (1.1), 352	2.3 (1.1), 354	2.3 (1.1), 346	2.5 (1.1), 360	2.4 (1.1), 706
Work	2.6 (1.0), 352	2.5 (1.0), 354	2.6 (1.0), 346	2.6 (1.0), 360	2.6 (1.0), 706

TABLE 34 Stratification factors (at the margins)

Factor	Progressive exercise				Injection				Overall	
	Best-practice advice		Progressive exercise		No		Yes			
	n	%	n	%	n	%	n	%	n	%
Sex										
Male	176	50.0	183	51.4	177	50.9	182	50.6	359	50.7
Female	176	50.0	173	48.6	171	49.1	178	49.4	349	49.3
Age group (years)										
18–35	24	6.8	31	8.7	25	7.2	30	8.3	55	7.8
≥ 36	328	93.2	325	91.3	323	92.8	330	91.7	653	92.2
Trial centre										
1	21	6.0	25	7.0	24	6.9	22	6.1	46	6.5
2	52	14.8	50	14.0	51	14.7	51	14.2	102	14.4
3	59	16.8	61	17.1	60	17.2	60	16.7	120	16.9
4	15	4.3	14	3.9	15	4.3	14	3.9	29	4.1
5	17	4.8	18	5.1	17	4.9	18	5.0	35	4.9
6	6	1.7	8	2.2	7	2.0	7	1.9	14	2.0
7	7	2.0	7	2.0	6	1.7	8	2.2	14	2.0
8	11	3.1	12	3.4	12	3.4	11	3.1	23	3.2
9	7	2.0	6	1.7	8	2.3	5	1.4	13	1.8
10	14	4.0	17	4.8	15	4.3	16	4.4	31	4.4
11	2	0.6	2	0.6	2	0.6	2	0.6	4	0.6
12	24	6.8	25	7.0	25	7.2	24	6.7	49	6.9
13	16	4.5	17	4.8	15	4.3	18	5.0	33	4.7
14	16	4.5	13	3.7	13	3.7	16	4.4	29	4.1
15	18	5.1	18	5.1	17	4.9	19	5.3	36	5.1
16	19	5.4	17	4.8	17	4.9	19	5.3	36	5.1
17	13	3.7	12	3.4	12	3.4	13	3.6	25	3.5
18	20	5.7	20	5.6	18	5.2	22	6.1	40	5.6
19	5	1.4	6	1.7	5	1.4	6	1.7	11	1.6
20	10	2.8	8	2.2	9	2.6	9	2.5	18	2.5

TABLE 35 Response rates

Response rate	8 weeks (N = 708), n (%)	6 months (N = 708), n (%)	12 months (N = 708), n (%)
Questionnaires posted	706 (99)	698 (99)	694 (98)
Overall response	642 (91)	615 (87)	618 (87)
Postal response	563 (80)	524 (74)	516 (73)
Telephone response	79 (11)	82 (12)	88 (12)
Electronic response	–	9 (1)	14 (2)
Non-responder (missing data)	67 (9)	93 (13)	90 (13)

TABLE 36 Timing of intervention delivery

Period	Injection plus best-practice advice, median (IQR)	Best-practice advice only, median (IQR)	Injection plus progressive exercise, median (IQR)	Progressive exercise only, median (IQR)
Randomisation to injection attendance (days)	6 (0–9)		7 (0–10)	
Randomisation to first exercise session attended (days)	21 (15–28)	15 (12–21)	22 (17–28)	16 (10–21)
Randomisation to last exercise session (days)			103 (68–135)	92 (64–121)
First to last exercise session attended (days)			78 (41–105)	77 (49–106)

TABLE 37 Exercises prescribed: progressive-exercise intervention

Level	Exercise	Exercises prescribed, n ^a						Total, n (%)
		Session 1	Session 2	Session 3	Session 4	Session 5	Session 6	
1	Shoulder flexion supported by table	13	5	2	3	3	0	26 (1)
	Shoulder abduction supported by table	34	11	6	6	4	1	62 (2)
	Shoulder flexion supported by table in standing	18	4	3	2	1	0	28 (1)
	Shoulder abduction supported by table in standing	15	6	5	2	1	1	30 (1)
	Shoulder flexion (self-assisted): supine	18	14	5	3	1	0	41 (1)
	Shoulder flexion (self-assisted): up a wall	43	21	12	7	4	2	89 (3)
2: core	Isometric shoulder external rotation	70	38	28	13	3	4	156 (5)
	Isometric shoulder abduction	41	25	18	9	6	3	102 (3)
	^b Resisted shoulder external rotation; 0°	138	112	71	33	24	16	394 (12)
	^b Resisted shoulder abduction	74	92	72	51	36	17	342 (10)
	Shoulder flexion up a wall	38	33	26	12	7	7	123 (4)
	Shoulder raise using a weight	27	44	37	27	22	13	170 (5)
	^b Resisted shoulder external rotation (supported): 90°	25	36	42	32	19	10	164 (5)
	^b Resisted shoulder external rotation (unsupported): 90°	19	34	28	28	25	18	152 (5)

continued

TABLE 37 Exercises prescribed: progressive-exercise intervention (continued)

Level	Exercise	Exercises prescribed, n ^a						Total, n (%)
		Session 1	Session 2	Session 3	Session 4	Session 5	Session 6	
2: optional	^b Bilateral shoulder flexion/abduction	119	136	116	77	46	26	520 (16)
	^b Resisted shoulder abduction/external rotation	32	37	43	28	15	12	167 (5)
	Isometric shoulder internal rotation	9	12	8	6	3	0	38 (1)
	^b Resisted shoulder internal rotation: 0°	13	12	11	8	6	5	55 (2)
	^b Resisted shoulder internal rotation (supported): 90°	8	13	16	15	6	2	60 (2)
	^b Resisted shoulder internal rotation (unsupported): 90°	7	7	13	9	14	10	60 (2)
	^b Resisted shoulder adduction/internal rotation	0	3	11	6	7	4	31 (1)
	Shoulder retraction: prone	9	7	9	11	8	5	49 (1)
	Shoulder flexion (elbow bent): prone	0	7	2	5	1	3	18 (1)
	Shoulder flexion (elbow straight): prone	1	3	6	4	1	0	15 (0)
	Shoulder flexion (crawl position)	9	14	16	13	11	7	70 (2)
	Press-ups (on knees)	14	17	17	17	15	7	87 (3)
	Press-ups (normal)	3	7	7	6	7	1	31 (1)
	Sleeper stretch	9	11	13	10	5	2	50 (1)
Optional stretches	Horizontal adduction stretch	5	4	6	4	3	1	23 (1)
	Therapist-designed exercise(s)	7	25	43	40	33	20	168 (5)
Unknown exercise		1	7	0	2	5	3	18 (1)
Total, n (%)		819 (25)	797 (24)	692 (21)	489 (15)	342 (10)	200 (6)	3339 (100)
a Number of times exercise prescribed. Participants generally received more than one exercise and participant may have received same exercise more than once.								
b With resistance band.								

TABLE 38 Progression of exercise intervention: progressive-exercise intervention

Progression of exercise	Progressive exercise only, n (%)	Injection plus progressive exercise, n (%)	Total, n (%)
Progressed ^a	118 (71)	109 (63)	227 (67)
Maintained ^b	34 (20)	39 (23)	73 (22)
Regressed ^c	15 (9)	24 (14)	39 (12)
Total	167 (100)	172 (100)	339 (100)

a Progression defined as an increase in exercise difficulty level, or either volume and/or load across attended exercise sessions.

b Maintained defined as no change in any of exercise difficulty level, or either volume and/or load across attended exercise sessions. If volume increased and load decreased (or vice versa), the exercise was considered to have been maintained (assuming exercise difficulty level remained the same).

c Regression defined as a decrease in exercise difficulty level, or either volume and/or load across attended exercise sessions.

TABLE 39 Participant-reported exercise adherence

Adherence	Best-practice advice		Progressive exercise		No injection		Injection		Overall	
	n	%	n	%	n	%	n	%	n	%
8 weeks										
Every day	34	9.7	40	11.2	34	9.8	40	11.1	74	10.5
6 days per week	15	4.3	15	4.2	15	4.3	15	4.2	30	4.2
5 days per week	152	43.2	215	60.4	160	46.0	207	57.5	367	51.8
4 days per week	26	7.4	19	5.3	27	7.8	18	5.0	45	6.4
3 days per week	15	4.3	6	1.7	15	4.3	6	1.7	21	3.0
2 days per week	9	2.6	2	0.6	6	1.7	5	1.4	11	1.6
1 day per week	3	0.9	0	0.0	1	0.3	2	0.6	3	0.4
None	28	8.0	11	3.1	18	5.2	21	5.8	39	5.5
Missing	70	19.9	48	13.5	72	20.7	46	12.8	118	16.7
6 months										
Every day	19	5.4	14	3.9	14	4.0	19	5.3	33	4.7
6 days per week	5	1.4	4	1.1	7	2.0	2	0.6	9	1.3
5 days per week	53	15.1	66	18.5	42	12.1	77	21.4	119	16.8
4 days per week	24	6.8	26	7.3	22	6.3	28	7.8	50	7.1
3 days per week	33	9.4	33	9.3	34	9.8	32	8.9	66	9.3
2 days per week	27	7.7	19	5.3	20	5.7	26	7.2	46	6.5
1 day per week	13	3.7	11	3.1	13	3.7	11	3.1	24	3.4
None	101	28.7	117	32.9	116	33.3	102	28.3	218	30.8
Missing	76	21.6	65	18.3	79	22.7	62	17.2	141	19.9

continued

TABLE 39 Participant-reported exercise adherence (continued)

Adherence	Best-practice advice		Progressive exercise		No injection		Injection		Overall	
	n	%	n	%	n	%	n	%	n	%
12 months										
Every day	15	4.3	16	4.5	9	2.6	22	6.1	31	4.4
6 days per week	3	0.9	1	0.3	3	0.9	1	0.3	4	0.6
5 days per week	22	6.3	15	4.2	13	3.7	24	6.7	37	5.2
4 days per week	16	4.5	12	3.4	14	4.0	14	3.9	28	4.0
3 days per week	24	6.8	26	7.3	21	6.0	29	8.1	50	7.1
2 days per week	19	5.4	22	6.2	17	4.9	24	6.7	41	5.8
1 day per week	18	5.1	16	4.5	21	6.0	13	3.6	34	4.8
None	165	46.9	183	51.4	176	50.6	172	47.8	348	49.2
Missing	69	19.6	64	18.0	74	21.3	59	16.4	133	18.8

TABLE 40 Progressive exercise vs. best-practice advice and injection vs. best-practice advice: inside-the-table analysis of SPADI overall

SPADI over 12 months	Progressive exercise (N = 174) vs. best-practice advice (N = 174)		Injection plus best-practice advice (N = 178) vs. best-practice advice (N = 174)	
Unadjusted mean (SD), n ^a	27.36 (23.49), 166	32.21 (25.39), 164	28.55 (23.11), 175	32.21 (25.39), 164
Adjusted mean (SE), n ^b	28.79 (1.39), 154	30.55 (1.43), 146	28.32 (1.41), 151	30.55 (1.43), 146
Unadjusted difference (99% CI) ^a	-4.64 (-10.20 to 0.91)		-3.50 (-8.99 to 1.99)	
Adjusted difference (99% CI), p-value ^b	-1.76 (-6.91 to 3.39), 0.380		-2.23 (-7.03 to 2.57), 0.230	

a Unadjusted SPADI analysis using a mixed-effects model with random effects for observations within participant, with time-by-treatment interaction. A total of 1870 participant data points contribute to the unadjusted model.

b SPADI-adjusted analysis using a mixed-effects model with fixed effects for age, sex and baseline SPADI, and random effects for observations within participant, physiotherapist and centre, with time-by-treatment interaction. A total of 1869 participant data points contribute to the adjusted model.

TABLE 41 Progressive exercise vs. best-practice advice and injection vs. best-practice advice: inside-the-table analysis of SPADI at each time point

SPADI at each time point	Progressive exercise vs. best-practice advice				Injection vs. best-practice advice			
	Adjusted mean (SE), n	Adjusted mean (SE), n	Adjusted difference (99% CI) ^a	p-value	Adjusted mean (SE), n	Adjusted mean (SE), n	Adjusted difference (99% CI) ^a	p-value
8 weeks	41.22 (1.78), 156	41.09 (1.72), 149	-0.13 (-6.52 to 6.27)	0.959	32.89 (1.75), 163	37.97 (1.68), 149	-8.33 (-14.46 to -2.19)	0.000
6 months	26.99 (1.81), 151	25.71 (1.74), 143	-1.28 (-7.76 to 5.20)	0.611	27.75 (1.76), 158	26.02 (1.70), 143	0.76 (-5.45 to 6.97)	0.752
12 months	23.12 (1.81), 153	19.19 (1.74), 143	-3.93 (-10.40 to 2.55)	0.118	24.17 (1.76), 160	21.90 (1.71), 143	1.05 (-5.15 to 7.26)	0.663

a SPADI-adjusted analysis using a mixed-effects model with fixed effects for age, sex and baseline SPADI, and random effects for observations within participant, physiotherapist and centre, with time-by-treatment interaction. A total of 1869 participant data points contribute to the adjusted model.

TABLE 42 Secondary outcomes analysis: unadjusted mean and SD

Secondary outcome	Best-practice advice		Progressive exercise		No injection		Injection	
	n	Unadjusted mean (SD)	n	Unadjusted mean (SD)	n	Unadjusted mean (SD)	n	Unadjusted mean (SD)
SPADI pain								
Baseline	352	65.1 (18)	354	62.7 (17.4)	346	63.3 (17.6)	360	64.4 (17.9)
8 weeks	314	46.0 (24.5)	326	46.7 (24.5)	306	50.2 (23.4)	334	42.7 (24.9)
6 months	301	34.4 (26.4)	314	30.9 (25.7)	294	31.7 (25.6)	321	33.5 (26.5)
12 months	304	28.7 (27.1)	314	24.6 (25.5)	296	25.5 (25.9)	322	27.7 (26.8)
Over 12 months	339	36.6 (27.0)	343	34.2 (26.9)	339	35.9 (27.1)	343	34.7 (26.8)
SPADI function								
Baseline	352	47.2 (22.6)	354	41.5 (21.3)	346	44.2 (22.4)	360	44.5 (21.9)
8 weeks	313	31.3 (23.6)	326	30.8 (23.5)	307	33.3 (23.5)	332	29.0 (23.3)
6 months	301	22.0 (22.6)	314	19.9 (22.1)	294	20.7 (22.6)	321	21.2 (22.2)
12 months	303	19.4 (22.6)	314	15.1 (21)	296	16.3 (21.8)	321	18.0 (22.1)
Over 12 months	339	24.3 (23.5)	343	22.0 (23.2)	339	23.6 (23.7)	343	22.8 (23.0)
FABQ-PA								
Baseline	349	15.6 (5.6)	354	14.5 (5.4)	344	14.9 (5.7)	359	15.2 (5.3)
8 weeks	279	11.9 (6.4)	307	11.9 (6.0)	276	12.0 (6.3)	310	11.8 (6.1)
6 months	276	9.9 (6.5)	287	9.4 (6.4)	265	9.4 (6.6)	298	9.8 (6.3)
12 months	280	9.5 (6.6)	291	8.1 (6.8)	271	8.5 (6.9)	300	9.1 (6.5)
Over 12 months	324	10.4 (6.6)	332	9.8 (6.6)	316	10.0 (6.8)	340	10.2 (6.4)
PSEQ-2								
Baseline	352	9.6 (2.4)	354	9.8 (2.3)	346	9.7 (2.3)	360	9.6 (2.3)
8 weeks	280	10.2 (2.4)	306	10.3 (2.2)	276	10.2 (2.3)	310	10.3 (2.3)
6 months	276	10.5 (2.1)	288	10.4 (2.2)	266	10.5 (2.1)	298	10.4 (2.2)
12 months	280	10.7 (2.0)	291	10.8 (2.2)	271	10.9 (1.8)	300	10.6 (2.3)
Over 12 months	325	10.5 (2.2)	332	10.5 (2.2)	317	10.5 (2.1)	340	10.4 (2.3)
ISI								
Baseline	349	10.7 (6.4)	350	10.3 (6.1)	343	10.2 (6.3)	356	10.7 (6.3)
8 weeks	277	7.5 (6.2)	303	8.0 (6.1)	274	8.7 (6.3)	306	7.0 (6.0)
6 months	275	6.1 (5.8)	290	6.2 (6.1)	267	6.1 (5.9)	298	6.2 (6.0)
12 months	281	5.8 (6.1)	292	5.2 (5.7)	272	5.4 (5.9)	301	5.6 (6.0)
Over 12 months	323	6.5 (6.1)	329	6.5 (6.1)	314	6.7 (6.2)	338	6.3 (6.0)
RDA								
Baseline	352	8.1 (2.6)	354	7.7 (2.6)	346	7.8 (2.7)	360	7.9 (2.5)
8 weeks	278	6.2 (2.5)	303	6.2 (2.5)	274	6.5 (2.6)	307	5.9 (2.4)
6 months	276	5.4 (2.4)	290	5.0 (2.3)	268	5.1 (2.4)	298	5.2 (2.3)
12 months	281	4.8 (2.3)	292	4.6 (2.3)	273	4.6 (2.4)	300	4.8 (2.3)
Over 12 months	325	5.5 (2.5)	332	5.3 (2.5)	317	5.4 (2.6)	340	5.3 (2.4)

TABLE 42 Secondary outcomes analysis: unadjusted mean and SD (continued)

Secondary outcome	Best-practice advice		Progressive exercise		No injection		Injection	
	n	Unadjusted mean (SD)	n	Unadjusted mean (SD)	n	Unadjusted mean (SD)	n	Unadjusted mean (SD)
GIT								
Baseline								
8 weeks	277	7.6 (2.1)	304	7.8 (1.8)	274	7.3 (2.0)	307	8.1 (1.8)
6 months	276	8.2 (2.2)	291	8.7 (2.1)	269	8.5 (2.2)	298	8.5 (2.2)
12 months	283	8.6 (2.3)	293	9.1 (2.2)	274	8.9 (2.1)	302	8.8 (2.4)
Over 12 months	326	8.2 (2.2)	332	8.5 (2.1)	317	8.2 (2.2)	347	8.5 (2.1)




FIGURE 25 Subgroup-adjusted SPADI analysis for progressive exercise vs. best-practice advice at 8 weeks.




FIGURE 26 Subgroup-adjusted SPADI analysis for progressive exercise vs. best-practice advice at 6 months.




FIGURE 27 Subgroup-adjusted SPADI analysis for progressive exercise vs. best-practice advice at 12 months.




FIGURE 28 Subgroup-adjusted SPADI analysis for injection vs. no injection at 8 weeks.




FIGURE 29 Subgroup-adjusted SPADI analysis for injection vs. no injection at 6 months.




FIGURE 30 Subgroup-adjusted SPADI analysis for injection vs. no injection at 12 months.

Appendix 5 Chapter 5 appendix

TABLE 43 Summary of prescribed medication unit cost (in 2019 £)

Medication	Unit type	Unit cost (£)	Source
Analgesics			
Amitriptyline (10 mg)	Pack of 28	1.01	NHS Electronic Drug Tariff ¹²⁷
Co-codamol (30 mg/500 mg)	Pack of 100	4.60	NHS Electronic Drug Tariff ¹²⁷
Solpadol (30 mg)	Pack of 100	5.28	NHS Electronic Drug Tariff ¹²⁷
Codeine (60 mg)	Pack of 28	1.89	NHS Electronic Drug Tariff ¹²⁷
Co-dydramol (10 mg)	Pack of 30	0.93	NHS Electronic Drug Tariff ¹²⁷
Tramadol (50 mg)	Pack of 30	0.85	NHS Electronic Drug Tariff ¹²⁷
Paracetamol (500 mg)	Pack of 100	2.28	NHS Electronic Drug Tariff ¹²⁷
Morphine sulphate (Sevredol®, Napp Pharmaceuticals Limited, Cambridge, UK) (10 mg)	Pack of 56	5.31	NHS Electronic Drug Tariff ¹²⁷
Celecoxib (100 mg)	Pack of 60	2.30	NHS Electronic Drug Tariff ¹²⁷
Gabapentin (600 mg)	Pack of 100	12.00	NHS Electronic Drug Tariff ¹²⁷
NSAIDs			
Ibuprofen (200 mg)	Pack of 16	2.67	NHS Electronic Drug Tariff ¹²⁷
Ibuprofen gel	Each	2.10	NHS Electronic Drug Tariff ¹²⁷
Meloxicam (15 mg)	Pack of 30	1.77	NHS Electronic Drug Tariff ¹²⁷
Naproxen (500 mg)	Pack of 56	4.14	NHS Electronic Drug Tariff ¹²⁷
Diclofenac (25 mg)	Pack of 28	3.86	NHS Electronic Drug Tariff ¹²⁷
Other medication usage			
Phorpain	Each	2.72	NHS Electronic Drug Tariff ¹²⁷
Temazepam (20 mg)	Pack of 28	1.60	NHS Electronic Drug Tariff ¹²⁷
Vitamin D	Pack of 30	4.93	NHS Electronic Drug Tariff ¹²⁷
Volartol emulgel	Each	2.04	NHS Electronic Drug Tariff ¹²⁷
Zapain (30 mg)	Pack of 100	4.77	NHS Electronic Drug Tariff ¹²⁷
Diazepam (2 mg)	Pack of 28	0.76	NHS Electronic Drug Tariff ¹²⁷
Movelat gel	Each	8.49	NHS Electronic Drug Tariff ¹²⁷
Adcal (750 mg)	Pack of 112	2.95	NHS Electronic Drug Tariff ¹²⁷
Alendronic (10 mg)	Pack of 28	2.63	NHS Electronic Drug Tariff ¹²⁷
Prednisolone (1 mg)	Pack of 28	0.85	NHS Electronic Drug Tariff ¹²⁷
Feldene gel (60 g)	Each	6.00	NHS Electronic Drug Tariff ¹²⁷
Sertraline (100 mg)	Pack of 28	3.82	NHS Electronic Drug Tariff ¹²⁷
continued			

TABLE 43 Summary of prescribed medication unit cost (in 2019 £) (continued)

Medication	Unit type	Unit cost (£)	Source
Docycycline (50 mg)	Pack of eight	2.25	NHS Electronic Drug Tariff ¹²⁷
Butrans patch (5 µg)	Pack of four	17.60	NHS Electronic Drug Tariff ¹²⁷
Corticosteroid injections			
Kenalog (40 mg)	Each	7.45	NHS Electronic Drug Tariff ¹²⁷
Depomedrone (40 mg)	Each	7.13	NHS Electronic Drug Tariff ¹²⁷
Local anaesthetic			
Lidocaine (50 mg/5 ml) (1%)	Pack of 20	6.50	NHS Electronic Drug Tariff ¹²⁷
Bupivacaine hydrochloride (50 mg/10 ml) (0.5%)	Pack of 10	7.56	NHS Electronic Drug Tariff ¹²⁷
NSAID, non-steroidal anti-inflammatory drug.			
Notes			
Source of unit cost data: NHS Electronic Drug Tariff. ¹²⁷ Costs for smallest appropriate pack size, non-proprietary (unless brand is stated). Individual recorded doses were used where possible, otherwise average daily doses were assumed.			

TABLE 44 Unit costs of health and social care items and additional financial cost due to rotator cuff disorder

Resource item	Unit	Unit cost (£) ^a	Source
Inpatient stay (because of shoulder)			
Surgery to repair rotator cuff tear	Episode	3711.07	NHS Reference Costs 2017: ⁹² elective HRG HN53A, HN53B, HN53C
Frozen shoulder surgery	Episode	3064.07	NHS Reference Costs 2017: ⁹² elective HRG HN54A, HN54B, HN54C
Subacromial decompression and cuff repair	Episode	3711.07	NHS Reference Costs 2017: ⁹² elective HRG HN53A, HN53B, HN53C
Outpatient care			
Orthopaedic clinic (shoulder)	Visit	120.00	NHS Reference Costs 2019: ¹²⁸ 110
Physiotherapy	Visit	38.88	PSSRU 2019: ⁸⁹ p. 68
Radiology (X-rays)	Test	31.00	NHS Reference Costs 2017: ⁹² DAPF
Radiology (ultrasound)	Test	39.00	NHS Reference Costs 2019: ¹²⁸ RD40Z
Radiology (MRI)	Test	108.00	NHS Reference Costs 2019: ¹²⁸ RD01A
Emergency department	Visit	106.00	NHS Reference Costs 2019: ¹²⁸ VB09Z
Community care (NHS)			
GP (surgery)	9.22-minute visit	39.23	PSSRU 2019: ⁸⁹ p. 120
GP (home)	Per minute	5.32	PSSRU 2010: ¹²⁹ p. 167

TABLE 44 Unit costs of health and social care items and additional financial cost due to rotator cuff disorder (continued)

Resource item	Unit	Unit cost (£) ^a	Source
GP (telephone contact)	7.1 minutes	27.62	PSSRU 2015: ¹³⁰ p. 177
Practice nurse	Hour visit	42.00	PSSRU 2019: ⁸⁹ p. 118
111 advice	Per call	14.32	<i>Financial Times</i> 2017 ¹³¹
Physiotherapist	Session	36.83	PSSRU 2019: ⁸⁹ p. 82
Community care (private)			
Orthopaedic clinic (shoulder)	Visit	200.00	<i>Orthopaedic Clinics UK</i> ¹³²
Physiotherapy	Visit	75.00	The Physiotherapy Centre ¹³³
Radiology (X-rays)	Test	90.00	<i>Orthopaedic Clinics UK</i> ¹³²
Radiology (ultrasound)	Test	358.00	Private Healthcare UK ¹³⁴
Radiology (MRI)	Test	285.00	<i>Orthopaedic Clinics UK</i> ¹³²
Chiropractor	Visit	35.00	<i>Orthopaedic Clinics UK</i> ¹³²
Complementary therapist (e.g. reflexology, acupuncture)	Visit	65.00	<i>Orthopaedic Clinics UK</i> ¹³²
Sports massage therapist	Visit	60.00	<i>Orthopaedic Clinics UK</i> ¹³²
Direct non-medical cost			
Help with housework			Trial
Help with childcare			Trial
Travel			Trial
Lost productivity			
Median wage	Per week	585.00	Office for National Statistics ¹³⁵

HRG, Healthcare Resource Group; MRI, magnetic resonance imaging; PSSRU, Personal Social Service Research Unit.

a Unit cost has been inflated to 2018/19 prices.

Note

If more than one code applies, costs are estimated weighted by activity as depicted in annex A (Department of Health and Social Care).¹³⁶

Model 1: regression analysis model with interaction term (base-case analysis)

For the 2 × 2 GRASP factorial trial, the regression model predicting costs with an interaction term took the form:

$$y_i = \beta_0 + \beta_A A_i + \beta_B B_i + \beta_{AB} A_i B_i + \varepsilon_i, \quad (2)$$

where y_i represents the outcome measure (cost or QALY), β_A represents the coefficient for treatment effects for exercise, β_B represents the coefficient for treatment effects for the corticosteroid injection, β_{AB} represents the interaction coefficient between exercise and corticosteroid injection and β_0 represents the constant term.

Note that the QALY equation included baseline utility.

Model 2: regression analysis without interaction term (sensitivity analysis)

This analysis was used as a sensitivity analysis. This analysis was carried out by analysing the same set of bootstraps, omitting the interaction between injection and progressive exercise, and results were combined across bootstraps and imputations using the same methods as the base-case analysis. This approach assumes that interventions are mutually exclusive. In other words, the cost and outcomes of the individually tailored progressive-exercise programme are assumed to not be affected by whether or not corticosteroid injection is given (and vice versa). In addition, regression analysis without interaction term, although similar to the at-the-margins approach, makes the prediction of group means and SEs easier. As interventions are assumed to be mutually exclusive options, these predictions can help us identify which of the four treatment options (progressive exercise, best-practice advice, corticosteroid injection plus progressive exercise or corticosteroid injection plus best-practice advice) maximises NMB and also estimates the cost and effects of each option separately.

For the 2×2 GRASP factorial trial, the regression model for this sensitivity analysis took the form:

$$y_i = \beta_o + \beta_A A_i + \beta_B B_i + \varepsilon_i, \quad (3)$$

where y_i represents the outcome measure (cost, QALY or NMB), β_A represents the coefficient for treatment effects for exercise, β_B represents the coefficient for treatment effects for the corticosteroid injection and β_o represents the constant term.

Note that the QALY equation included baseline utility.

TABLE 45 Mean health resource utilisation: baseline to 8 weeks (available-case analysis, excluding patients with missing data on that resource)

Type of care	Best-practice advice (N = 150)			Injection plus best-practice advice (N = 165)			Progressive exercise (N = 157)			Injection plus progressive exercise (N = 169)		
	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)
Primary care (NHS community-based services)	129			150			146			162		
GP visit	127	98.45	0.15 (0.47)	149	99.33	0.06 (0.29)	138	94.52	0.13 (0.42)	157	96.91	0.04 (0.19)
GP telephone contact	117	90.7	0.04 (0.24)	143	95.33	0.01 (0.08)	125	85.62	0.02 (0.18)	154	95.06	0.05 (0.50)
GP home visit	113	87.6	0	142	94.67	0	124	84.93	0	152	93.83	0
Practice nurse	114	88.37	0.02 (0.19)	142	94.67	0	125	85.62	0.04 (0.45)	154	95.06	0.01 (0.11)
Physiotherapy (not as part of the GRASP trial)	114	88.37	0.05 (0.56)	143	95.33	0.001 (0.08)	132	90.41	0.121 (0.51)	154	95.06	0.02 (0.14)
Other NHS community services	114	88.37	0	143	95.33	0	126	86.3	0.03 (0.28)	152	93.83	0.01 (0.08)
Secondary care (NHS outpatient services)	129			150			146			163		
Orthopaedic clinic (for shoulder)	124	96.12	0.01 (0.09)	145	96.67	0.01 (0.16)	136	93.15	0	160	98.16	0
Physiotherapy department (not as part of the GRASP trial)	123	95.35	0	145	96.67	0.03 (0.42)	138	94.52	0.03 (0.27)	161	98.77	0.02 (0.32)
Radiology: X-ray	125	99.21	0.02 (0.13)	147	98.66	0.02 (0.14)	144	100	0.08 (0.34)	160	98.77	0
Radiology: ultrasound	124	98.41	0.01 (0.09)	147	98.66	0.02 (0.14)	136	94.44	0	162	100	0.01 (0.11)
Radiology: MRI	123	97.62	0	144	96.64	0	136	94.44	0	160	98.77	0
Accident and emergency	125	96.9	0.02 (0.13)	147	98	0.02 (0.14)	136	100	0	160	98.16	0
Other outpatient services	123	95.35	0	146	97.33	0.01 (0.12)	136	100	0	160	98.16	0
Secondary care (NHS inpatient services)	129			150			145			162		
Inpatient care	129	100	0	150	100	0	145	100	0	162	100	0

continued

TABLE 45 Mean health resource utilisation: baseline to 8 weeks (available-case analysis, excluding patients with missing data on that resource) (continued)

Type of care	Best-practice advice (N = 150)			Injection plus best-practice advice (N = 165)			Progressive exercise (N = 157)			Injection plus progressive exercise (N = 169)		
	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)
Private care	129			151			146			162		
Orthopaedic clinic (for shoulder)	127	98.45	0	150	100	0	144	98.63	0.01 (0.08)	162	100	0
Physiotherapy department	128	73.56	0.03 (0.35)	150	100	0	143	97.95	0	162	100	0
Radiology: X-ray	127	100	0	150	99.34	0	143	100	0	162	100	0
Radiology: ultrasound	127	100	0	151	100	0	143	100	0	162	100	0
Radiology: MRI	127	100	0	150	99.34	0	143	100	0	162	100	0
Chiropractor	127	98.45	0	150	99.34	0	144	98.63	0.01 (0.08)	162	100	0
Complementary therapist	128	99.22	0.05 (0.53)	150	99.34	0	144	98.63	0.01 (0.17)	162	100	0
Injection utilisation	130			151			147			163		
Injections	130		0.02 (0.18)	151			147		0.02 (0.14)	163		0.06 (0.24)
Non-medical expenses	129			150			146			162		

MRI, magnetic resonance imaging.
a Relates to the number of participants for whom follow-up data were available.
b Completion rate of the corresponding question related to usage or not of resource utilisation.
c Refers to mean resource utilisation per patient.

TABLE 46 Mean health resource utilisation: 8 weeks to 6 months (available-case analysis, excluding patients with missing data on that resource)

Type of care	Best-practice advice (N = 144)			Injection plus best-practice advice (N = 158)			Progressive exercise (N = 151)			Injection plus progressive exercise (N = 162)		
	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)
Primary care (NHS community-based services)	127			147			140			150		
GP visit	123	96.85	0.15 (0.59)	142	96.6	0.09 (0.36)	135	96.43	0.16 (0.56)	149	99.33	0.14 (0.45)
GP telephone contact	117	92.13	0.08 (0.44)	133	90.48	0.01 (0.09)	123	87.86	0.02 (0.18)	135	90	0.01 (0.09)
GP home visit	112	88.19	0	133	90.48	0	122	87.14	0	134	89.33	0
Practice nurse	113	88.98	0.01 (0.09)	132	89.8	0	122	87.14	0	134	89.33	0
Physiotherapy (not as part of the GRASP trial)	117	92.13	0.19 (1.13)	138	93.88	0.09 (0.57)	126	90	0.08 (0.52)	136	90.67	0.02 (0.19)
Other NHS community services	113	88.98	0.02 (0.02)	132	89.8	0	123	87.86	0.03 (0.36)	136	90.67	0.01 (0.12)
Secondary care (NHS outpatient services)	127			146			140			150		
Orthopaedic clinic (for shoulder)	123	96.85	0.03 (0.22)	141	96.58	0.03 (0.17)	135	96.43	0.03 (0.21)	148	98.67	0
Physiotherapy department (not as part of the GRASP trial)	122	96.06	0.02 (0.13)	138	94.52	0.04 (0.43)	135	96.43	0.07 (0.49)	150	100	0.03 (0.28)
Radiology: X-ray	121	95.28	0.01 (0.11)	137	93.84	0.02 (0.13)	132	94.29	0.01 (0.11)	148	98.67	0
Radiology: ultrasound	121	95.28	0	137	93.84	0	132	94.29	0	148	98.67	0
Radiology: MRI	121	95.28	0	137	93.84	0	132	94.29	0	148	98.67	0
Accident and emergency	121	95.28	0.01 (0.09)	137	93.84	0	132	94.29	0	148	98.67	0
Other outpatient services	121	95.28	0.01 (0.09)	137	93.84	0	132	94.29	0	148	98.67	0
Secondary care (NHS inpatient services)	127			147			140			150		
Inpatient care	127	100	0	147	100	0.03 (0.15)	140	100	0	150	100	0

continued

TABLE 46 Mean health resource utilisation: 8 weeks to 6 months (available-case analysis, excluding patients with missing data on that resource) (continued)

Type of care	Best-practice advice (N = 144)			Injection plus best-practice advice (N = 158)			Progressive exercise (N = 151)			Injection plus progressive exercise (N = 162)		
	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)
Private care	128			147			140			150		
Orthopaedic clinic (for shoulder)	121	94.53	0.02 (0.18)	141	95.92	0	132	94.29	0	147	98	0.01 (0.08)
Physiotherapy department	124	96.88	0.08 (0.45)	143	97.28	0.12 (1.26)	134	95.71	0.01 (0.12)	150	100	0.07 (0.53)
Radiology: X-ray	120	93.75	0	141	95.92	0	132	94.29	0	147	98	0
Radiology: ultrasound	120	93.75	0	141	95.92	0	132	94.29	0	146	97.33	0
Radiology: MRI	120	93.75	0	141	95.92	0	132	94.29	0	146	97.33	0
Chiropractor	122	95.31	0.03 (0.29)	142	96.6	0.04 (0.50)	135	96.43	0.15 (1.19)	147	98	0.01 (0.08)
Complementary therapist	122	95.31	0.05 (0.4)	142	96.6	0.01 (0.17)	133	95	0.02 (0.26)	146	97.33	0
Injection utilisation	130			147			140			149		
Injections	130	100	0.07 (0.25)	147	100	0.04 (0.19)	140	100	0.08 (0.32)	149	100	0.06 (0.30)
Non-medical expenses	129			147			140			150		

MRI, magnetic resonance imaging.

a Relates to the number of participants for whom follow-up data were available.

b Completion rate of the corresponding question related to usage or not of resource utilisation.

c Refers to mean resource utilisation per patient.

TABLE 47 Mean health resource utilisation: 6–12 months (available-case analysis, excluding patients with missing data on that resource)

Type of care	Best-practice advice (N = 143)			Injection plus best-practice advice (N = 161)			Progressive exercise (N = 153)			Injection plus progressive exercise (N = 161)		
	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)
Primary care (NHS community-based services)	133			150			140			152		
GP visit	129	96.99	0.19 (0.69)	145	96.67	0.21 (0.63)	138	98.57	0.21 (0.84)	147	96.71	0.26 (0.83)
GP telephone contact	118	88.72	0.03 (0.21)	130	86.67	0.02 (0.19)	126	90	0	133	87.5	0.13 (0.92)
GP home visit	116	87.22	0	128	85.33	0	126	90	0	129	84.87	0.01 (0.09)
Practice nurse	116	87.22	0	128	85.33	0	126	90	0	128	84.21	0
Physiotherapy (not as part of the GRASP trial)	120	90.23	0.1 (0.67)	133	88.67	0.11 (0.71)	130	92.86	0.09 (0.60)	135	88.82	0.16 (0.81)
Other NHS community services	118	88.72	0.03 (0.21)	131	87.33	0.02 (0.15)	129	92.14	0.02 (0.15)	129	84.87	0.01 (0.09)
Secondary care (NHS outpatient services)	133			150			141			152		
Orthopaedic clinic (for shoulder)	128	96.24	0.08 (0.45)	140	93.33	0.07 (0.39)	135	95.74	0.04 (0.32)	147	96.71	0.12 (0.47)
Physiotherapy department (not as part of the GRASP trial)	126	94.74	0.06 (0.49)	142	94.67	0.13 (0.70)	133	94.33	0.02 (0.17)	140	92.11	0.04 (0.31)
Radiology: X-ray	126	94.74	0.01 (0.11)	142	94.67	0.02 (0.17)	133	94.33	0.02 (0.19)	140	92.11	0.01 (0.11)
Radiology: ultrasound	126	94.74	0.01 (0.07)	142	94.67	0	133	94.33	0	140	92.11	0.01 (0.07)
Radiology: MRI	126	94.74	0.01 (0.07)	142	94.67	0.01 (0.08)	133	94.33	0.01 (0.08)	140	92.11	0.02 (0.13)
Accident and emergency	124	93.23	0.01 (0.08)	137	91.33	0.01 (0.12)	132	93.62	0	137	90.13	0
Other outpatient services	124	93.23	0.02 (0.18)	136	90.67	0.01 (0.17)	132	93.62	0	138	90.79	0.01 (0.17)

continued

TABLE 47 Mean health resource utilisation: 6–12 months (available-case analysis, excluding patients with missing data on that resource) (continued)

Type of care	Best-practice advice (N = 143)			Injection plus best-practice advice (N = 161)			Progressive exercise (N = 153)			Injection plus progressive exercise (N = 161)		
	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)	n ^a	Completion rate ^b (%)	Mean ^c (SD)
Secondary care (NHS inpatient services)	132			150			140			152		
Inpatient care	133			150			141			152		
Private care	126	94.74	0.02 (0.18)	147	98	0	134	95.04	0.01 (0.17)	145	95.39	0.02 (0.19)
Orthopaedic clinic (for shoulder)	127	95.49	0.05 (0.37)	148	98.67	0.01 (0.08)	136	96.45	0.05 (0.37)	148	97.37	0.11 (0.66)
Physiotherapy department	126	94.74	0	147	98	0	135	95.74	0	148	97.37	0.01 (0.07)
Radiology: X-ray	126	94.74	0	147	98	0	135	95.74	0	148	97.37	0
Radiology: ultrasound	126	94.74	0	147	98	0	135	95.74	0	148	97.37	0.01 (0.07)
Radiology: MRI	126	94.74	0.01 (0.09)	147	98	0	135	95.74	0.05 (0.42)	145	95.39	0.03 (0.26)
Chiropractor	126	94.74	0.07 (0.80)	148	98.67	0.10 (1.23)	134	95.04	0.02 (0.27)	143	94.08	0
Complementary therapist	133			150			141			150		
Injection utilisation	133		0.11 (0.35)	150		0.07 (0.29)	141		0.09 (0.35)	150		0.1 (0.36)
Injections	133			150			141			152		
Non-medical expenses	133			150			140			152		

MRI, magnetic resonance imaging.

a Relates to the number of participants for whom follow-up data were available.

b Completion rate of the corresponding question related to usage or not of resource utilisation.

c Refers to mean resource utilisation per patient.

TABLE 48 Mean NHS costs (SD) by treatment group and follow-up time point (2019 prices): baseline to 8 weeks (available cases)

Type of care	Best-practice advice (N = 150)		Injection plus best-practice advice (N = 165)		Progressive exercise (N = 157)		Injection plus progressive exercise (N = 169)	
	Mean cost (£)	SD	Mean cost (£)	SD	Mean cost (£)	SD	Mean cost (£)	SD
Primary care (NHS community-based services)								
GP visit	5.86	18.54	2.36	11.38	5.11	7.54	3.57	13.87
GP telephone contact	1.18	6.68	0.19	2.31	0.44	4.94	1.43	13.69
Practice nurse	0.74	7.87	0.00	0.00	1.68	18.78	0.55	4.77
Physiotherapy (not as part of the GRASP trial)	1.93	20.69	0.26	3.08	4.46	18.78	0.72	5.11
Secondary care (NHS outpatient services)								
Orthopaedic clinic (for shoulder)	0.97	10.78	1.66	19.93	0.00	0.00	0.00	0.00
Physiotherapy department (not as part of the GRASP trial)	0.00	0.00	1.33	16.11	1.12	10.42	0.96	12.23
Radiology: X-ray	0.49	3.91	0.63	4.39	2.36	10.42	0.00	0.00
Radiology: ultrasound	0.31	3.50	0.79	5.53	0.00	0.00	0.48	4.32
Accident and emergency	1.69	13.35	2.16	15.03	0.00	0.00	0.00	0.00
Total	9.31	35.65	7.75	39.2	11.82	35.95	4.85	23.37

TABLE 49 Mean NHS costs (SD) by treatment group and follow-up time point (2019 prices): 8 weeks to 6 months (available cases)

Type of care	Best-practice advice (N = 150)		Injection plus best-practice advice (N = 165)		Progressive exercise (N = 157)		Injection plus progressive exercise (N = 169)	
	Mean cost (£)	SD	Mean cost (£)	SD	Mean cost (£)	SD	Mean cost (£)	SD
Primary care (NHS community-based services)								
GP visit	6.05	23.03	3.59	13.94	6.39	22.07	5.52	17.67
GP telephone contact	2.12	12.11	0.21	2.39	0.45	4.98	0.20	2.38
Practice nurse	0.37	3.95	0.00	0.00	0.00	0.00	0.00	0.00
Physiotherapy (not as part of the GRASP trial)	6.92	41.01	3.46	21.28	2.92	18.98	0.81	7.04
Secondary care (NHS outpatient services)								
Orthopaedic clinic (for shoulder)	3.9	26.32	3.4	19.99	3.55	25.14	0.00	0.00
Physiotherapy department (not as part of the GRASP trial)	0.64	4.95	1.41	16.52	2.59	19.08	1.03	9.99
Radiology: X-ray	0.36	3.31	0.52	4.00	0.36	3.31	0.00	0.00
Accident and emergency	0.88	9.64	0.00	0.00	0.00	0.00	0.00	0.00
Secondary care (NHS inpatient services)								
Inpatient care	0.00	0.00	24.64	298.82	0.00	0.00	0.00	0.00
Total	14.78	59.69	30.37	293.54	12.51	44.02	6.13	20.59

TABLE 50 Mean NHS costs (SD) by treatment group and follow-up time point (2019 prices): 6–12 months (available cases)

Type of care	Best-practice advice (N = 150)		Injection plus best-practice advice (N = 165)		Progressive exercise (N = 157)		Injection plus progressive exercise (N = 169)	
	Mean cost (£)	SD	Mean cost (£)	SD	Mean cost (£)	SD	Mean cost (£)	SD
Primary care (NHS community-based services)								
GP visit	7.60	27.33	8.11	24.85	8.24	32.99	10.40	32.57
GP telephone contact	0.70	5.67	0.64	5.39	0.00	0.00	3.53	25.31
GP home visit	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.49
Physiotherapy (not as part of the GRASP trial)	3.68	24.53	4.15	25.91	3.40	22.21	6.00	29.92
Secondary care (NHS outpatient services)								
Orthopaedic clinic (for shoulder)	9.37	53.47	8.57	46.95	5.33	38.41	13.87	57.08
Physiotherapy department (not as part of the GRASP trial)	2.46	18.84	4.91	27.28	0.58	6.73	1.66	12.20
Radiology: X-ray	0.36	3.33	0.53	5.21	0.72	5.75	0.35	3.27
Radiology: ultrasound	0.23	2.98	0.00	0.00	0.00	0.00	0.22	2.92
Radiology: MRI	0.63	8.26	0.62	8.16	0.63	8.25	1.80	13.86
Accident and emergency	0.85	9.52	1.55	12.76	0.00	0.00	0.00	0.00
Secondary care (NHS inpatient services)								
Inpatient care	22.83	261.35	0.00	0.00	0.00	0.00	23.99	294.84
Total	36.33	293.35	23.16	84.3	14.99	56.62	50.19	309.46
MRI, magnetic resonance imaging.								

TABLE 51 Mean prescribed drug cost

Time point	Best-practice advice		Injection plus best-practice advice		Progressive exercise		Injection plus progressive exercise	
	n ^a	Mean cost (£) (SD)	n ^a	Mean cost (£) (SD)	n ^a	Mean cost (£) (SD)	n ^a	Mean cost (£) (SD)
Baseline to 8 weeks	150	6.64 (57.73)	165	0.74 (3.32)	157	0.71 (2.70)	169	5.11 (54.02)
8 weeks to 6 months	144	1.94 (8.09)	158	1.74 (6.93)	151	0.75 (3.17)	162	3.28 (11.69)
6–12 months	143	1.65 (5.62)	161	2.57 (11.27)	153	1.17 (6.55)	161	7.87 (34.81)
a Relates to the number of participants for whom follow-up data were available.								

TABLE 52 Utilisation of steroid injections outside the GRASP trial

Time point	Best-practice advice			Injection plus best-practice advice			Progressive exercise			Injection plus progressive exercise		
	n (%)	Privately paid, %	Mean (SD)	n (%)	Privately paid, %	Mean (SD)	n (%)	Privately paid, %	Mean (SD)	n (%)	Privately paid, %	Mean (SD)
Baseline to 8 weeks	1 (0.77)	0	0.81 (9.17)	7 (4.63)	0	2.78 (13.22)	3 (2.04)	33.33	1.07 (7.42)	10 (6.13)	0	3.21 (12.59)
8 weeks to 6 months	9 (6.92)	0.77	3.62 (13.33)	6 (4.08)	0	2.14 (10.38)	9 (6.43)	0.71	4.11 (16.68)	6 (4.03)	0.67	2.81 (15.84)
6–12 months	12 (9.02)	0.75	5.51 (18.51)	8 (5.33)	0	3.49 (15.65)	9 (6.39)	0	4.45 (18.22)	12 (8)	0.67	5.23 (18.93)

TABLE 53 Utility and QALY estimates: EQ-5D visual analogue scale scores (available cases with no adjustment for baseline utility)

Time point	Best-practice advice		Injection plus best-practice advice		Progressive exercise		Injection plus progressive exercise	
	n ^a	Mean (SE)	n ^a	Mean (SE)	n ^a	Mean (SE)	n ^a	Mean (SE)
Baseline	174	74.68 (1.42)	178	77.34 (1.16)	172	77.25 (1.17)	181	75.55 (1.31)
8 weeks	132	77.04 (1.24)	151	79.95 (1.11)	147	78.89 (1.17)	165	76.78 (1.38)
6 months	134	78.49 (1.44)	151	80.68 (1.20)	143	81.36 (1.29)	154	78.33 (1.50)
12 months	138	81.30 (1.26)	158	79.32 (1.23)	143	82.17 (1.33)	154	80.21 (1.33)
Change from baseline to 12 months	107	4.65 (18.27)	133	1.22 (12.53)	123	1.70 (11.47)	139	1.26 (15.53)
QALYs	107	0.73 (0.17)	132	0.75 (0.12)	124	0.76 (0.12)	137	0.72 (0.18)

^a Relates to the number of participants for whom follow-up data were available.

TABLE 54 Regression analysis without interaction term, including imputation of missing values and adjustment for baseline utility, sex and age

	Total costs (£), mean (SE)	QALYs, mean (SE)	NMB (£), ^a mean (SE)
Injection	256 (17)	0.749 (0.009)	14,729 (185)
No injection	221 (35)	0.747 (0.010)	14,715 (221)
Injection main effect	35 (31) ($p = 0.239$)	0.003 (0.011) ($p = 0.818$)	15 (233) ($p = 0.947$)
Progressive exercise	277 (18)	0.748 (0.010)	14,685 (201)
No progressive exercise	199 (34)	0.748 (0.010)	14,758 (201)
Progressive exercise main effect	78 (30) ($p = 0.012$)	0.00 (0.011) ($p = 0.984$)	-73 (231) ($p = 0.753$)

^a NMB calculated at a ceiling ratio of £20,000 per QALY.

Notes

Values represent the mean (SE) for each group for males of age 55.46 years and a baseline utility of 0.653. As there was assumed to be no interaction between baseline variables and treatments, the simple effects for each treatment and the interaction between treatments are assumed to be the same for all participant subgroups, although the absolute costs and absolute QALYs may vary, depending on participants' sex, age and baseline utility.

TABLE 55 Regression analysis with an interaction term, including both NHS and broader societal perspective

	Total societal costs (£), mean (SE)	QALYs, mean (SE)	NMB (£), ^a mean (SE)
Best-practice advice	396 (159)	0.737 (0.014)	14,340 (344)
Injection plus best-practice advice	362 (118)	0.757 (0.011)	14,783 (266)
Progressive exercise	336 (108)	0.756 (0.012)	14,778 (285)
Injection plus progressive exercise	710 (247)	0.741 (0.012)	14,118 (366)
Injection simple effect	-34 (137) ($p = 0.813$)	0.020 (0.015) ($p = 0.183$)	443 (359) ($p = 0.218$)
Exercise simple effect	-60 (113) ($p = 0.604$)	0.019 (0.016) ($p = 0.229$)	438 (352) ($p = 0.215$)
Interaction: exercise by injection	408 (343) ($p = 0.194$)	-0.035 (0.022) ($p = 0.106$)	-1103 (583) ($p = 0.049$)

^a NMB calculated at a ceiling ratio of £20,000 per QALY.

Notes

Values represent the mean (SE) for each group for males of age 55.46 years and a baseline utility of 0.653. As there was assumed to be no interaction between baseline variables and treatments, the simple effects for each treatment and the interaction between treatments are assumed to be the same for all patient subgroups, although the absolute costs and absolute QALYs may vary, depending on patients' sex, age and baseline utility.

TABLE 56 Results of the worst-case scenario for training costs: regression analysis with an interaction term, including imputation of missing values and adjustment for baseline utility, sex and age

	Total costs (£), mean (SE)	QALYs, mean (SE)	NMB (£), ^a mean (SE)
Best-practice advice	295 (69)	0.738 (0.018)	14,469 (384)
Injection plus best-practice advice	303 (28)	0.760 (0.016)	14,905 (327)
Progressive exercise	388 (29)	0.757 (0.019)	14,754 (383)
Injection plus progressive exercise	449 (45)	0.745 (0.016)	14,441 (327)
Injection simple effect	8 (58) ($p = 0.737$)	0.022 (0.022) ($p = 0.301$)	436 (449) ($p = 0.326$)
Exercise simple effect	92 (55) ($p = 0.138$)	0.019 (0.022) ($p = 0.368$)	285 (460) ($p = 0.504$)
Interaction: exercise by injection	53 (72) ($p = 0.495$)	-0.035 (0.033) ($p = 0.285$)	-749 (678) ($p = 0.259$)

^a NMB calculated at a ceiling ratio of £20,000 per QALY.

Notes

Values represent the mean (SE) for each group for males of age 55.46 years and a baseline utility of 0.653. As there was assumed to be no interaction between baseline variables and treatments, the simple effects for each treatment and the interaction between treatments are assumed to be the same for all patient subgroups, although the absolute costs and absolute QALYs may vary, depending on patients' sex, age and baseline utility.

TABLE 57 Results of the best-case scenario: regression analysis with an interaction term, including imputation of missing values and adjustment for baseline utility, sex and age

	Total costs (£), mean (SE)	QALYs, mean (SE)	NMB (£), ^a mean (SE)
Best-practice advice	149 (54)	0.737 (0.013)	14,584 (291)
Injection plus best-practice advice	160 (20)	0.757 (0.011)	14,986 (229)
Progressive exercise	195 (22)	0.756 (0.013)	14,920 (257)
Injection plus progressive exercise	255 (30)	0.741 (0.012)	14,572 (262)
Injection simple effect	11 (44) ($p = 0.722$)	0.021 (0.015) ($p = 0.176$)	403 (320) ($p = 0.206$)
Exercise simple effect	46 (44) ($p = 0.299$)	0.019 (0.016) ($p = 0.217$)	337 (325) ($p = 0.297$)
Interaction: exercise by injection	49 (57) ($p = 0.399$)	-0.035 (0.022) ($p = 0.108$)	-751 (457) ($p = 0.100$)

^a NMB calculated at a ceiling ratio of £20,000 per QALY.

Notes

Values represent the mean (SE) for each group for males of age 55.46 years and a baseline utility of 0.653. As there was assumed to be no interaction between baseline variables and treatments, the simple effects for each treatment and the interaction between treatments are assumed to be the same for all patient subgroups, although the absolute costs and absolute QALYs may vary, depending on patients' sex, age and baseline utility.

Appendix 6 Chapter 6 appendix

TABLE 58 Summary of trials comparing the effects of supervised vs. unsupervised exercise interventions

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results	Conclusion
Krischak <i>et al.</i> (2013) ¹¹⁰	Pilot RCT	Forty-three patients with unilateral, symptomatic, atraumatic full-thickness rotator cuff tears verified by MRI (usual physiotherapy, <i>n</i> = 23; home exercise, <i>n</i> = 20); 14 females : 24 males; mean age 55.3 (11.8 SD) years; analysed participants only	<i>Usual physiotherapy</i>	<i>Home (unsupervised) exercise</i>	<i>Primary outcome</i>	Usual physiotherapy, <i>n</i> = 22; HEP, <i>n</i> = 16	<i>Pain VAS</i>	Home-based therapy programme on the basis of an illustrated booklet with independent exercises twice a day is comparable to formal occupational therapy (physiotherapy) in the conservative treatment of rotator cuff tears
	Two arms Follow-up: 2 months		Physiotherapy with supervised exercises (duration 8 weeks, frequency three times per week)	Received an exercise guide booklet with detailed instructions and demonstrations. Contents of booklet discussed and patients taught how to perform exercises correctly	Average change in pain intensity VAS (0–10) at 2 months		Baseline: HEP mean 5.2 (2.9 SD), physiotherapy 5.0 (1.4)	
			Content of the rehabilitation programme determined exclusively by the treating therapist (supervised)	Exercises were aimed at restoring neuromuscular control at the shoulder, as well as strength and ROM. Contents of booklet instructed patients on the type of exercises, repetitions, intensity, training and rest phases, and included a diary-type weekly plan	<i>Secondary outcomes</i>		2 months: HEP mean 3.5 (SD 2.3), physiotherapy 3.8 (SD 2.6)	
					Constant–Murley score, EQ-5D, shoulder ROM, clinical signs of impingement, strength of abduction/adduction and rotation		<i>Constant–Murley score</i>	
							Baseline: HEP 63.6 (SD 14.7), physiotherapy 60.1 (SD 18.9)	
							2 months: HEP 75.5 (SD 17.8), physiotherapy 73.8 (SD 19.1)	
							<i>EQ-5D index</i>	
							Baseline: HEP 0.907 (SD 0.047), physiotherapy 0.885 (SD 0.049)	
							2 months: HEP 0.923 (SD 0.037), physiotherapy 0.933 (SD 0.056)	
							<i>EQ-5D VAS</i>	
							Baseline: HEP 53.8 (SD 19), physiotherapy 58.6 (SD 21.8)	
							2 months: HEP 71.6 (SD 14.3), physiotherapy 61.8 (SD 19.6)	

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results	Conclusion
Granviken and Vasseljen (2015) ¹¹¹	Parallel Two arms Follow-up: 6 weeks and 26 weeks	Forty-six participants with subacromial impingement (n = 23 in each group); 22 females : 24 males; mean age 47.9 (9.9 SD) years	<i>Supervised exercise</i> Up to 10 supervised exercise treatments in addition to home exercises for 6 weeks	<i>Unsupervised (home) exercise group</i> One supervised exercise treatment followed by exercises at home for 6 weeks	<i>Primary outcome</i> SPADI [0 (best) to 100 (worse)] <i>Secondary outcomes</i> Average pain in the past week (VAS 0–10), FABQ physical activity scale [0 (best) to 24 (worse)], FABQ work scale [0 (best) to 42 (worse)], self-reported work status, participant satisfaction (patient perceived treatment benefit, seven-point Likert scale; treatment satisfaction, five-point Likert scale; treatment), shoulder AROM (flexion, abduction, internal/external rotation)	26 weeks: supervised exercise, n = 21; unsupervised (home) exercise group, n = 18	<p><i>SPADI</i></p> <p>Baseline: home exercise mean 49 (SD 12), supervised exercise mean 48 (SD 19)</p> <p>6 weeks: home exercise mean 32 (SD 15), supervised exercise mean 32 (SD 20)</p> <p>26 weeks: home exercise mean 24 (SD 24), supervised exercise mean 21 (SD 18)</p> <p><i>Average pain VAS</i></p> <p>Baseline: home exercise mean 6.3 (SD 1.3), supervised exercise mean 5.9 (SD 2.2)</p> <p>6 weeks: home exercise mean 4.3 (SD 2.2), supervised exercise mean 4.1 (SD 2.1)</p> <p><i>FABQ physical activity</i></p> <p>Baseline: home exercise mean 14 (SD 4), supervised exercise mean 14.4 (SD 5)</p> <p>6 weeks: home exercise mean 10.6 (SD 5.3), supervised exercise mean 12.8 (SD 5.8)</p> <p><i>FABQ work</i></p> <p>Baseline: home exercise mean 20.6 (SD 7.1), supervised exercise mean 19.3 (SD 12.4)</p> <p>6 weeks: home exercise mean 17.4 (SD 7.6), supervised exercise mean 16.2 (SD 13.1)</p>	<p>Supervision of more than the first session of a 6-week exercise regimen did not cause significant differences in pain and disability in people with subacromial impingement</p> <p>No differences were found in the primary outcome, the SPADI. Furthermore, no differences were found in the secondary outcomes of pain, the FABQ (physical activity and work), participant satisfaction or active range of motion after the intervention period</p>
continued								

TABLE 58 Summary of trials comparing the effects of supervised vs. unsupervised exercise interventions (*continued*)

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results	Conclusion
							<i>Work status (on sick leave)</i>	
							6 weeks: home exercise 7/21, supervised exercise 10/23	
							26 weeks: home exercise 4/18, supervised exercise 3/21	
							No significant differences between groups for work status at 6 or 26 weeks	
							<i>Perceived benefit</i>	
							Much improved: home exercise 24%, supervised exercise 52%	
							Slightly improved: home exercise 57%, supervised exercise 30%	
							No change: home exercise 19%, supervised exercise 9%	
							Slightly worse: home exercise 0%, supervised exercise 0%	
							Much worse: home exercise 0%, supervised exercise 9%	
							<i>Treatment satisfaction</i>	
							Satisfied: home exercise 52%, supervised exercise 83%	
							Somewhat satisfied: home exercise 29%, supervised exercise 4%	
							Neither: home exercise 19%, supervised exercise 9%	
							Dissatisfied: home exercise 0%, supervised exercise 4%	

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results	Conclusion
Roddy <i>et al.</i> (2021) ¹¹⁵	Factorial	A total of 256 patients with subacromial impingement randomised ($n = 64$ to each treatment group, i.e. 128 to each exercise group); 52% female: 48% male; mean age 54 years; mean SPADI score 61 (SD 18)	(1) <i>Ultrasound-guided injection and physiotherapist-led exercise, or (3) unguided injection and physiotherapist-led exercise (supervised)</i>	(2) <i>Ultrasound-guided injection and exercise leaflet, or (4) unguided injection and exercise leaflet (unsupervised)</i>	Primary outcome measure	6 weeks: 94%	Physiotherapist-led exercise vs. exercise leaflet	Physiotherapist-led exercise for patients with SIS leads to greater improvements in pain and function at 6 months, but not at 12 months, compared with providing a standardised advice and exercise leaflet
	2 × 2 arm				SPADI at 6 months for exercise interventions	6 months: 88%	SPADI	
	Follow-up: 6 weeks, 6 months and 12 months				Secondary outcomes	12 months: 80%	Superior pain and function scores for physiotherapist-led exercise than exercise leaflet at 6 months (adjusted mean SPADI difference between groups -8.23 , 95% CI -14.14 to -2.32 ; $p < 0.001$), but not at 6 weeks or 12 months	
			The exercise programme comprised (1) scapular stability and active exercise with no resistance, (2) range of motion exercise with scapular control, isometrics and stretches and (3) through-range resistance exercise. Six to eight sessions over 12 weeks plus daily home exercise: stage 1, hourly; stage 2, three or four times per day; and stage 3, three times per week	Leaflet includes information about shoulder anatomy and SIS, plus simple self-help messages about pain relief (including the application of cold packs) and activities. It includes a small number of standardised exercises, including specific muscle strengthening and ROM exercises. Exercises are not individualised, supervised or progressed by physiotherapists	Current pain intensity VAS, overall rating of change, pain self-efficacy, fear of movement, physical health, exercise adherence and patient satisfaction		Treatment satisfaction More satisfaction with treatment for physiotherapist-led exercise than exercise leaflet at 6 weeks (odds ratio 15.81; $p < 0.001$) and 6 months (odds ratio 8.86; $p < 0.001$)	
							Exercise adherence Greater adherence to physiotherapist-led exercise than exercise leaflet at 6 weeks (odds ratio 7.56; $p = 0.001$) and 6 months (odds ratio 6.09; $p = 0.002$)	
continued								

TABLE 58 Summary of trials comparing the effects of supervised vs. unsupervised exercise interventions (continued)

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results	Conclusion
Littlewood et al. (2016) ⁶⁷	Parallel	Eighty-six patients with rotator cuff tendinopathy randomised (usual physiotherapy, n = 44; self-management single exercise programme, n = 42); 50% female; mean age 55 years; mean SPADI score 49	Usual physiotherapy	Self-management single exercise programme	Primary outcome measure	3 months: n = 33 physiotherapy; n = 27 self-management single exercise programme	SPADI	For the primary outcome (i.e. the mean SPADI score at 3 months), there was no difference between the self-managed group and usual physiotherapy treatment group. At 6 and 12 months, there remained no significant difference between groups
	Two arms				SPADI at 3 months		Mean SPADI score at 3 months 32.4 (SD 20.2) for the self-managed group, 30.7 (SD 19.7) for usual physiotherapy treatment group; adjusted MD 3.2 (95% CI -6.0 to 12.4; p = 0.49)	
	Follow-up: 3 months, 6 months and 12 months				Secondary outcomes	6 months: n = 25 physiotherapy; n = 23 self-management single exercise programme	Adjusted MD at 6 months: -6.2 (95% CI -16.1 to 3.6)	
					SPADI at 6 and 12 months, health-related quality of life (SF-36)	12 months: n = 22 physiotherapy; n = 20 self-management single exercise programme	Adjusted MD at 12 months: -6.0 (95% CI -19.7 to 7.6)	

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results	Conclusion
Asensio-García <i>et al.</i> (2018) ¹¹²	Parallel Two arms Follow-up: 5 weeks	Seventy-four patients randomised (intervention, $n = 36$; control, $n = 38$); 58% females; mean age 61 (10.9 SD) years	<i>Intervention group</i> Initial meeting with physiotherapy, advice about recommendations, postural hygiene and description of shoulder exercises (with printed guide) to perform at home. Followed by attendance at five 1-hour, consecutive group sessions (over 10 days) with physiotherapy for performance/review of exercise programme and a subsequent session 2 weeks later (supervised)	<i>Control group</i> Same initial and subsequent session as intervention group, but no attendance at five group sessions. In interim, exercises to be performed at home only (unsupervised)	Follow-up at 5 weeks only: shoulder pain VAS (0–10), Constant–Murley scale [pain, ADL, ROM, strength; 0 (worse) to 100 (better)], QuickDASH scale (30 questions)	$n = 36$ intervention; $n = 25$ control	<p><i>Pain VAS</i></p> <p>Difference between means -0.1 (95% CI -1.0 to 0.7; $p = 0.723$)</p> <p>Intervention group, mean change 3.0 (1.4 SD)</p> <p>Control group, mean change 3.1 (1.8 SD)</p> <p><i>Constant–Murley scale</i></p> <p>Difference between means 4.1 (95% CI -8.8 to 0.6; $p = 0.085$)</p> <p>Intervention group, mean change -15.7 (SD 6.8)</p> <p>Control group, mean change -11.6 (SD 11.6)</p> <p><i>QuickDASH scale</i></p> <p>Difference between means 14.7 (95% CI 7.7 to 21.7; $p < 0.001$)</p> <p>Intervention group, mean change 26.3 (SD 14.3)</p> <p>Control group, mean change 11.6 (SD 11.9)</p>	Group physiotherapy produced a significant reduction in functional limitations (QuickDASH). There were no differences, however, in the VAS and Constant–Murley scores between the two groups
continued								

TABLE 58 Summary of trials comparing the effects of supervised vs. unsupervised exercise interventions (*continued*)

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results	Conclusion
Contreras <i>et al.</i> (2018) ¹¹³	Parallel Two arms Follow-up: 6 weeks, 12 weeks and 24 weeks	A total of 271 patients were randomised (standard physiotherapy, <i>n</i> = 133; self-administered, <i>n</i> = 138); 75% female : 25% male; mean age 56 (12 SD) years	<i>Standard physiotherapy</i> Ten exercise sessions in 6-week blocks (i.e. minimum of 10 sessions and up to a maximum of 40 sessions over 24 weeks, depending on improvement) (supervised)	<i>Self-administered</i> Rehabilitation provided with home exercise instruction manual and DVD. Exercises included daily ROM (postural, active assisted, active training of scapular muscles), daily flexibility (anterior and posterior shoulder stretches) and three strength exercises per week (scapular, rotator cuff) with resistance bands (green). Included advice regarding analgesics and pain relief (unsupervised)	<i>Primary outcome</i> Patient-perceived recovery at 6 weeks <i>Secondary outcomes</i> Patient-perceived recovery at 12 and 24 weeks: shoulder pain VAS (0–10), Constant–Murley scale [pain, ADLs, ROM, strength; 0 (worse) to 100 (better)], SF-36 mental and physical scales, simple shoulder test, DASH score and work status at 6, 12 and 24 weeks	Numbers not given	<i>Pain VAS</i> Baseline: unsupervised mean 7.2 (SD 1.8), supervised mean 7.4 (SD 2) 6 weeks: unsupervised mean 5.3 (SD 2.7), supervised mean 4.6 (SD 2.9) 12 weeks: unsupervised mean 4.7 (SD 2.9), supervised mean 4.3 (SD 3.1) 24 weeks: unsupervised mean 4.9 (SD 3.4), supervised mean 4.5 (SD 3.0) <i>Constant–Murley scale</i> Baseline: unsupervised mean 63.2 (SD 15.2), supervised mean 60.9 (SD 17.2) 6 weeks: unsupervised mean 70.9 (SD 18.5), supervised mean 71.8 (SD 19.1) 12 weeks: unsupervised mean 71.6 (SD 18.3), supervised mean 68.2 (SD 18.9)	The self-administered rehabilitation programme compared with standard physiotherapy in adults with a painful shoulder is no different with regard to function, quality of life or disability in short and medium term. Similarly, it is not worse with regard to patient perceived recovery in the short term, but in the medium term (i.e. 24 weeks) there was an increase in patient perceived recovery by those treated with standard physiotherapy

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results	Conclusion
							24 weeks: unsupervised mean 68.5 (SD 20.7), supervised mean 67.4 (SD 19.5)	
							<i>DASH</i>	
							Baseline: unsupervised mean 50.3 (SD 23.1), supervised mean 53.8 (SD 19.7)	
							6 weeks: unsupervised mean 38.8 (SD 21.2), supervised mean 39.8 (SD 23)	
							12 weeks: unsupervised mean 43.4 (SD 26.3), supervised mean 41.7 (SD 26.2)	
							24 weeks: unsupervised mean 43.6 (SD 28.2), supervised mean 37.4 (SD 28)	
							<i>Patient-perceived recovery</i>	
							6 weeks: unsupervised 25%, supervised 34.7%	
							12 weeks: unsupervised 36%, supervised 49.5%	
							24 weeks: unsupervised 45%, supervised 60% ($p = 0.0361$)	
								continued

TABLE 58 Summary of trials comparing the effects of supervised vs. unsupervised exercise interventions (*continued*)

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results	Conclusion
Türkmen <i>et al.</i> (2020) ¹¹⁴	Parallel Two arms Follow-up: 6 weeks	Thirty-three patients randomised (VBR, <i>n</i> = 16; physiotherapy, <i>n</i> = 17); 10 females : 20 males; mean age 51 (8.54 SD) years of analysed participants only	<i>Physiotherapist-supervised rehabilitation group</i> Two exercise sessions per week with physiotherapist as well as performing same exercises as VBR group three sets of 10 repetitions per day at home for 6 weeks (supervised)	<i>VBR group</i> A video rehabilitation programme was recorded by the physiotherapist with the participation of a patient. Exercises performed three sets of 10 repetitions per day for 6 weeks. Patients attended two sessions with the physiotherapist during the 6-week period to observe 'condition of the patients, accuracy of the exercises given, and the clarity of the commands...but no feedback was given to not interfere with the effectiveness of the program' ¹¹⁴ (unsupervised)	Rest, activity and night pain VAS (0–10); DASH; ASES shoulder evaluation; SF-12 mental and physical scales [0 (worst) to 100 (best)]; participant global rating of change [one (worst) to five (best) on a Likert scale]; shoulder ROM	30 patients analysed (<i>n</i> = 15 in each group)	<p><i>Rest pain VAS</i></p> <p>Baseline: VBR mean 1.13 (SD 1.8), physiotherapy mean 3.47 (SD 2.74)</p> <p>6 weeks: VBR mean 0 (SD 0), physiotherapy mean 0.13 (SD 0.35)</p> <p><i>Activity pain VAS:</i></p> <p>Baseline: VBR mean 6.47 (SD 1.18), physiotherapy mean 6.87 (SD 1.72)</p> <p>6 weeks: VBR mean 1.47 (SD 0.99), physiotherapy mean 1.27 (SD 0.79)</p> <p><i>Night pain VAS</i></p> <p>Baseline: VBR mean 5.13 (SD 2.56), physiotherapy mean 5.6 (SD 2.06)</p> <p>6 weeks: VBR mean 0.27 (SD 0.79), physiotherapy mean 0.07 (SD 0.25)</p> <p><i>DASH</i></p> <p>Baseline: VBR mean 32.68 (SD 14.48), physiotherapy mean 37.45 (SD 18.25)</p> <p>6 weeks: VBR mean 5.39 (SD 5.67), physiotherapy mean 5.5 (SD 5.12)</p>	Both rehabilitation programmes were effective on shoulder ROM, pain, functionality and quality of life for the conservative treatment of partial rotator cuff tears. In addition, there is no statistically significant difference between the rehabilitation programmes

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results	Conclusion
							<p>ASES</p> <p>Baseline: VBR mean 64.51 (SD 11.47), physiotherapy mean 54.18 (SD 15.2)</p> <p>6 weeks: VBR mean 95.3 (SD 4.51), physiotherapy mean 94.4 (SD 5.38)</p> <p><i>SF-12 physical</i></p> <p>Baseline: VBR 39.54 (SD 6.23), physiotherapy 38.72 (SD 4.77)</p> <p>6 weeks: VBR 51.64 (SD 3.49), physiotherapy mean 52.04 (SD 3.61)</p> <p><i>SF-12 mental</i></p> <p>Baseline: VBR mean 33.2 (SD 4.79), physiotherapy mean 32.71 (SD 5.81)</p> <p>6 weeks: VBR mean 38.06 (SD 3.49), physiotherapy mean 38.28 (SD 3.38)</p> <p><i>Global rating of change</i></p> <p>Much better: VBR 10/15 (66.7%), physiotherapy 9/15 (60%)</p> <p>Better: VBR 5/15 (33.3%), physiotherapy 6/15 (40%)</p>	
<p>ADL, activities of daily living; AROM, active range of shoulder movement; ASES, American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form; DASH, Disabilities of the Arm, Shoulder and Hand; HEP, home exercise programme; MRI, magnetic resonance imaging; QuickDASH, Disabilities of the Arm, Shoulder and Hand, abbreviated version; RCT, randomised controlled trial; ROM, range of shoulder movement; SF-12, Short Form questionnaire-12 items; SF-36, Short Form questionnaire-36 items; SIS, subacromial impingement symptoms; VAS, visual analogue scale; VBR, video-based rehabilitation.</p>								

TABLE 59 Studies comparing subacromial corticosteroid injection with no injection or placebo injection

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results/conclusions
Gialanella and Prometti (2011) ¹¹⁶	Parallel Three arms Follow-up: 3 and 6 months	Mean age: one CSI – 79 years; no injection – 79 years; two CSIs – 77 years Sex: 92% female Population: rotator cuff tears DoS: 5.4	(1) Unguided single CSI (n = 20) Triamcinolone acetonide (40 mg)	(2) No injection (n = 20) No treatment (3) Two unguided CSIs (n = 20) Triamcinolone acetonide (40 mg) at baseline and 21 days later	(1) Shoulder pain VAS score (2) Shoulder function: Constant–Murley score	CSI, n = 20; no CSI, n = 20	Intra-articular injection of triamcinolone improved pain relief at 3 months. There was no difference between groups in shoulder pain at 6 months There was no difference between groups in shoulder function
Adebajo <i>et al.</i> (1990) ¹¹⁷	Parallel Three arms Follow-up: 4 weeks	Mean age: CSI – 51 years; placebo – 55 years; NSAID – 58 years Sex: 47% female Population: rotator cuff tendinitis DoS: CSI = 8.6; placebo = 8.5; NSAID = 7.7	Unguided CSI (n = 20) 1 ml of 80 mg/ml triamcinolone with 2 ml of 0.5% lignocaine plus diclofenac-matched placebo tablets (one tablet three times daily)	(1) Placebo injection (n = 20) 3 ml of 0.5% lignocaine and placebo diclofenac tablets (one tablet three times daily) (2) Oral diclofenac (n = 20) 50-mg oral diclofenac tablets three times daily and subacromial injection of 3 ml of 0.5% lignocaine	(1) Shoulder pain VAS score (0–10) (2) Shoulder function: patient scale (0–3)	CSI, n = 20; placebo, n = 20	Triamcinolone injection improved shoulder pain at 4 weeks compared with placebo injection. This difference was not statistically significant
Alvarez <i>et al.</i> (2005) ¹¹⁸	Parallel Two arms Follow-up: 2 weeks, 6 weeks, 3 months and 6 months	Mean age: CSI – 50 years; placebo – 46 years Sex: 47% female Population: chronic rotator cuff tendinosis DoS: CSI = 3.8 (years); placebo = 2.5 (years)	Unguided CSI (n = 31) 4 ml of 2% xylocaine without adrenaline combined with 1 ml (6 mg) of betamethasone	Placebo injection (n = 31) 5 ml of 2% xylocaine without adrenaline	(1) Shoulder pain and function (ASES score) (2) Shoulder pain VAS score (0–100) (3) Disease-specific quality of life (WORC)	CSI, n = 30; placebo, n = 28	No statistically significant difference between the two groups for all outcomes and time intervals

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results/conclusions
Alvarez-Nemegyei <i>et al.</i> (2008) ¹¹⁹	Parallel	Mean age: 53 years	Unguided CSI (n = 27)	Placebo injection (n = 29)	(1) Shoulder pain VAS score (0–100)	CSI, n = 15; placebo, n = 17	No differences were detected between the study groups in the change in the range of shoulder movement at 3 and 6 months of follow-up. Subacromial injection of a mixture of methylprednisolone plus lidocaine was not more effective than lidocaine only
	Two arms	Sex: 77% female	2 ml of methylprednisolone acetate suspension plus 1 ml of lidocaine 1%	3 ml of lidocaine 1%	(2) Shoulder function (SDQ score)		
	Follow-up: 6 months	Population: subacromial impingement syndrome DoS: CSI = 8.1; placebo = 3.1					
Blair <i>et al.</i> (1996) ¹²⁰	Parallel	Mean age: CSI – 56 years; placebo – 57 years	Unguided CSI (n = 19)	Placebo injection (n = 21)	(1) Shoulder pain VAS scale (0–4)	NR	The mean pain score after the injection was 1.2 points for the corticosteroid group and 2.0 points for the control group. This difference was significant (<i>p</i> < 0.005). The use of such injections can substantially decrease pain and increase the range of motion of the shoulder
	Two arms	Sex: 80% female	2 ml of 40 mg/ml triamcinolone acetonide with 4 ml of 1% lidocaine without adrenaline	6 ml of 1% lidocaine without adrenaline	(2) Shoulder function: clinician assessed		
	Follow-up: CSI – 33 weeks; placebo – 28 weeks	Population: subacromial impingement syndrome DoS: 8 (combined average)					
Holt <i>et al.</i> (2013) ⁷	Parallel; external pilot RCT	Mean age: CSI – 62 years; placebo – 56 years	Unguided CSI (n = 19)	Placebo injection (n = 21)	(1) Shoulder function (OSS) – secondary outcome		This pilot trial showed that it is feasible to recruit participants with shoulder pain in the primary care setting for a blinded, randomised trial of corticosteroid injection. Clinical outcomes were not analysed as part of the pilot trial
	Two arms	Sex: 65% female	40 mg of methylprednisone acetate with lidocaine 1% in 1 ml	Lidocaine 1% in 1 ml			
	Follow-up: 4 and 12 weeks	Population: rotator cuff tendinopathy or adhesive capsulitis DoS: CSI = 15.9; placebo = 10					
continued							

TABLE 59 Studies comparing subacromial corticosteroid injection with no injection or placebo injection (*continued*)

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results/conclusions
Hong <i>et al.</i> (2011) ¹²¹	Parallel Three arms Follow-up: 8 weeks	Mean age: CSI 40 mg – 51 years; placebo – 51 years; CSI 20 mg – 49 years Sex: 59% female Population: periarticular shoulder disorders DoS: CSI 40 mg = 8.9; placebo = 8.6; CSI 20 mg = 13	(1) Guided CSI 40 mg (n = 30) 4 ml of 40 mg triamcinolone acetonide	(2) Guided placebo (n = 30) 4 ml of 1% lidocaine (3) Guided CSI 20 mg (n = 30) 2 ml of 20 mg triamcinolone acetonide and 2 ml of 1% lidocaine	(1) Shoulder pain VAS score (0–10) (2) Shoulder function (SDQ)	CSI 40 mg, n = 27; placebo, n = 27	In groups 1 (40 mg of triamcinolone acetonide) and 2 (20 mg of triamcinolone acetonide) there were significant differences in mean changes post treatment at weeks 2, 4 and 8 compared with pre treatment (paired <i>t</i> -test, all <i>p</i> = 0.001), whereas in group 3 (placebo) there was no significant difference post treatment at weeks 2, 4 and 8 compared with pre treatment (paired <i>t</i> -test, <i>p</i> = 0.084, <i>p</i> = 0.107 and <i>p</i> = 0.113, respectively)
Penning <i>et al.</i> (2012) ¹²²	Parallel Three arms Follow-up: 3, 6 and 12 weeks	Mean age: CSI – 52 years; placebo – 54 years; HA – 53 years Sex: 53% female Population: subacromial impingement syndrome DoS: 62% of CSI group mean > 26 weeks; 71% of placebo group mean > 26 weeks	(1) Unguided CSI (n = 53) 2 ml of triamcinolone acetonide 10 mg/ml with 8 ml of lidocaine 1%	(2) Placebo injection (n = 55) 2 ml of NaCl 0.9% with 8 ml of lidocaine 1% (3) HA injection (n = 51) 2 ml of HA with 8 ml of lidocaine 1%	(1) Shoulder pain and function: Constant–Murley score (2) Shoulder pain VAS scale (3) Shoulder function	CSI, n = 45; placebo, n = 48	Compared with placebo injections, corticosteroids were significantly better in terms of pain reduction, but only in the short term at 6 weeks (<i>p</i> = 0.006)

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results/conclusions
Petri <i>et al.</i> (1987) ¹²³	Parallel	Mean age: NR	1) Unguided CSI (n = 25)	(2) Placebo injection (n = 25)	(1) Shoulder pain (VAS 0–5)	CSI, n = 25; placebo, n = 25	Both triamcinolone ($p = 0.00005$) and naproxen ($p = 0.02$) are superior to placebo in the treatment of the painful shoulder
	Four arms	Sex: 31% female					
	Follow-up: 4 weeks	Population: supraspinatus tendinitis ± subacromial bursitis	1 cc of 40 mg/ml triamcinolone with 3 cc of 1% lidocaine plus placebo naproxen pill twice a day for 30 days	4 cc of 1% lidocaine plus placebo naproxen pill two times per day for 30 days	(2) Shoulder function (clinician assessed)		
		DoS: 3.9		(3) Unguided CSI plus NSAID (n = 25)			
				1 cc of 40 mg/ml triamcinolone with 3 cc of 1% lidocaine plus naproxen pill (500 mg) two times per day for 30 days			
				(4) Placebo injection plus NSAID (n = 25)			
				4 cc of 1% lidocaine plus naproxen (500 mg) two times per day for 30 days			
							continued

TABLE 59 Studies comparing subacromial corticosteroid injection with no injection or placebo injection (continued)

Study	Design/follow-up	Participants	Intervention	Comparator	Outcomes	Number analysed	Results/conclusions
Vecchio <i>et al.</i> (1993) ¹²⁴	Parallel	Mean age: CSI – 56 years; placebo – 57 years	Unguided CSI (n = 29)	Placebo injection (n = 28)	(1) Shoulder pain	NR	Although steroid-treated patients seem to have improved to a greater extent than lignocaine-treated patients at 2 weeks, this was not statistically significant. This small improvement was not sustained by 12 weeks
	Two arms	Sex: 60% female	40 mg of methylprednisolone plus 1 ml of lignocaine 1%	Lignocaine 1% (1 ml)			
	Follow-up: 12 weeks	Population: acute rotator cuff tendinitis DoS: CSI = 5 weeks; placebo = 4 weeks					
Withrington <i>et al.</i> (1985) ⁹⁰	Parallel	Mean age: CSI – 61 years; placebo – 55 years	Unguided CSI (n = 12)	Placebo injection (n = 13)	(1) Shoulder pain VAS (0–10)	CSI, n = 12; placebo, n = 13	The VAS score in group 1 (steroid) improved by a mean of 2.72 between weeks 0 and 8, whereas group 2 (placebo) showed a mean improvement of 1.16 in the same period. This difference was not statistically significant (<i>p</i> > 0.05)
	Two arms	Sex: 76% female	80 mg of methylprednisolone diluted in 2ml of 2% lignocaine	4 ml of saline (0.9%)			
	Follow-up: 8 weeks	Population: supraspinatus tendonitis DoS: CSI = 4.1; placebo = 4.6					

ASES, American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form; CSI, corticosteroid injection; DoS, duration of symptoms; HA, hyaluronic acid; NaCl, sodium chloride; NR, not reported; NSAID, non-steroidal anti-inflammatory drug; OSS, Oxford Shoulder Score; RCT, randomised controlled trial; SDQ, Strengths and Difficulties Questionnaire; VAS, visual analogue scale; WORC, Western Ontario Rotator Cuff.

Note
Duration of symptoms is in months unless otherwise specified.

MEDLINE search strategy

Medline (Ovid MEDLINE® Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE® Daily and Ovid MEDLINE®)

Date range searched: 1946 to present.

Date searched: June 2020.

Search strategy

1. Shoulder Pain/ (4378)
2. Shoulder Impingement Syndrome/ (1655)
3. Rotator Cuff/and Tendinopathy/ (477)
4. Shoulder/and Bursitis/or Tendinopathy/ (438)
5. ((shoulder* or rotator cuff or subacromial or sub-acromial) adj5 (bursitis or impinge* or tendinitis or tendonitis or tendinopathy or pain*)).ti,ab. (12,483)
6. 1 or 2 or 3 or 4 or 5 (14,765)
7. (Cortisone/or Glucocorticoids/) and Injections/ (1354)
8. ((subacromial or sub-acromial or corticosteroid* or cortisone or glucocorticoid*) adj5 inject*).ti,ab. (5093)
9. **CSI.ti,ab. (3029)**
10. 7 or 8 or 9 (9227)
11. 6 and 10 (480)
12. randomized controlled trial.pt. (477,274)
13. controlled clinical trial.pt. (92,948)
14. (randomized or randomised).ab. (522,076)
15. placebo.ab. (195,900)
16. drug therapy.fs. (2,088,506)
17. randomly.ab. (306,731)
18. trial.ab. (455,979)
19. groups.ab. (1,887,811)
20. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 (4,404,372)
21. exp animals/not humans.sh. (4,554,611)
22. 20 not 21 (3,810,278)
23. 11 and 22 (320).

EME
HS&DR
HTA
PGfAR
PHR

Part of the NIHR Journals Library
www.journalslibrary.nihr.ac.uk

*This report presents independent research funded by the National Institute for Health Research (NIHR).
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the
Department of Health and Social Care*

Published by the NIHR Journals Library